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Retinal vascular reactivity is impaired in patients with diabetes and is thought to be involved 
in the onset and progression of diabetic retinopathy (DR). Previous studies that have utilized 
hyperoxia to assess retinal vascular reactivity have been limited due to confounding factors 
associated with the administration of oxygen and have used a variety of different instruments 
to measure retinal blood flow. The influence of blood glucose at the time of blood flow 
assessment has also not been systemically investigated.  
 
The specific aims of each Chapter are as follows: 
Chapter 3: To compare three systems used to administer hyperoxia to human subjects.  
Chapter 4: To quantify the magnitude and timeline of change of retinal hemodynamic 
parameters induced by an isocapnic hyperoxic stimulus.   
Chapters 5, 6 and 7: To quantify the magnitude of change of retinal hemodynamic parameters 
induced by hyperoxia, hyperglycemia and combined hyperoxia / hyperglycemia, respectively, 
in groups of diabetic patients with no clinically visible, and mild-to-moderate, DR and in age-
matched subjects without diabetes.  
 
Methods 
Chapter 3: Subjects breathed air followed by oxygen, or oxygen plus carbon dioxide using a 
non-rebreathing system, or air followed by oxygen using a sequential rebreathing system. The 




Chapter 4: Baseline retinal blood flow data was acquired while the subjects breathed air using 
a sequential rebreathing system. An isocapnic hyperoxic stimulus was initiated and 
maintained for 20 minutes. Air was then re-administered for 10 minutes. Retinal blood flow 
measurements were acquired every minute over the course of the study. The magnitude of 
change of each hemodynamic parameter was determined by fitting individual data with a 
sigmoidal function. 
For Chapter 5, 6 and 7 diabetic patients with no clinically visible, and mild-to-moderate, DR 
were stratified into groups based upon their retinopathy status. Age-matched non-diabetic 
subjects were recruited as controls. Baseline retinal blood flow data was acquired while 
subjects breathed air. Retinal blood flow measurements were then acquired after exposure to 
(a) hyperoxia, (b) hyperglycemia and (c) combined hyperoxic / hyperglycemic stimuli. 
Change in hemodynamic parameters was compared between groups and correlated with 
objective measures of retinal edema. 
 
Results 
Chapter 3: The difference in group mean end-tidal CO2 levels between baseline and hyperoxia 
was significant for oxygen administration using a non-rebreathing system. The sequential 
rebreathing technique resulted in a significantly lower variability of individual CO2 levels 
than either of the other techniques. 
Chapter 4: An ~11% decrease of diameter, ~36% decrease of velocity and ~48% decrease of 
blood flow was observed in response to isocapnic hyperoxia in young, healthy subjects. A 




velocity, respectively.  
Chapter 5: Retinal blood velocity, flow, and WSR significantly decreased in response to 
isocapnic hyperoxia in all groups. The magnitude of the reduction of blood flow was 
significantly reduced with increasing severity of retinopathy. There was a significant 
relationship between baseline objective edema index values and retinal vascular reactivity.  
Chapter 6: A significant change in blood glucose level was observed for all groups. No 
significant change in any hemodynamic parameter was found in patients with diabetes and in 
age-matched subjects without diabetes.  
Chapter 7: Retinal blood velocity and flow significantly decreased in all groups in response to 
combined hyperoxic / hyperglycemic provocation. The vascular reactivity response was not 
significantly different across the groups.  
 
Conclusions 
Chapter 3: Control of CO2 is necessary to attain standardized, reproducible hyperoxic stimuli 
for the assessment of retinal vascular reactivity.  
Chapter 4: Arteriolar retinal vascular reactivity to isocapnic hyperoxic provocation occurs 
within a maximum of 4 minutes. Although there was a trend for diameter to respond before 
velocity, the response characteristics were not significantly different between diameter and 
velocity. Different response characteristics of the retinal vasculature to transmural pressure 
mediated autoregulation as opposed to metabolic mediated vascular reactivity are suggested.    
Chapter 5: The vascular reactivity response in terms of the reduction of blood flow relative to 




significantly reduced with increasing severity of retinopathy. A loss of retinal vascular 
reactivity is indicated in patients with moderate DR without clinically evident diabetic 
macular edema (DME), and in patients with DME.  
Chapter 6: Unaltered retinal arteriolar blood flow was found 1 hour after glucose ingestion in 
patients with diabetes and in age-matched subjects without diabetes. These results do not 
support the theory that retinal blood flow is affected by an acute increase of blood glucose in 
diabetic patients and in subjects without diabetes. 
Chapter 7: The vascular reactivity response to a combined hyperoxic / hyperglycemic 
provocation produced a pronounced reduction in blood flow. Unlike the response to hyperoxia 
alone, the vascular reactivity response was not significantly different across the groups. This 










I would like to sincerely thank my supervisor Dr. Chris Hudson for support and 
encouragement.  
 
I would like to express sincere gratitude to my committee members, Dr John Flanagan, Dr. 
Natalie Hutchings and Dr. Tony Cullen. Thanks for your guidance. 
 
Sincere thanks to fellow graduate students at the “Multi-Disciplinary Laboratory for the 
Research of Sight-Threatening Diabetic Retinopathy”, namely, Subha Venkataraman, Tien 
Wong, Kit Guan, Pat Rose, Mila Kisilevsky, Laura Schmidt, Faryan Tayyari and Adrienne 
Tong and also to Dr. Raj Suryakumar.  
 
I would like to express my gratitude to Erin Harvey, Robin Jones, Jim Davidson, Chris 
Mathers, Andy Lankin, Andrew Nowinski, staff and faculty at the University of Waterloo, 
fellow graduate students, and Drs. Kertes and Brent, Department of Ophthalmology, Toronto 
Western Hospital. 
 
Finally I would like to thank my parents David and Hazel, my family, my fiancée Zora Juričić 
and her family (my soon-to-be in-laws!) for love, support and encouragement. I could not 






This work is dedicated to my parents David and Hazel. You are the most hard-working, 
loving, dedicated, selfless people I have ever met and I am blessed to have such wonderful 














TABLE OF CONTENTS………………………………………………………...………....ix 
LIST OF TABLES...……………..……………………………………………………..…xviii 
LIST OF FIGURES………………………………………………………………………...xxi 
LIST OF ABBREVIATIONS...……………………………….……………………..…...xxiv 
1 Introduction...................................................................................................................... 1 
1.1 Retinal blood supply and drainage................................................................................. 1 
1.1.1 Structure of the retinal vessels ............................................................................... 2 
1.2 Blood flow...................................................................................................................... 3 
1.2.1 Ocular perfusion pressure (OPP) ........................................................................... 4 
1.2.1.1 Blood pressure.............................................................................................................................5 
1.2.1.2 Intra-ocular pressure....................................................................................................................5 
1.3 Regulation of retinal blood flow .................................................................................... 6 
1.3.1 Autoregulation ....................................................................................................... 7 
1.4 Endothelial vasoactive substances ................................................................................. 7 
1.4.1 Endothelium derived relaxing factors .................................................................... 8 




1.5 Quantification of retinal hemodynamics...................................................................... 10 
1.5.1 Pulsatile ocular blood flow .................................................................................. 10 
1.5.2 Interferometry ...................................................................................................... 10 
1.5.3 Fluorescein angiography ...................................................................................... 11 
1.5.4 Blue field entoptic phenomenon .......................................................................... 12 
1.5.5 Retinal vessel analyzer (RVA)............................................................................. 12 
1.5.6 Doppler shift theory ............................................................................................. 13 
1.5.7 Colour Doppler imaging ...................................................................................... 14 
1.5.8 Heidelberg Retina Flowmeter (HRF, Heidelberg Engineering, Germany).......... 14 
1.5.9 Bi-Directional Laser Doppler Velocimetry.......................................................... 15 
1.5.10 Canon laser blood flowmeter (CLBF model 100) ............................................... 17 
1.6 Respiration ................................................................................................................... 19 
1.6.1 Neuronal control of muscles for respiration......................................................... 20 
1.7 Summary ...................................................................................................................... 21 
1.8 Review of Diabetes ...................................................................................................... 22 
1.8.1 Complications of diabetes .................................................................................... 22 
1.9 Diabetic retinopathy..................................................................................................... 24 
1.9.1 Clinical classification and etiology of DR ........................................................... 24 
1.9.2 Retinal morphological / biochemical changes associated with hyperglycemia ... 26 
1.10 Clinical detection and monitoring of DME.................................................................. 31 
1.10.1 Stereo-fundus photography .................................................................................. 31 




1.10.3 Psychophysical detection of DME....................................................................... 32 
1.10.4 Color discrimination tests .................................................................................... 32 
1.10.5 Short-wavelength automated perimetry ............................................................... 33 
1.11 Imaging technologies for the non-invasive quantification of DME............................. 34 
1.11.1 Optical Coherence Tomography .......................................................................... 34 
1.11.2 Retinal Thickness Analyzer ................................................................................. 35 
1.11.3 Scanning laser tomography (SLT) ....................................................................... 36 
1.12 Treatment ..................................................................................................................... 38 
1.12.1 Laser..................................................................................................................... 38 
1.12.2 Pharmacological Treatment ................................................................................. 39 
1.12.3 Vitrectomy ........................................................................................................... 39 
1.13 Summary ...................................................................................................................... 40 
1.14 Retinal hemodynamics in patients with diabetes ......................................................... 40 
1.15 Vascular reactivity in diabetes ..................................................................................... 41 
1.15.1 Physiological vascular reactivity provocation ..................................................... 41 
1.16 Conclusion ................................................................................................................... 43 
1.17 References .................................................................................................................... 45 
2 Rationale ......................................................................................................................... 87 
3 Comparison of different hyperoxic paradigms to induce vasoconstriction - 
Implications for the investigation of retinal vascular reactivity........................................ 92 
3.1 Abstract ........................................................................................................................ 93 




3.3 Materials and Methods................................................................................................. 95 
3.3.1 Sample.................................................................................................................. 95 
3.3.2 Procedures ............................................................................................................ 96 
3.3.3 Data acquisition and analysis ............................................................................... 99 
3.4 Results ........................................................................................................................ 102 
3.5 Discussion .................................................................................................................. 107 
3.6 Conclusion ................................................................................................................. 111 
3.7 References .................................................................................................................. 112 
4 Retinal arteriolar diameter, blood velocity and blood flow response to an isocapnic 
hyperoxic provocation. ........................................................................................................ 117 
4.1 Abstract ...................................................................................................................... 118 
4.2 Introduction................................................................................................................ 120 
4.3 Materials and Methods............................................................................................... 121 
4.3.1 Sample................................................................................................................ 121 
4.3.2 Gas Delivery System.......................................................................................... 122 
4.3.3 Canon Laser Blood Flowmeter .......................................................................... 122 
4.3.4 Procedures .......................................................................................................... 124 
4.3.5 Gas analysis and systemic responses ................................................................. 124 
4.3.6 Function fitting................................................................................................... 126 
4.4 Results ........................................................................................................................ 128 
4.5 Discussion .................................................................................................................. 135 




4.7 References .................................................................................................................. 139 
5 Retinal arteriolar diameter, blood velocity and blood flow response to an isocapnic 
hyperoxic provocation in early sight-threatening diabetic retinopathy.......................... 145 
5.1 Introduction................................................................................................................ 146 
5.2 Introduction................................................................................................................ 147 
5.3 Materials and Methods............................................................................................... 149 
5.3.1 Sample................................................................................................................ 149 
5.3.2 Isocapnic hyperoxia delivery system ................................................................. 151 
5.3.3 Quantification of retinal vessel diameter, blood velocity and flow ................... 152 
5.3.4 Quantitative assessment of retinal edema .......................................................... 153 
5.3.5 Procedures .......................................................................................................... 154 
5.3.6 Gas analysis and systemic vascular responses ................................................... 155 
5.3.7 Analysis.............................................................................................................. 156 
5.4 Results ........................................................................................................................ 157 
5.5 Discussion .................................................................................................................. 166 
5.6 Conclusion ................................................................................................................. 172 
5.7 References .................................................................................................................. 173 
6 Retinal arteriolar hemodynamic response to an acute hyperglycemic provocation in 
early and sight-threatening diabetic retinopathy.............................................................. 179 
6.1 Abstract ...................................................................................................................... 180 
6.2 Introduction................................................................................................................ 182 




6.3.1 Sample................................................................................................................ 184 
6.3.2 Oral glucose tolerance test (glucose load drink) ................................................ 186 
6.3.3 Quantification of retinal vessel diameter, blood velocity and flow ................... 186 
6.3.4 Quantitative assessment of retinal edema .......................................................... 187 
6.3.5 Procedures .......................................................................................................... 188 
6.3.6 Analysis.............................................................................................................. 189 
6.4 Results ........................................................................................................................ 190 
6.5 Discussion .................................................................................................................. 196 
6.6 Conclusion ................................................................................................................. 201 
6.7 References .................................................................................................................. 202 
7 Retinal arteriolar diameter, blood velocity and blood flow response to a combined 
isocapnic hyperoxia and glucose provocation in early and sight-threatening diabetic 
retinopathy............................................................................................................................ 208 
7.1 Abstract ...................................................................................................................... 209 
7.2 Introduction................................................................................................................ 211 
7.3 Materials and Methods............................................................................................... 213 
7.3.1 Sample................................................................................................................ 213 
7.3.2 Oral glucose tolerance test (glucose load drink) ................................................ 215 
7.3.3 Isocapnic hyperoxia delivery system ................................................................. 215 
7.3.4 Quantification of retinal vessel diameter, blood velocity and flow ................... 216 
7.3.5 Quantitative assessment of retinal edema .......................................................... 217 




7.3.7 Gas analysis and systemic vascular responses ................................................... 219 
7.3.8 Analysis.............................................................................................................. 219 
7.4 Results ........................................................................................................................ 221 
7.5 Discussion .................................................................................................................. 231 
7.6 Conclusion ................................................................................................................. 236 
7.7 References .................................................................................................................. 237 
8 General Discussion....................................................................................................... 241 
8.1 Future work ................................................................................................................ 244 
9 Appendix A: Frequency-of-seeing characteristics of the short-wavelength sensitive 
visual pathway in clinically normal subjects and diabetic patients with focal sensitivity 
loss. ........................................................................................................................................ 245 
9.1 Abstract ...................................................................................................................... 246 
9.2 Introduction................................................................................................................ 247 
9.3 Materials and Methods............................................................................................... 248 
9.3.1 Sample................................................................................................................ 248 
9.3.2 Clinically normal group ..................................................................................... 248 
9.3.3 Patients with diabetes......................................................................................... 249 
9.3.4 Visits .................................................................................................................. 249 
9.3.5 Procedures .......................................................................................................... 250 
9.4 Frequency-of-seeing (FOS)........................................................................................ 250 
9.4.1 FOS function fitting ........................................................................................... 252 




9.6 Results ........................................................................................................................ 254 
9.6.1 Clinically normal group ..................................................................................... 254 
9.6.2 Group mean slope .............................................................................................. 256 
9.6.3 Group mean sensitivity ...................................................................................... 256 
9.6.4 Group mean r-values .......................................................................................... 257 
9.6.5 Repeatability of FOS determination................................................................... 257 
9.6.6 Patients with diabetes......................................................................................... 258 
9.6.7 Group mean slope .............................................................................................. 260 
9.6.8 Group mean sensitivity ...................................................................................... 260 
9.6.9 Group mean r-values .......................................................................................... 261 
9.7 Discussion .................................................................................................................. 262 
9.8 References .................................................................................................................. 264 
10 Appendix B: Eccentricity and measurement variability and repeatability with the 
Retinal Thickness Analyzer................................................................................................. 270 
10.1 Abstract ...................................................................................................................... 271 
10.2 Introduction................................................................................................................ 272 
10.3 Materials and Methods............................................................................................... 273 
10.3.1 Sample................................................................................................................ 273 
10.3.2 Retinal Thickness Analyzer ............................................................................... 274 
10.3.3 Procedures .......................................................................................................... 274 
10.3.4 Analysis.............................................................................................................. 275 




10.4 Results ........................................................................................................................ 278 
10.5 Discussion .................................................................................................................. 281 
10.6 References .................................................................................................................. 285 
11 Appendix C – Copyright permissions .................................................................... 290 
11.1 Investigative Ophthalmology and Visual Science ..................................................... 290 
11.2 American Journal of Physiology................................................................................ 291 
11.3 British Journal of Ophthalmology.............................................................................. 292 
11.4 Nature………………………………………..………………………………………293 









List of Tables 
Table 3.1: Group mean and SD of inspired O2, expired O2, Inspired CO2, end-tidal CO2, and 
heart rate as a function of technique. ............................................................................. 101 
Table 3.2: Group mean difference in PETCO2 between baseline and oxygen breathing using 3 
different techniques........................................................................................................ 102 
Table 4.1: Group mean and SD of inspired and end-tidal O2, inspired and end-tidal CO2, 
respiration rate, pulse rate and saturation of O2 in blood. .............................................. 134 
Table 5.1: Group mean age, duration of diabetes, number treated with insulin, male to female 
ratio, A1c and random glucose as a function of group (A1c: glycosylated hemoglobin. 
M; male, F; female)........................................................................................................ 150 
Table 5.2: Group mean diameter, velocity, flow, max:min velocity ratio and WSR during air 
and oxygen breathing as a function of group ................................................................. 158 
Table 5.3: Group mean reduction in diameter, velocity and flow in percentage change due to 
isocapnic hyperoxia as function of group. ..................................................................... 160 
Table 5.4: Group mean baseline and effect values for fractional expired carbon dioxide 
(PETCO2), inspired oxygen (FiO2), mean arterial blood pressure (MAP) and mean pulse 
rate (PR) during air and isocapnic hyperoxia as a function of group............................. 162 
Table 5.5: Group mean edema index values within 500μm and 1500μm radius of the fovea as 
a function of group ......................................................................................................... 164 




urine albumin as a function of group ............................................................................. 165 
Table 6.1: Group mean age, duration of diabetes, number treated with insulin, male to female 
ratio, A1c and random glucose as a function of group. ................................................. 185 
Table 6.2: Group mean (SD) baseline, effect and change in glucose as function of group... 191 
Table 6.3: Group mean mean functional hemodynamic indices before and after ingestion of 
glucose as a function of group ....................................................................................... 192 
Table 6.4: Group mean edema index values within 500μm and 1500μm radius of the fovea as 
a function of group. ........................................................................................................ 195 
Table 7.1: Group mean age, duration of diabetes, number treated with insulin, male to female 
ratio, and A1c value. ...................................................................................................... 214 
Table 7.2: Group mean diameter, velocity, flow, max:min ratio and WSR during air / pre-
glucose and during oxygen / post-glucose as a function of group. ................................ 224 
Table 7.3: Group mean change in diameter, velocity and flow in percentage change due to 
combined hyperoxic / hyperglycemic provocation as function of group....................... 225 
Table 7.4: Group mean fractional expired carbon dioxide (PETCO2) and inspired oxygen 
(FiO2) mean arterial blood pressure (MAP) and mean pulse rate during air / pre-glucose 
and during oxygen / post-glucose as a function of group. ............................................. 227 
Table 7.5: Group mean (SD) baseline, effect and change in glucose as function of group... 228 




a function of group. ........................................................................................................ 229 
Table 7.7: Group mean blood sodium, potassium, creatinine and albumin, urine creatinine, 
and urine albumin as a function of group....................................................................... 230 
Table 9.1: Mean sensitivity and FOS slope for WW and SW stimulus parameters at 4.24º and 
9.90º eccentricity for clinically normal subjects. ........................................................... 256 
Table 9.2: Mean r-value for WW and SW stimulus parameters at 4.24º and 9.90º eccentricity 
for clinically normal subjects. ........................................................................................ 257 
Table 9.3: COR of sensitivity and FOS slope for WW and SW stimulus parameters at 4.24º 
and 9.90º eccentricity for clinically normal subjects. .................................................... 258 
Table 9.4: Mean sensitivity and FOS slope for SW stimulus parameters at the DME and non-







List of Figures 
Figure 1.1 Structure of a blood vessel........................................................................................ 2 
Figure 1.2 Schematic illustration of local control mechanisms in the vascular system............. 6 
Figure 1.3 Diagramatic representation of the Doppler principle. ............................................ 13 
Figure 1.4 Diagrammatic representation of bidirectional laser Doppler velocimetry. ............ 16 
Figure 1.5 Photograph of the Canon Laser Blood Flowmeter ................................................. 18 
Figure 1.6 Fundus photograph taken using the CLBF ............................................................. 18 
Figure 1.7 Biochemical and morphological consequences of hyperglycemia......................... 23 
Figure 1.8 Diagrammatic representation of clinically significant diabetic macular edema..... 26 
Figure 1.9 Increased retinal oxygenation decreases edema formation by vasoconstriction and 
reduced VEGF production ............................................................................................... 30 
Figure 3.1   Schematic diagram showing the components of the non-rebreathing system...... 97 
Figure 3.2   Schematic diagram showing the components of the sequential rebreathing system
.......................................................................................................................................... 98 
Figure 3.3   Change in end-tidal CO2 for each individual using (A) pure O2 delivered by a 
non-rebreathing system, (B) O2 with added CO2 delivered by a non-rebreathing system 
and (C) O2 delivered via a sequential rebreathing system. ............................................ 103 
Figure 3.4   Change in (A) arteriolar diameter, (B) blood velocity and (C) flow induced by a 




Figure 3.5   Change in retinal blood flow (as measured by the Canon Laser Blood Flowmeter, 
CLBF-100) induced by O2 delivered using the sequential rebreathing circuit. ............. 106 
Figure 4.1 Photograph of sequential rebreathing system fitted to participant.. ..................... 125 
Figure 4.2 Change in (A) retinal arteriolar diameter, (B) blood velocity and (C) blood flow for 
a single participant induced by isocapnic hyperoxia using the sequential rebreathing 
circuit (fit with sigmoidal function). .............................................................................. 129 
Figure 4.3a Upper; Group mean magnitude of retinal arteriolar diameter before, during and 
after the isocapnic hyperoxic provocation. Lower; Group mean magnitude of retinal 
blood velocity before, during and after the isocapnic hyperoxic provocation.. ............. 130 
Figure 4.3b Upper; Group mean magnitude of retinal blood flow before, during and after the 
isocapnic hyperoxic provocation. Lower; Group mean magnitude of FeO2 before, during 
and after the isocapnic hyperoxic provocation............................................................... 131 
Figure 5.1 Change in retinal arteriolar diameter (upper left), blood velocity (middle left), 
blood flow (lower left), max:min velocity ratio (upper right), and wall shear rate (middle 
right) with isocapnic hyperoxia provocation as a function of group. ............................ 159 
Figure 6.1 Change in retinal arteriolar diameter, blood velocity, blood flow, max:min velocity 
ratio, wall shear rate with isocapnic hyperoxia as a function of group.......................... 193 
Figure 7.1 Change in retinal arteriolar diameter (upper left), blood velocity (middle left), 
blood flow (lower left), max:min velocity ratio (upper right), and wall shear rate (middle 




group. ............................................................................................................................. 222 
Figure 9.1 Schematic diagram showing position of FOS stimulus locations for clinically 
normal subjects (right eye)............................................................................................. 251 
Figure 9.2 Individual FOS functions using WW stimulus parameters for clinically normal 
subjects ........................................................................................................................... 254 
Figure 9.3 Individual FOS functions using SW stimulus parameters for clinically normal 
subjects ........................................................................................................................... 255 
Figure 9.4 Individual horizontal hemifield analysis (right eye) and FOS functions using SW 
stimulus parameters for a patient with diabetes ............................................................. 259 
Figure 10.1 Schematic diagram showing the default RTA scan locations. ........................... 276 
Figure 10.2 Upper; Group mean profile of retinal thickness (0-3000μm) derived using the 
circular band analysis for visits 1 (filled circle) and 2 (open square). Middle; Group 
Mean profile of COV derived using the circular band analysis for visits 1 (filled circle) 
and 2 (open square). Lower; Bar chart showing group mean COR derived from the 





List of Abbreviations 
Advanced glycation end-products (AGE); Average velocity (Vmean); Basement membrane 
(BM); Blood flow (Q); Blood pressure (BP); Blood retinal barrier (BRB); Branch retinal vein 
occlusion (BRVO); Calcium ion concentration (Ca2+); Canon laser blood flowmeter (CLBF); 
Carbon dioxide (CO2); Central inspiratory activity (CIA); Central retinal artery (CRA); 
Clinically significant DME (CSDME); Closed circuit device (CCD); Concentration of CO2 in 
the expired breath (PETCO2); Diabetic macular edema (DME); Diabetic retinopathy (DR); 
Diameter (D); Dorsal respiratory group (DRG); Early Treatment Diabetic Retinopathy Study 
(ETDRS); Endothelial-derived contracting factors (EDCF); Endothelial-derived relaxing 
factors (EDRF); Endothelin (ET); Fractional inspired oxygen (FiO2); Frequency (f); 
Fluorescein angiography (FA); Glucose transporters (GLUT); Glycosylated hemoglobin 
(A1c); Heidelberg retinal flowmeter (HRF); Heidelberg retinal tomography (HRT); Impaired 
glucose tolerance (IGT); Internal limiting membrane (ILM); Intra-cellular adhesion molecule 
(ICAM); Intra-ocular pressure (IOP); Length (L); Lens Opacity Classification System III 
(LOCS III); Macular edema module (MEM); Maximum frequency shift (Δfmax); Maximum to 
minimum (max:min); Microaneurysms (MAs); Nitric oxide (NO); Optical Coherence 
Tomography (OCT); Oral glucose tolerance test (OGTT); Oxygen (O2); Partial pressure of 
arterial carbon dioxide (PCO2); Partial pressure of arterial oxygen (PO2); Positive end-
expiratory pressure (PEEP); Pressure gradient (ΔP); Protein kinase C (PKC); Pulsatile ocular 
blood flow (POBF); Resistance (R); Retinal vessel analyzer (RVA); Retinal pigment 
epithelium (RPE); Retinal Thickness Analyzer (RTA); Scanning laser tomography (SLT); 




cells (SMCs); Stereo-fundus photography (SFP); Vascular endothelial growth factor (VEGF); 





1.1 Retinal blood supply and drainage 
Blood reaches the inner retina via the aortic artery, common carotid arteries, internal carotid 
artery, ophthalmic artery and finally the central retinal artery (CRA). The CRA pierces the 
optic nerve 10-15mm behind the globe and runs forward in the central portion of the nerve 
lying alongside the central retinal vein.  
 
Bifurcation of the central retinal artery on the surface of the nerve head provides four major 
arterioles, one of which supplies each retinal quadrant. Retinal tissue is nourished by two 
separate vascular systems: the inner retina is supplied by a double-layer of vessels derived 
from the central retinal artery and the outer retina (posterior to outer plexiform layer) is 
supplied from the underlying choriocapillaris primarily via the short posterior ciliary arteries 
and to a lesser extent by the long posterior ciliary arteries (derived from the ophthalmic 
artery).1,2 Blood is drained by the retinal venules and into the central retinal vein and finally 
the ophthalmic vein to leave the orbit.  
 
Retinal blood flow in the inner retina is characterized as a low flow system making the retina 
vulnerable to interruption in blood supply. Consequently, the extraction of oxygen as blood 
passes through the capillary beds is very high. The retinal arterio-venous difference in blood 




arterio-venous difference in blood oxygen is ~4%.5
 
1.1.1 Structure of the retinal vessels 
Retinal arterioles and venules are composed of 3 layers: (1) adventitia, (2) smooth muscle 
cells, and (3) endothelial cells (Figure 1.1).  
 
endothelium







Figure 1.1 Structure of a blood vessel 
 
The central retinal artery and especially the downstream arterioles are thought to be 
responsible for regulating the flow of blood to the capillaries; the arterioles are termed 
“resistance” vessels. Retinal capillaries are composed of a single layer of endothelial cells 
surrounded by a basement membrane (BM) containing pericytes and are arranged in a laminar 
fashion, the number of layers depending on retinal location (3 or 4 in the central retina 




“exchange” vessels) of metabolites at the tissue level and, in conjunction with the pericytes, 
allow “fine tuning” of capillary perfusion.6 The tight junctions between the endothelial cells 
(zonula occludens) constitute the inner blood retinal barrier (BRB), preventing leakage of 
blood constituents into the retinal tissue for optimal retinal functioning.  
 
1.2 Blood flow 
Blood flow (Q) within the general circulation is proportional to perfusion pressure and 
inversely proportional to vascular resistance (referred to as Ohm’s law). Perfusion pressure is 
defined as the difference between arterial and venous pressures (i.e. the pressure gradient; 
ΔP); it describes the force with which blood is moved through the vascular bed. Friction 
between the vessel wall and blood produces resistance (R) to flow. 
Q = ΔP/ R       (1.1) 
     
Resistance to flow is dependant on the properties of the fluid and the tube through which it is 
flowing. Using steady blood flow conditions through a cylindrical rigid tube, resistance is 
proportional to the viscosity (η) and length (L) and inversely proportional to the fourth power 




R = 8ηL/πr4        (1.2) 
 
Poiseuille combined equations 1 and 2 and formulated a law that now bears his name:  
   Q = ΔPπr4 / 8ηL       (1.3) 
 
Thus, large alterations of blood flow can be achieved with small changes in vessel diameter. 
 
The cardiovascular system differs from the rigid tubes studied by Poiseuille in a number of 
ways. Vessels in the human body are tapering and elastic, heart contractions result in pulsatile 
not steady flow, laminar flow is not always present in larger vessels and blood is not a perfect 
Newtonian fluid (i.e. viscosity varies with velocity). Despite these limitations, Poiseuille’s 
equation is a useful approximation for the calculation of blood flow and is believed to exist in 
the retinal blood vessels that are 80μm in diameter or larger.7-11   
 
1.2.1 Ocular perfusion pressure (OPP)
The pressure of blood entering the eye (OPP) is determined by the blood pressure (BP) and 
the intra-ocular pressure (IOP), in the relationship: 
 
 – IOP       (1.4) OPP= 2/3 BPmean
where BPmean is the mean arterial blood pressure and IOP is the intra-ocular pressure (both are 







1.2.1.1 Blood pressure 
The pressure with which blood is ejected from the heart is transmitted throughout the entire 
vascular network so that blood is forced from the heart to the capillaries and back to the heart 
again. The maximum pressure produced during systole (ventricular contraction) is called the 
systolic pressure and is generally 120mmHg and the minimum during diastole (ventricular 
relaxation) is generally 80mmHg in young clinically healthy persons. BP is measured using a 
sphygmomanometer and stethoscope. The area under the pressure wave over time equals the 
mean BP 
   BP mean = ∫   BP.dt        (1.5) 
Clinically the mean BP is calculated using the following formula: 
 
BPmean = BP dias + (BPsys - BPdias / 3)        (1.6) 
where BPsys is the systolic pressure and BPdias is the diastolic pressure. 
 
1.2.1.2 Intra-ocular pressure 
Aqueous is secreted by the ciliary epithelium of the ciliary processes and flows through the 
pupil to drain out of the eye via the trabecular meshwork in the anterior chamber angle and 
subsequently into Schlemm canal (called the conventional route) or across the iris root and 
anterior face of the ciliary body and subsequently to the supra-choroidal space (known as the 
uveoscleral route). The pressure generated as a result of this fluid filling this space is called 
the IOP and is commonly measured using an applanation tonometer. Normally, the IOP 
measures between 10 and 21 mmHg. 
 
 
1.3 Regulation of retinal blood flow 
A sympathetic and parasympathetic nerve supply innervates retinal vessels but is ineffective 
in altering vascular tone anterior to the lamina cribrosa.13-17 Consequently, changes in 
vascular tone are initiated from within the retinal tissue itself in response to local demands 
(Figure 1.3).18,19 Since the retinal vascular bed can be imaged non-invasively, it presents a 
unique opportunity to study hemodynamics.  
 
Figure 1.2 Schematic illustration of local control mechanisms in the vascular system. 
Reprinted from Progress in Retinal and Eye research, Vol 22, Yu DY, Su ER, Cringle SJ, and Yu PK. Isolated 
preparations of ocular vasculature and their applications in ophthalmic research. Pages 138. Copyright (2003), 






Autoregulation is defined as “the ability of a vascular bed to maintain constant blood flow to 
the tissues under conditions of varying perfusion pressure”. Previously published studies have 
documented efficient retinal blood flow regulation (within certain limits) both during 
manipulation of IOP20,21 and after exercise induced changes in perfusion pressure.22-28 Retinal 
blood flow is regulated by myogenic and metabolic stimuli and endothelium-derived 
vasoactive factors.19,29 Myogenic blood flow regulation maintains constant blood flow in 
response to increased blood pressure (perfusion pressure) by vasoconstriction and therefore 
increased resistance. Calcium ion movement into the smooth muscle cells promotes 
constriction and reduces blood flow in order to avoid hyper-perfusion, capillary damage and 
edema.29 The reverse is also true whereby a reduction in perfusion pressure would have the 
opposite effect. Metabolic blood flow regulation alters vascular resistance so that the blood 
supply maintains the concentrations of certain metabolites and waste-products within narrow 
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1.4 Endothelial vasoactive substances
The endothelium produces vasoactive substances that are important determinants of retinal 
blood flow. They can be divided into two groups based on their actions: (a) endothelial-
derived relaxing factors (EDRF) and (b) endothelial-derived contracting factors (EDCF). A 
counter-balancing basal production of EDRFs and EDCFs maintains homeostatic retinal 
blood flow. Certain conditions result in increased or decreased production or action of one or 
both types of endothelial derived factors and an alteration of blood flow.30  
 
1.4.1 Endothelium derived relaxing factors 
Nitric oxide (NO) is the most important EDRF and is derived from L-arginine by nitric oxide 
synthase. NO induces vasodilatory effects by increasing cyclic guanidine monophospate that 
in turn reduces calcium ion concentration (Ca2+) in smooth muscle cells resulting in relaxation 
and subsequent dilation. NO is also involved in anti-coagulation, vascular remodeling and 
angiogenesis. In the retinal circulation, NO (together with other endothelium-derived agents) 
controls basal blood flow by maintaining vasodilation31,32; inhibition of NO results in a 
pronounced vasoconstriction in ocular vascular tissue.33-36 Increased shear stress (i.e. 
frictional forces produced on the inner endothelial wall resulting from blood flow) increases 
NO production37 causing vasodilation and increased blood flow38 however, this response may 
be limited to the larger conduit arteries and may not be primarily responsible for the alteration 
of blood flow in the resistance arterioles of the retina. 
 
1.4.2 Endothelium derived constricting factors 
The endothelin family comprise 3 polypeptides, endothelin-1 (ET-1), endothelin-2 (ET-2) and 
endothelin-3 (ET-3), that are important in vascular regulation.39 ET-1 is the most potent and is 







(and vasodilation at low concentrations).40 Vasoconstriction is mediated through the ETa 
receptor subtype41 found on vascular smooth muscle cells and pericytes in rats42 and 
humans.43 Vasoconstriction occurs secondary to increased intracellular Ca2+.44-46 
Vasoconstriction and reduction of retinal blood flow has been demonstrated in animals47,48 
and humans49 after intravenous administration of ET-1. Hyperoxia has been shown to 
stimulate ET-1 release from retinal vascular endothelial cells in vitro,50 in animal models,51 
and in human tissue.52 Shear stress down-regulates endothelin synthesis.53 and NO inhibits the 
release of ET-154 while ET-1 impairs NO bioavailability possibly contributing to impairment 
of vascular reactivity.55  
 
1.5 Quantification of retinal hemodynamics:  
1.5.1 Pulsatile ocular blood flow  
Pulsatile ocular blood flow (POBF) assessment provides an indirect measurement of choroidal 
perfusion.  Ocular blood volume increases during systole and results in increased IOP while 
the reverse is true during diastole. The air pressure required to indent the cornea is measured 
200 times a second via a pressurized tip in contact with the cornea. Calculation of POBF from 
the change in IOP is based upon a model eye assuming a standard ocular rigidity.56-58 An 
initial decrease followed by an increase in POBF has been documented in patients with 
diabetes who subsequently develop diabetic retinopathy (DR).59-61 Increase in blood glucose 




This technique was developed by Schmetterer et al.63 and assesses change in axial length i.e. 
position of the fundus relative to the corneal surface with each cardiac cycle. Laser light is 
directed along the pupillary axis and reflected light from both the cornea and the fundus 
collected to produce an interference pattern. As a bolus of blood enters the eye during systole 
the choroidal blood volume increases and the axial length decreases. This produces a change 
in the interference pattern. The change in the intereference pattern is measured in 







with proliferative DR exhibited decreased amplitude of fundus pulsation.64       
 
1.5.3 Fluorescein angiography 
Fluorescein dye was first used by to assess retinal blood flow quantitatively by Hickam and 
Frayser.65 Fluorescein is a vegetable based dye and is injected into the antecubital vein of the 
arm to enter the circulation. As the dye passes through the ocular vasculature, it is illuminated 
with light of a certain wavelength (~490nm) causing it to fluoresce. As it does so, it emits 
light of ~530nm. A barrier filter is used to increase the contrast as it passes through the ocular 
vascular beds. Relative concentrations of fluorescein in the retinal blood vessels are calculated 
for each successive picture. Over the past decade, scanning laser ophthalmoscopes with 
confocal optics have improved the quality of images and allow high temporal resolution 
imaging. Commonly used parameters to describe retinal blood flow include mean circulation 
time (average time fluorescein stays in a given vascular bed),65 arterio-venous passage time 
(time between first appearance of fluorescein in an artery and its corresponding vein)66 and 
mean dye velocity (time for fluorescein to travel a certain distance along an arteriole).66 The 
main limitations of this technique include the assumption that an artery is completely drained 
by a corresponding vein, the sum of vessel diameters is directly related to blood volume and 
that no leakage of fluorescein occurs during measurements.67 The technique is invasive and 
metabolic changes associated with diabetes may artifactually alter the successive retinal 
frames.68   
 
1.5.4 Blue field entoptic phenomenon  
This technique allows determination of leukocyte velocity in the macular capillaries. The blue 
field entoptic phenomenon (BFEP) is best perceived by using a narrow band (half-height 
width of ~20nm) of blue light (430nm). The erythrocytes absorb, while leukocytes reflect, 
blue light and the subject becomes aware of the movement of the leukocytes to which they 
compare to a simulated particle field.69 By asking subjects to match the speed and pulsatility 
of the movement of their leukocytes with that of the simulated field retinal blood flow69 and 
the retinal vascular reactivity response to various stimuli can be quantified.70 The major 
limitation of this technique is that it is subjective, has large individual variation,71 poor 
reproducibility68 and requires good visual acuity.68  
 
1.5.5 Retinal vessel analyzer (RVA) 
The RVA comprises a fundus camera, a charge coupled device (CCD) and a personal 
computer.72 An image of the fundus is displayed on a monitor for real time inspection.27 A 
region of interest is defined by the examiner and the diameter of the vessel (arteriole, venule, 
or both) inside this region is determined using an algorithm that detects the vessel edges at a 
maximum frequency of 50Hz.73 Measurement of vessel diameter continues during small 
changes in position of the vessel of interest (i.e. during minor eye movements), however, 
acquisition of diameter measurements is interrupted during major eye movements or blinks 
and restarted when a clear retinal image is re-acquired.74 Change in vessel diameter is 




change in diameter (relative units) but is not capable of measuring blood velocity or flow. 
 
1.5.6 Doppler shift theory 
In 1842, Christian Doppler related the frequency of sound (or light) reflected from an object 
to its velocity. This phenomenon later became known as the “Doppler principle”. In the 
context of perfusion measurements, laser light (frequency=f) reflected from a moving particle 
has a shift in frequency (Δf) that is proportional to the velocity of the moving particle. Light 
scattered from stationary tissue is not shifted and acts as the reference frequency from which a 





 f’ = f + Δf 
Red blood cells 
 
Figure 1.3 Diagramatic representation of the Doppler principle.  
Light scattered from stationary tissue is reflected at frequency f. Light reflected from the red blood cells (moving 





1.5.7 Colour Doppler imaging 
This device measures blood velocity in extraocular blood vessels.75 Sound waves of a certain 
frequency are emitted and reflection by moving particles produces a frequency shift while 
stationary tissue reflects the sound wave with the same frequency as the source. By measuring 
the frequency shift, blood velocity can be determined.76,77 Published studies in patients with 
mild-to-moderate DR have demonstrated reduced blood velocities in the central retinal artery 
relative to subjects without diabetes,61,78,79 80,81 increased resistance  and decreased vascular 
response to hyperoxia.82 This device cannot measure vessel diameter and therefore cannot 
quantify flow. 
  
1.5.8 Heidelberg Retina Flowmeter (HRF, Heidelberg Engineering, Germany)
The HRF comprises a confocal scanning laser ophthalmoscope and a single photodetector.83 
Briefly, the fundus is illuminated with a 780nm diode laser and measurements of the intensity of 
back scattered light from a measurement area of 10º by 2.5º are acquired with a resolution of 256 
pixels and 64 lines. Each line of 256 pixels is scanned 128 times at a frequency of 4000Hz. The 
intensity of back-scattered laser light from the retina is measured as a function of time (to produce 
an intensity-time curve) for each pixel within the image. The incident and reflected light interfere 
resulting in an oscillation, or “beat”, of the measured light intensity. The frequency of the 
intensity oscillation is proportional to the Doppler frequency shift and derives a measure of 




limitations of this technology.84 Importantly, the Doppler signal depends on the angle between the 
incident and reflected light.9 Problems associated with the HRF include susceptibility to eye 
motion during measurement making some data unusable. Also, there is an artifactual flow reading 
even when no cells are moving, and an artifactual increase in the total number of cells when in 
motion.85 Work from our own laboratory has shown that artificially induced light scatter 
erroneously elevates HRF values.86 In summary, the HRF is only capable of providing relative 
measurements of blood flow at the same sites over time.85 HRF investigation of blood flow in 
patients with DR revealed increased blood flow in some patients while others demonstrated no 
change.87
 
1.5.9 Bi-Directional Laser Doppler Velocimetry
By utilizing two photo-detectors separated by a known angle, the absolute quantification of 
centre-line blood velocity is possible.11,88,89 90 Early instruments developed by Riva et al.  and 
Feke et al.11 comprised a fundus camera or slit lamp, respectively, to which a laser and photo-
detectors were attached for the assessment of retinal hemodynamics. These instruments were 
not capable of maintaining the center-line position of the measurement laser on the vessel 
during micro-saccades leading to aberrant velocity measurements and was not capable of 
measuring vessel diameter.85 Velocity was calculated by determining the difference in the 
frequency shift in 2 directions (represented by the wave vectors K1 and K2 below) separated 



















Figure 1.4 Diagrammatic representation of bidirectional laser Doppler velocimetry.  
The incident beam is directed perpendicular to the vessel with red blood cells moving with centre-line velocity 
Vmax. The maximum frequency shift is detected at K1 and K2 that are separated by a known angle.   
 
Δf = f2 max – f1 max = (α2 – α1).v/λ       (1.7) 





 max and f2 max are the maximum frequency shifts at K1 and K2, respectively. 
 
Vmax = λ.Δf / n.Δα.cosβ      (1.8) 
where Δα is the angle between K1 and K2 and β is the angle between the vector Vmax and 
the incident beam. 
 
Mean velocity is calculated using the following relationship assuming Poiseuille flow9
 
V  = V  / 2       (1.9) mean max
 
Flow is calculated using the following equation91
Flow = 1/2.π.D2/4.V .60      (1.10) mean
where D= vessel diameter and V = mean velocity across a cardiac cycle mean
 
1.5.10 Canon laser blood flowmeter (CLBF model 100)
The CLBF surpasses all other instruments because it permits the non-invasive bi-directional 
quantification of blood velocity with simultaneous assessment of retinal vessel diameter and 
therefore is able to derive blood flow in real units.11 These features allow intra- and inter-






Figure 1.5 Photograph of the Canon Laser Blood Flowmeter 
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The instrument comprises a fundus camera incorporating a laser and 2 pairs of photo-
detectors. A red diode laser (675nm, 80μm x 50μm oval) is used to measure velocity every 
0.02 second across a 2 second measurement window resulting in a velocity-time trace. The 
CLBF also uses a green diode vessel tracking laser system (543nm, 1500μm x 150μm 
rectangle) that is used to stabilize the laser position at the measurement site and allows 
rejection of velocity measurements involving significant saccades.93,94 Diameter readings are 
acquired every 4 milliseconds during the first and final 60 milliseconds of the 2 second 
velocity measurement window. Two sequential maximum velocity measurements are 
determined from the maximum frequency shifts at each photomultiplier along 2 optical paths 
(path 1 and path 2).  
 
Magnification effects associated with refractive and axial components of ametropia are 
corrected to provide absolute measurements of diameter (μm), velocity (mm/sec) and flow 
(μL/min). The technological principles utilized in this device have been described in detail 
elsewhere.11,88,91,95 In addition, the CLBF has been extensively evaluated in clinically normal 
subjects10,96 and those with various types of retinal diseases.91,92
 
1.6 Respiration 
Respiration allows the transfer of oxygen and carbon dioxide between the atmosphere and 




thorax. The right and left bronchi enter the right and left lung respectively and produce many 
branches to form bronchioles which further sub-divide into alveoli to increase the surface area 





2) to come in close proximity to air (rich in O , low in CO2 2) and each gas diffuses along 
their concentration gradient across the alveolar epithelium.97
 
The breathing cycle 
For the majority of the time, breathing occurs unconsciously. Inspiration is initiated by 
increased activity of the inspiratory muscles (principally the diaphragm). Contraction of the 
diaphragm, and with larger breaths the intercostal muscles, increases the thoracic space and 
moves the ribs up and out allowing alveolar pressure to decrease. Air rushes into the lungs 
down a pressure gradient until alveolar pressure equals atmospheric pressure. Inspiration ends 
with a sharp decrease in excitatory activity in the inspiratory muscles. Expiration follows due 
to the elastic recoil of the ribs and muscles. The alveoli decrease in volume, the diaphragm 
and intercostals muscles relax forcing air out of the lungs again. During exercise, inspiration 
and expiration become less passive and other voluntary muscles become involved to increase 
the respiration rate to meet the metabolic needs of muscle tissue.97
 
1.6.1 Neuronal control of muscles for respiration
Neuronal control of breathing comes from 2 groups of cells in the medulla oblongata, the 
dorsal respiratory group (DRG) and the ventral respiratory group (VRG). Inspiration results 
from reduced inhibition of the central inspiratory activity (CIA) neurons located in the 
medullary reticular formation. In turn, this excites the DRG / VRG complex driving 
inspiration. Inspiration ends when a certain threshold is reached within the VRG due to 
feedback from the CIA and lung receptor neurons. Duration of expiration is determined by the 
intensity of inhibition of the inspiratory cells of the DRG / VRG complex, after which 
inspiration starts again.97  
 
1.7 Summary 
In summary, the retina is a unique vascular bed because the retinal vessels can be visualized 
directly and non-invasively. Retinal blood flow follows Poiseuille law and is auto-regulated. 
The retinal arterioles are the resistance vessels of the retina. Arteriolar tonus is regulated 
principally by NO and ET-1. A number of instruments permit the non-invasive measurement 
of parameters that reflect retinal blood flow. Of these instruments, the CLBF is unique in that 
it is able to quantify retinal blood flow in absolute units. The absolute quantification of blood 
flow in conjunction with a validated technique to produce isocapnic hyperoxia (described 






1.8 Review of Diabetes 
Diabetes is a metabolic disorder of multiple etiologies characterized by chronic 
hyperglycemia resulting from defects of insulin secretion, insulin action or both.98 The two 
main classes that have been described are type 1 (10% of individuals; characterized by 
autoimmune destruction of Islet cells) and type 2 (90% of individuals; characterized by 
insulin resistance and / or reduced insulin secretion).99 The World Health Organization has 
estimated that the number of people diagnosed with diabetes will increase from 143 million in 
1997 to 300 million by 2025.100 Diabetes affects over 16 million people in the United States101 
and approximately 2 million people in Canada (Canadian Diabetes Association). At least 
US$100 billion is spent annually to treat patients with diabetes and its complications,102,103 
while in Canada the equivalent figure is $13.5 billion (Canadian Diabetes Association). 
 
1.8.1 Complications of diabetes 
The Diabetes Control and Complications Trial and United Kingdom Prospective Diabetes 
Study identified chronic hyperglycemia as an initiating factor in the complications seen in 
diabetes that impacts the retina, kidneys and nerves and macro-vascular complications that 
result in myocardial infarction and cerebro-vascular accident.104,105  The macro- and micro-
vascular complications of diabetes are reduced when strict control of blood glucose is 
maintained.104,105 The effects of cellular damage resulting from hyperglycemia has been 




















Figure 1.7 Biochemical and morphological consequences of hyperglycemia (eNOS, endothelial nitric oxide 
synthase; ET-1, endothelin-1; VEGF, vascular endothelial growth factor; TGF-beta, transforming growth factor; 
PAI, plasinogen activator inhibitor).  
 





1.9 Diabetic retinopathy 
DR is one of the most common causes of blindness in North Americans between 20 and 74 
years.107 DR is highly prevalent and is positively associated with duration of diabetes.108-114 
The incidence of development and progression of retinopathy is reduced in those individuals 
with blood glucose levels that are closest to those of non-diabetic individuals.104  
 
1.9.1 Clinical classification and etiology of DR
DR can be categorized as a disorder that preferentially affects the vasculature resulting in 
capillary closure, ischemia, leakage and eventually neo-vascularization. From a clinical 
perspective, it can be divided into 3 major categories including non-proliferative, proliferative 
and maculopathy. Non-proliferative DR is characterized by one or more of the following 
features: (1) microaneurysms (MAs; localized bulging, or aborted budding, of the capillary 
endothelial wall) are one of the earliest clinically visible signs of retinopathy,115,116 (2) 
hemorrhages may be flame-shaped (if located in the nerve fibre layer) or dot and blot (outer 
plexiform and inner nuclear layers) and generally occur due to vascular rupture,97 (3) hard 
exudates have a glistening appearance, are located in the outer plexiform layer and may be 
associated with retinal edema,117 (4) cotton-wool spots appears as fluffy white alterations of 
the nerve fibre layer and occur as a result of interruption of axoplasmic flow in the ganglion 
cell layer,118 (5) venous beading is caused by focal venous dilation and thinning of the vessel 







intra-retinal microvascular abnormalities describes dilation of capillary segments between 
arterioles and venules and occur in close proximity to areas of non-perfusion.   
 
Proliferative DR is characterized by the presence of new vessels originating from the retina or 
optic nerve head and is associated with mid-peripheral retinal ischemia.120 New vessels grow 
along the vitreo-retinal interface that may result in pre-retinal fibrosis, pre-retinal hemorrhage, 
tractional detachments of the retina and severe vision loss.121  
 
Diabetic maculopathy is characterized by edematous, exudative or ischemic events, occurring 
within the retinal arcades. Aspects of all three types of maculopathy frequently occur 
concomitantly; however, individuals generally exhibit a preponderance of one particular type 
of maculopathy. Breakdown of the inner or outer blood retinal barrier (BRB) is associated 
with intra-retinal accumulation of protein, then water (as a result of oncotic pressure) and hard 
exudates, resulting in increased retinal thickness and disruption of neural components of the 
retina (producing visual impairment).122  
 
Diabetic macular edema (DME) remains the most common cause of visual impairment in 
diabetes.123 Over any ten year period, ninety-five thousand diabetic patients will develop sight 
loss due to DME.124 Longer duration of diabetes, higher glycemic levels, severity of 
retinopathy as well as systemic factors such as hypertension, renal disease and / or 
cardiovascular disease may exacerbate DME.117,125 DME can be sub-classified in 
terms of distribution that is either focal or diffuse. Focal DME results from microaneurysms 
and / or dilated, leaking capillaries126 while diffuse DME is thought to result from breakdown 
of the outer BRB.117,126-128 Clinically significant DME (CSDME) is defined as retinal 
thickening within 500μm of the centre of the fovea, hard exudates within 500μm of the fovea 
associated with retinal thickening, or retinal thickening of 1500μm diameter any part of which 
lies within 1500μm of the fovea (Figure 1.9). Clinical trials have been undertaken to identify 
the point at which treatment for DME should be initiated.129  
 
Figure 1.8 Diagrammatic representation of clinically significant diabetic macular edema 
 
1.9.2 Retinal morphological / biochemical changes associated with hyperglycemia
Retinal endothelial cells are particularly susceptible to hyperglycemia. Glucose enters 
endothelial cells of the inner blood retinal barrier by glucose transporters (GLUT), 







glucose in and through endothelial cells.130,131 Although glucose transport through GLUT-1 is 
almost saturated at normal physiological glucose levels,130 chronic hyperglycemia results in 
increased intracellular glucose concentrations that may be due to hyperglycemia itself,132 
increase in GLUT-1 density,131 translocation of GLUT-1133 or a novel glucose transporter.132   
 
After glucose has gained entry to the cell a diverse range of pathophysiological changes take 
place. Regulation of blood flow is affected by alterations in the concentrations of NO and ET-
1. During hyperglycemia, NO levels are reduced due to protein kinase C (PKC) activation, 
activation of the polyol pathway and increased superoxide production.  
 
Endothelins are important regulators of retinal blood flow during homeostatic conditions49,134-
136 and during hyperoxia.52 Endothelins are up-regulated in diabetes and mediate structural 
and functional alterations.137,138 During hyperglycemia, ET-1 levels are increased as a result 
of PKC and mitogen-activated protein kinase activation. 
 
In addition, the biochemical pathways involved in hyperglycemia induced damage include: 
the polyol pathway, increased production of advanced glycation end-product precursors, PKC 
activation and increased activity of the hexosamine pathway.106  
 




early in diabetic patients and animals.139-142 Diabetes induces upregulation of adhesion 
molecules142-144 and promotes vascular leakage145-147 by upregulation of intra-cellular 
adhesion molecule (ICAM), vascular endothelial growth factor (VEGF) or advanced glycation 
end-products.148,149 Platelet-fibrin thrombi in retinal capillaries are increased in DR secondary 
to chronic hyperglycemia and platelet activating factor which contributes to thrombus 
formation.  
 
Pericytes facilitate the “fine control” of capillary blood flow and are responsible for 
endothelial cell proliferation.150 Selective loss of pericytes occurs quite early in the disease 
process and affects capillary tone and capillary blood flow regulation.151 Hyperglycemia 
inhibits pericyte growth and contraction and promotes apoptosis secondary to accumulation of 
toxic products intracellularly.152-155  
 
BM thickening secondary to increased production of collagen, laminin and fibronectin by the 
endothelial cells and pericytes as well as glycation of proteins under hyperglycemic 
conditions occurs early in the disease process.151,156 Decreased compliance of capillaries due 
to BM thickening may represent an early hemodynamic abnormality.   
 
Smooth muscle cells surround the endothelial cells of arterioles and venules157 and together 
with the pericytes are responsible for the maintenance of blood flow and pressure. Depletion 




vessel contractibility and increased permeability of the blood retinal barrier has been 
demonstrated in mice deficient in smooth muscle actin (a molecule necessary for cell 
structural integrity).159  
 
The morphological changes described above are involved in the pathogenesis of capillary 
closure resulting in non-perfused acellular ghost “vessels” of BM. Retinal ischemia secondary 
to widespread non-perfusion ensues and leads to the expression of inflammatory mediators 
and angiogenic growth factors and neovascularization.   
 
One of the most important growth factors that is upregulated in DR is VEGF. This growth 
factor stimulates the degradation of extracellular matrix, the migration, proliferation and tube 
formation of endothelial cells. VEGF levels are increased in early DR adjacent to areas of 
hypoxia or neovascularization. Importantly, VEGF increases endothelial cell permeability by 
alteration of endothelial cell junctions and is therefore important in the development of 
DME.160    
 
Formation or regression of edema is dependent on the net movement of water between the 
vascular and tissue compartments.161 Hydrostatic pressure drives fluid into the tissue, oncotic 
pressure drives fluid out of the tissue; Starling’s law states that for no net movement of fluid 
the hydrostatic pressure must balance the oncotic pressure. As the retinal arterioles control 
downstream hydrostatic pressure, increased hydrostatic pressure in capillaries and 
venules will dilate according to the law of LaPlace (assuming constant oncotic pressure).162 
Nguyen et al.163 have shown that supplemental oxygen for 3 months reduced retinal thickness 
substantially in patients with DME presumably secondary to vasoconstriction and decreased 
hydrostatic pressure (Figure 1.10) 
 
 
Figure 1.9 Increased retinal oxygenation decreases edema formation by vasoconstriction and reduced VEGF 
production  
Reprinted by permission.  Surv Ophthalmol. Ocular oxygenation and treatment of diabetic retinopathy; 51;4:364-






1.10 Clinical detection and monitoring of DME 
Stereo-fundus slit lamp biomicroscopy (using a high powered plus lens e.g. 66D, 78D or 90D 
after pupillary dilation) has traditionally been the clinical “gold standard” technique for the 
detection of DME.164 This technique relies upon the subjective interpretation of the thickness 
of the transparent retina.165,166 Consequently, the clinical estimation of the extent and location 
of retinal thickening of a given patient is highly variable between examiners and is also highly 
variable between visits for a single examiner.167  
 
1.10.1 Stereo-fundus photography 
Stereo-fundus photography (SFP) is regarded as the “gold standard” for the documentation of 
macular edema and was used by the Early Treatment Diabetic Retinopathy Study 
(ETDRS).129,166,168 The acquisition of quality images (from which stereoscopic information is 
available) is affected by pupil dilation, media opacities, and patient co-operation. Stereo 
images are viewed and the area determined to exhibit thickening is demarcated. Recently 
published studies have assessed the agreement between SFP and fundus biomicroscopy as 
well as newer technologies to objectively assess retinal thickness (Retinal Thickness Analyzer 
(RTA) and Optical Coherence Tomography (OCT)). SFP determination of retinal thickness in 
terms of location and severity (area of retinal involvement) agreed very favorably with fundus 






Breakdown of the inner BRB allows transport of electrolytes and plasma into the intra-retinal 
space, resulting in DME.172 In patients with diabetic maculopathy, fluorescein angiography 
(FA) is used to identify areas of capillary non-perfusion (i.e. ischemic maculopathy for which 
laser treatment is ineffective), cystoid macular edema (i.e. a severe form of edema that 
typically does not respond well to laser treatment), and identify areas of diffuse or focal 
leakage.172-177 One of the limitations of this technique is that FA identifies capillary leakage 
which may or may not correspond with the location of retinal thickening.178-180  
 
1.10.3 Psychophysical detection of DME
A number of psychophysical techniques exist that have been used to detect pre-clinical 
changes that predict the ultimate development of sight-threatening DR and DME and are 
described in the following sections. 
  
1.10.4 Color discrimination tests
Selective loss of S-cones has been documented early in diabetes181-183 that precedes VA loss 
and is correlated with the presence of sight threatening DR.184 The foveal S-cone free area is 




increasing vascular abnormalities.186 Reduced short-wavelength cone sensitivity is related to 
severity of DR.187  
 
1.10.5 Short-wavelength automated perimetry 
Short-wavelength automated perimetry (SWAP) uses a blue stimulus to preferentially 
stimulate the SWS visual pathway and a high luminance yellow background to saturate both 
medium- and long-wavelength sensitive pathways and simultaneously suppress rod 
activity.188 A selective loss of short-wavelength (SW) sensitive pathway sensitivity has been 
demonstrated in patients with no, or minimal retinopathy.189-194 Indeed, SW field loss is 
correlated with severity of retinopathy195 and precedes white-on-white (WW) field loss in DR 
and maculopathy196-199 and predicts the development of DME with high sensitivity and 
specificity suggesting functional loss precedes morphological abnormalities.196 SWAP is also 
a useful tool to detect early macular ischemia associated with DR.198 Although the application 
of SWAP for the detection of diabetic maculopathy is far more favorable than that of the 
detection of glaucoma, the inherent variability of the SWS visual pathway is a limiting factor 
in the clinical application of this technique.200 Other limitations associated with SWAP 
include greater long term fluctuation, crystalline lens and macular pigment absorption, longer 





1.11 Imaging technologies for the non-invasive quantification of DME  
1.11.1 Optical Coherence Tomography 
Optical Coherence Tomography (OCT) provides high resolution cross sectional images of the 
retina.202 The longitudinal resolution has been reported to be 10-20μm203 while the lateral 
resolution is 25μm.204 Technically, partially coherent near-infrared light (843nm) is split by 
an interferometer into a “probe” and “reference” beam.205 After reflection from the retina, the 
“probe” beam interferes with the “reference” beam to give retinal thickness and distance 
information. Processing of the cross sectional scan pseudo-corrects for eye movements before 
it is displayed in a false color representation. “Warm” colors (red to white) represent 
structures of high reflectivity, whereas “cool” colors (blue to black) represent structures of 
low reflectivity. Normal thickness of the fovea is approximately 170μm.206,207 Published 
studies have demonstrated retinal thickening in diabetic patients without clinically evident 
DME208-211 210-213 and in patients with DME,  the locus of the retinal thickening being primarily 
in the outer layers of the retina.203 Retinal structural changes in DME have been described 
using OCT.214 Sensitivity and specificity for the detection of DME in the central fovea is 89% 





 FA characteristics218 and stereo fundus photography170,219 in patients with 
DME have been undertaken. The limitations of this technique are that image quality is 
degraded by media opacities and depends on operator technique220. Also, longitudinal analysis 
of change is weakened since it is impossible to register and align successive images and the 
image processing algorithms within OCT are unable to truly correct for eye movement.  
  
1.11.2 Retinal Thickness Analyzer
The Retinal Thickness Analyzer (RTA) comprises a laser slit biomicroscope and digital 
camera  attached to an ophthalmic table, a patient headrest, and a personal computer. In brief, a 
green helium-neon laser light of 543 nm wavelength is scanned across the retina to produce 16 
discrete slit images within a 3 mm x 3 mm area of retina. The reflected slit images are 
recorded digitally. Retinal thickness is derived from the separation between the anterior (that 
is, at, or close to, the internal limiting membrane, ILM) and posterior (that is, at, or close to, 




epithelium, RPE) reflectance interfaces221 for 16 points along each slit 
using densitometry). Consequently, the derivation of retinal thickness is dependent upon the 
clarity of the RTA derived slit image. Patient fixation is aided by means of an internal fixation 
target that can be moved. Depth resolution and depth precision are reported to be 5–10 µm 
and 50 µm, respectively.222 A more detailed explanation of the RTA optical principles has 
been described elsewhere.222-225 The repeatability of scan thickness is poorest in the central 
foveal region226 and the scan quality is reduced in the presence of lenticular opacities. 
 
The RTA has been used in patients with diabetes to determine the sensitivity and specificity 
of detecting DME. In comparison studies with OCT, the RTA has been reported to be more 
specific for the detection of DME.219 Others have reported that agreement between fundus 
biomicroscopy assessment of patients with DME was better with the macular edema module 
(MEM) of the Heidelberg retinal tomograph (HRT) compared to RTA.227
 
1.11.3 Scanning laser tomography (SLT)
The description of the SLT technique in this thesis is more detailed than that of OCT or RTA 
because we have used the technique in the study protocol. SLT is a non-invasive technique for 
topographical assessment of the retina using confocal imaging. A two-dimensional optical 
section image is produced at the focal plane of the instrument while scattered light is 
suppressed using a pinhole. The process is repeated for sequential planes of focus along the 
optical axis (at more posterior positions). This image series is corrected for minor eye 
movements that occur during image acquisition and the sections are aligned to make a 
composite image from which retinal topography can be determined. Reflectance as a function 
of depth for each pixel element is calculated according to the following formula: 
 
Relative intensity = (Measured intensity / maximum intensity) * 100 (1.11) 
 
A z-profile is generated when relative intensity is plotted as a function of scan depth. The 









In normal retina, the z-profile is narrow and symmetrically distributed but is broadened in 
areas of retina thickening. In DME, the z-profile signal width is correlated with the magnitude 
of retinal thickening.228 Z-profile signal width is determined at 50% of the maximum relative 
intensity. Variation of reflectance intensity between successive images is reduced by 
employing a normalization procedure.228 In addition, maximum reflectance intensity is 
reduced in areas of retinal edema.96,228  
 
In the MEM of the HRT I and II, edema index values are determined using:  
 
Edema index = Normalized signal width  / Maximum reflectance intensity229 (1.12) 
 
The units of the macular edema module are therefore arbitrary. Edema index evaluation 
objectively quantifies DME and has been shown to have high sensitivity and specificity for 
the detection of DME.227 The edema index has been shown to correlate with sensitive 
measures of visual function including SWAP and VA.230 In addition, Kisilevsky and co-
workers231 investigated the agreement between the HRT MEM and fundus biomicroscopy 
assessment (“clinical gold standard”), FA and SWAP in patients with and without clinically 
manifest DME using a sector analysis procedure. MEM demonstrated very good agreement 
with fundus biomicroscopy assessment and good agreement with FA and SWAP. In addition, 
many sectors flagged as being abnormal by MEM but not by fundus biomicroscopy 
assessment were also flagged as being abnormal by FA and / or SWAP implying that 
structural or functional abnormalities are occurring in retinal areas that are not yet clinically 
visibly thickened using fundus biomicroscopy. Using MEM findings with FA and SWAP 




1.12.1 Laser  
Laser photocoagulation is the treatment of choice for focal and diffuse DME as well as for 
proliferative DR.129,168,232-235 In DME, it has been shown to result in the long-term 





 is cost effective236 and offers improved quality-of-life for patients.237 
However, a single session of laser stabilizes VA in approximately only 60% of patients with 
many requiring repeat laser sessions.129,168,238,239 Diffuse DME can be difficult to treat with 
laser photocoagulation since some cases remain unresponsive.240 The side-effects associated 
with laser include post laser scotomata,241,242 altered retinal function,243 enlarging atrophic 
laser scars,244 subretinal neovascularization and fibrosis.245. Recent studies have tested the use 
of “lighter” or “sub-threshold” treatment and micropulse laser,246 to reduce post laser retinal 
scarring and loss of visual sensitivity.247-250 Generally, laser only stabilizes VA rather than 
improving it in the majority of cases. Due to its destructive nature, other pharmacological 
treatment modalities have been developed (described below). 
 
1.12.2 Pharmacological Treatment





 AGE inhibitors,255-259 antioxidants,255,260-262 supplemental 
O2,163,263,264 growth factor modulators including VEGF inhibitors,265-271 PKC inhibitors,272-274 
corticosteroids,275-279 or non-steroidal anti-inflammatory drugs.280,281  
 
Potential targets for treatment of DME include reduction of blood retinal barrier breakdown 
with steroids,282 anti-VEGF factors,265 and PKC inhibitors.283 The major complications 




Increased macular thickness secondary to refractory DME may be improved with vitrectomy 
(surgical removal of the vitreous).287 Vitrectomy is also an effective treatment in patients with 
neovascularization.288-290 In both cases, removal of the vitreous allows increased retinal 
oxygenation by diffusion and therefore VEGF production is downregulated.162   
 
1.13 Summary 
DME is the most common cause of visual impairment in diabetes. Hyperglycemia induced 
cellular damage and vascular alteration has been described and results in the formation of 
DME. A number of techniques have been developed that allow quantification of DME. 
Among these, SWAP and MEM have been shown to allow pre-clinical detection of DME and 
offer improved diagnostic performance. Early and precise identification of the location of 
retinal thickness in conjunction with effective, non-destructive treatment may prevent vision 
loss in patients with DME in the future. New treatment options are becoming available for the 
treatment of DR and DME, however it is important that they are initiated early enough to 
prevent or slow the progression of retinopathy i.e. prior to the development of significant 
pathological changes. Quantification of the time course and or clinical features associated 
with impairment of vascular reactivity will permit a fuller understanding of the 
pathophysiology of DR and DME.    
  
1.14 Retinal hemodynamics in patients with diabetes 
Studies investigating change in retinal blood flow in patients with diabetes (relative to that of 





 decreased,294-296 87,297-299 or no change  of retinal blood 




increased,292,293,297,300,301 decreased,302-304 292,298,299 or no change  of retinal blood 
hemodynamics. Patients with proliferative DR have been shown to exhibit increased293 or 
decreased305 retinal blood hemodynamics. 
 
Progression of retinopathy has also been investigated. One study detailed increased blood 
flow in patients progressing from mild-to-moderate non-proliferative DR to severe DR,306 
whilst another study found a bimodal relationship between retinopathy status and blood flow 
i.e. initially decreasing flow followed by increasing flow as retinopathy progressed.296,307
 
The disparity of the results in the studies described above may be partly attributable to 
different techniques used to measure retinal hemodynamics, patients with differing 
morphological and / or glycemic characteristics and the utilization of different retinal 
locations and vessels.  
 
1.15 Vascular reactivity in diabetes 
1.15.1 Physiological vascular reactivity provocation 
Vascular reactivity is “the ability of a tissue to regulate its blood flow according to its 
metabolic needs”. Administration of oxygen (O2) and glucose have previously been used to 
provoke retinal vascular reactivity. Retinal blood flow varies inversely with the partial 




level. Most previously published retinal vascular reactivity studies have employed gas 
delivery systems that utilize a reservoir bag and one-way valves to essentially negate the 
mixing of inspired and expired gases i.e. a non-rebreathing system. Hyperoxia typically 
stimulates hyperventilation (faster or deeper respiration) that results in an uncontrolled and 
variable reduction of the partial pressure of arterial carbon dioxide (PCO2).308,309 Any 
reduction of PCO2 will produce an exaggerated vasoconstrictive effect on retinal vasculature. 
A number of authors310-314 have attempted to correct for the reduction in PCO2 during 
hyperoxia by manually adding CO2 to the inspired gases of the non-rebreathing system. 
Impairment of retinal vascular reactivity to hyperoxia in DR has been demonstrated 
previously.139,315-317  
 
Published studies investigating the retinal vascular response to hyperglycemia are conflicting. 
Some authors have reported increased retinal blood flow,91,294,304,318 while others report no 
change in retinal blood flow319,320 in response to elevated blood glucose. 
 
The disparity of the results may be partly attributable to different techniques used to measure 
retinal hemodynamics, patients with differing morphological and / or glycemic characteristics 
and the utilization of different retinal locations and vessels as well as the use of non-
standardized hyperoxia and glucose stimuli.  
 
1.16 Conclusion 
The blood supply to the eye is well documented. The retina is anatomically and functionally 
unique. Retinal blood flow is believed to be efficiently autoregulated and endothelial derived 
vasoactive factors are important determinants of retinal blood flow. Blood in the retinal 
vessels exhibits laminar flow.  
 
Many instruments quantify aspects of retinal hemodynamics. Previously published studies are 
conflicting regarding the influence of diabetes and on retinal blood flow. The Canon Laser 
Blood Flowmeter permits the non-invasive quantification of retinal blood flow in real units 
and presents a novel opportunity to quantify retinal hemodynamic alterations induced by 
diabetes. In addition, the time course between the development of clinically visible DR and 
alteration of retinal hemodynamics remains to be elucidated. Previously published studies that 
have assessed vascular reactivity have not used a standardized hyperoxic stimulus.   
 
Hyperglycemia initiates the biochemical and morphological alterations observed in DR. Strict 
control of blood glucose levels may delay the development of DR. Retinal perfusion 
abnormalities may precede the morphological changes in DR. The influence of short-term 
glycemic control has yet to be determined.  
 







the quantification of DME have been developed that allow earlier detection and more precise 
localization of DME. The assessment of retinal hemodynamics in individuals with DME may 
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Disturbance of retinal hemodynamics is a surrogate marker of early diabetic retinopathy (DR). 
Previously published studies are conflicting in terms of the reported change of blood flow 
attributable to early diabetes. The apparent disparity of these results may be partly attributable 
to the different techniques used to measure retinal hemodynamics, the inclusion of patients 
with differing morphological and varying glycemic control characteristics and the use of 
differing sites to measure blood flow. Many studies have measured either change in diameter 
or velocity but have been unable to quantify change in flow. Assessment of retinal vascular 
reactivity (i.e. the vascular response to a given stimulus) has previously been investigated 
using a variety of instruments and stimuli in patients with diabetes. Previously published 
studies that have employed an inspired oxygen stimulus in human subjects were unable to 
maintain homeostatic concentrations of carbon dioxide (CO2) during hyperoxia. Maintenance 
of baseline concentrations of CO2 is termed isocapnia. Alteration of CO2 alters vascular tone 
and has a profound impact on retinal blood flow.  
 
The global aim of this work was to assess retinal vascular reactivity in healthy volunteers and 
groups of patients with diabetes with mild-moderate DR using standardized blood flow 
assessment and a standardized hyperoxic stimulus. The Canon Laser Blood Flowmeter 
(CLBF-100) was employed to assess retinal arteriolar hemodynamics. It allows the 
simultaneous quantification of vessel diameter and centre-line blood velocity to calculate 




measurement site was employed to acquire blood flow measurements. Furthermore, a unique 
isocapnic hyperoxic stimulus for the assessment of vascular reactivity was developed. The 
combination of a standardized blood flow assessment technique and a standardized stimulus 
to provoke change in retinal hemodynamics, when applied to carefully defined volunteer 
groups, was anticipated to reveal greater understanding of the physiology of blood flow 
regulation and its disturbance in DR.  
 
The first aim of this thesis was to detail three different techniques to administer hyperoxia and 
compare between them in terms of their ability to maintain isocapnia during hyperoxia. The 
techniques included administration of O2 only using a non-rebreathing system, the 
administration of O2 with added CO2 using a non-rebreathing system (with CO2 flow 
continually adjusted) and the administration of O2 using a sequential rebreathing system (with 
O2 flow set equal to the subjects’ minute ventilation). (Chapter 3) The hypothesis was that the 
sequential rebreathing system would be superior to the other systems and would result in 
smaller variation of systemic carbon dioxide levels. In addition, a perturbation of PETCO2 
(concentration of CO2 in the expired breath) was used to determine the influence of change of 
PETCO2 on retinal hemodynamics.  
 
Having developed a standardized isocapnic hyperoxic stimulus, the second aim of the thesis 
was to define the magnitude of change and response characteristics of retinal hemodynamics 




measurements were acquired every minute over the course of the study using the CLBF-100 
while each subject breathed air, followed by isocapnic hyperoxia, and finally air again. The 
magnitude of change in flow and the recovery to baseline values was characterized for each 
individual. Change in diameter and velocity relative to the onset of the stimulus and to each 
other was determined for each individual to allow investigation of the retinal physiological 
response to oxygen. (Chapter 4) The hypothesis was that administration of hyperoxia via the 
sequential rebreathing system would produce a pronounced reduction of blood flow that 
would return to baseline values after the stimulus was removed. 
 
The third aim of the thesis was to detail the magnitude of change in retinal hemodynamics to 
isocapnic hyperoxia in a group of diabetic patients with mild-to-moderate DR stratified by 
their retinopathy status and in age matched subjects without diabetes. Isocapnic hyperoxia 
was administered using the sequential rebreathing technique that was validated in previous 
experiments. Retinal hemodynamic measurements were acquired during air breathing and 
during isocapnic hyperoxia using the CLBF-100. The magnitude of change in arteriolar 
diameter, blood velocity, blood flow, maximum-to-minimum velocity ratio and wall shear 
rate was calculated and compared between the groups. Analysis of the differences in 
responses of the groups will provide insight into the pathophysiology of early DR (Chapter 5). 
The hypothesis was that the magnitude of the vascular reactivity would be impaired in those 





Previously published studies that have employed a glucose stimulus show conflicting results 
in terms of its impact upon retinal hemodynamics. The fourth aim of the thesis was to detail 
the change in retinal hemodynamics to a standardized oral glucose load drink in a group of 
diabetic patients with mild-to-moderate DR stratified by their retinopathy status and in age 
matched subjects without diabetes. The stimulus employed was the same as that used to 
determine oral glucose tolerance in those who may have symptoms of diabetes or fasting 
blood glucose levels outside the normal range. Retinal hemodynamic measurements were 
acquired using the CLBF-100 prior to, and 1 hour after glucose drink ingestion. The 
magnitude of change in arteriolar diameter, blood velocity, blood flow, maximum-to-
minimum velocity ratio and WSR was calculated and compared between the groups. 
Alteration of blood hemodynamics during acute hyperglycemia would necessitate the 
determination of blood glucose levels prior to assessment of retinal hemodynamics (Chapter 
6). The hypothesis was that hyperglycemia would result in an increase of retinal blood. 
 
Previously published studies that have employed a combined hyperglycemic / hyperoxic 
provocation also show conflicting results. The fifth aim of the thesis was to detail the change 
in retinal hemodynamics to a combined hyperglycemic / hyperoxic provocation in a group of 
diabetic patients with mild-to-moderate DR stratified by their retinopathy status and age 
matched subjects without diabetes. The stimuli employed were identical to that developed in 
previous chapters. Retinal hemodynamic measurements were acquired using the CLBF-100 




blood velocity, blood flow, maximum-to-minimum velocity ratio and WSR was calculated 
and compared between the groups. Alteration of the vascular reactivity response to isocapnic 
hyperoxia during acute hyperglycemia would necessitate the determination of blood glucose 
levels prior to assessment of retinal vascular reactivity using isocapnic hyperoxia (Chapter 7). 




3 Comparison of different hyperoxic paradigms to induce 
vasoconstriction - Implications for the investigation of retinal 
vascular reactivity 
 
Gilmore ED, Hudson C, Venkataraman ST, et al. Comparison of different hyperoxic 
paradigms to induce vasoconstriction: implications for the investigation of retinal vascular 
reactivity. Investigative ophthalmology & visual science 2004;45(9):3207-3212. 
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3.1 Abstract 
Purpose: To compare 3 different techniques used to induce hyperoxia. The impact of each 
technique on end-tidal CO  (PETCO ) was assessed since change in PETCO2 2 2 will confound the 
interpretation of the vascular response to manipulation of the partial pressure of O  (PETO ). 2 2
Methods: The sample comprised 9 subjects (mean age 25 years; range 21-49 yrs). Each 
subject attended for 3 sessions. At each session, subjects initially breathed air followed by O2 
only, or O  plus CO using a non-rebreathing circuit (with CO2 2 2 flow continually adjusted to 
negate “drift” of PETCO ), or air followed by O2 2 using a sequential re-breathing circuit (with 




2 2 and CO2 concentrations in the 
inspired and expired breath were compared across the different techniques.  
Results: The difference in group mean PETCO  values between baseline and elevated O2 2 
breathing was significantly different (t-test, p=0.0038) for O2 only administration using a non-
rebreathing system but not for the other two techniques. The sequential rebreathing technique 
resulted in a significantly lower difference (i.e. pre- and during hyperoxia) of individual 
PETCO  values (t-test, p=0.0317) than either of the other two techniques. 2
Conclusion: The sequential rebreathing technique resulted in a reduced variability of PETCO2 
values compared to the two techniques using a non-rebreathing system. In turn, the sequential 
rebreathing technique should result in reduced variability of retinal blood flow values and 
thereby reduce the required sample size of blood flow studies.  






Administration of oxygen (O2) has previously been used as a stimulus to provoke retinal 
vascular reactivity. Vasoconstriction of retinal vessels1,2 and the resulting reduction of retinal 
blood flow3-16 has been demonstrated using a variety of measurement techniques, including 
laser Doppler and blue-field entoptic phenomena. Retinal blood flow varies inversely with the 
partial pressure of arterial oxygen (PO2) to maintain retinal oxygenation at a relatively 
constant level16; however, retinal blood flow also varies directly with the partial pressure of 
arterial carbon dioxide (PCO2).12 The change of end-tidal CO2 concentration (PETCO2; the 
maximum concentration of CO2 during each expiration) reflects the change in arterial PCO2.17  
Indeed, CO2 is thought to represent a more potent vasoactive agent than O2.7 Change of retinal 
perfusion, measured using laser Doppler blood flow techniques, induced by perturbation of O2 
or CO2 can be used to provide a measure of the magnitude of retinal vascular reactivity. 
 
All previously published retinal vascular reactivity studies have employed gas delivery 
systems that utilize a reservoir bag and one-way valves to essentially negate the mixing of 
inspired and expired gases i.e. a non-rebreathing system. Hyperoxia typically stimulates 
hyperventilation (faster or deeper respiration), however, this results in an uncontrolled and 
variable reduction of PCO2.18,19 Any reduction of PCO2 will produce an exaggerated 
vasoconstrictive effect on retinal vasculature. The vasoconstrictive effect previously attributed 
to O2 when administered by non-rebreathing circuits likely represents the combined effect of 
elevated PO2 and reduced PCO2. Harris et al.,16,20,21 Roff et al.14 and Chung et al.15 have 
recognized this potential artifact and have attempted to correct for the reduction in PCO2 
during hyperoxia by adding CO  to the inspired gases of the non-rebreathing system.14-16,20,212  
The maintenance of homeostatic PCO2 is termed “isocapnia”. Another method to prevent 
reduction of PCO2 involves the use of a sequential rebreathing circuit that provides a feedback 
loop to compensate any hyperventilation induced reduction in PCO .222  This system has the 
advantage that it passively adjusts the inspired CO2 to the minute ventilation in order to 
stabilize PCO . 2
 
The magnitude of change and the variability of PETCO2 need to be quantified and compared 
across the various techniques used to induce hyperoxia. Three different techniques were 
compared i.e. administration of O  only using a non-rebreathing system, O  with added CO2 2 2 
using a non-rebreathing system (with CO2 flow continually adjusted to negate “drift” of 
PETCO ) and O  using a sequential rebreathing system (with O2 2 2 flow set equal to the subjects’ 
minute ventilation). In addition, the relationship between change in PETCO2 and retinal blood 
flow was assessed to determine the clinical research relevance of this parameter. 
 
3.3 Materials and Methods  
3.3.1 Sample 
The study received approval by the University of Waterloo Office of Research Ethics. 




consequences of the study according to the tenets of the Declaration of Helsinki. The sample 
comprised 4 males and 6 females of average age 25 years (range 21-49 years). In order to 
determine the relationship between PETCO2 and retinal blood flow, a second sample of 6 
males and 2 females of average age 26.5 years (range 24-36 years) was subsequently 




Each subject attended for 3 sessions of approximately 30 minutes each. The group mean 
number of days between each of the 3 sessions was 11 days. At each session, subjects initially 
breathed air followed by O  only or O  plus CO2 2 2 using a non-rebreathing system, or 
compressed air followed by O2 using a sequential rebreathing system. Each gas condition (air 
or O2) was administered for 15 minutes. The non-rebreathing system comprised a silicone 
mouthpiece and two low resistance one-way valves (Figure 3.1) connected to the gas supply 
via a reservoir bag. The sequential rebreathing system comprised fresh gas and rebreathed gas 
reservoirs that were interconnected by two one-way valves and a single peep valve (Figure 
3.2). It was assembled by adding a gas reservoir to the expiratory port of a commercial 3-
valve oxygen delivery system (Hi-Ox80, ViasysHealthcare, Loma Linda, CA). For the purpose 
of this study, a silicone mouthpiece was attached to the sequential rebreathing system that, in 
turn, was connected to the gas supply. For both systems, flow from the gas tanks was 




container prior to being administered to the subject via the non-rebreathing circuit. 
 





Figure 3.2   Schematic diagram showing the components of the sequential rebreathing system 
 
Each subject was seated for 5 minutes prior to commencing the study. For every situation, an 
initial air breathing period was employed to allow stabilization of baseline breathing 
parameters e.g. respiration rate. For the O  plus CO2 2 using a non-rebreathing system (Figure 
3.1), CO  flow was continually adjusted to negate “drift” of PETCO . For the O2 2 2 using a 
sequential rebreathing system (Figure 3.2), O2 flow was set equal to the subjects’ minute 





In order to determine the impact, if any, of perturbation of PETCO2 on retinal blood flow, the 
sequential rebreathing system was utilized to manipulate PETCO2 while quantifying retinal 
blood flow with the CLBF. A steady state perturbation of PETCO2 was produced since the 
time between PETCO2 fluctuation and its impact upon retinal hemodynamics is unknown and 
since the CLBF does not provide a continuous measurement of retinal blood flow. A 
methodology that initially raised PETCO2 values and then returned to homeostatic levels was 
employed. Following stabilization of cardiovascular and respiratory parameters, air flow 
delivered to the subject via the sequential rebreathing system was reduced to elevate PETCO2 
by approximately 5mmHg (i.e. volunteers were compelled to rebreath). At this point in time, a 
minimum of 10 CLBF readings was acquired. Air flow was subsequently returned to baseline 
levels and a further 6 CLBF readings were acquired.  
 
3.3.3 Data acquisition and analysis
Tidal gas concentrations were continuously sampled from the mouthpiece using a rapid 
response critical care gas analyzer (Cardiocap 5, Datex-Ohmeda, USA). In addition, 
hemoglobin oxygen saturation via pulse oximetry, respiratory and pulse rate were also 
continually recorded. All data outputs were downloaded to an electronic data acquisition 
system (S5 Collect, Datex-Ohmeda, USA). Data was analyzed using box plots that depicted 
the median, upper 25th and lower 75th percentiles, SD and outliers of inspired- and end-tidal 
gas concentrations. Data points lying outside the upper 25th or lower 75th percentiles were 







points resulted from inappropriate interpretation of tidal waveforms by the gas monitor.  
 
Group mean inspired and expired O2 (FIO2 and PETO2, respectively), inspired and expired 
CO2 (FICO2 and PETCO2, respectively) and respiration rates (RR) as a function of delivery 
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Table 3.1: Group mean and SD of inspired O2, expired O2, Inspired CO2, end-tidal CO2, and heart rate as a function of technique. 
(SD - standard deviation; SRB - sequential rebreathing). 
 
3.4 Results 
The group mean difference of PETCO  (and SD) between baseline and elevated O2 2 breathing 
for each of the three techniques is shown in Table 3.2. Figure 3.3 shows PETCO2 for each 






ET CO2 (%) Pure O O  + CO SRB 2 2 2
Group Mean Difference (O -Air) -0.21 -0.06 -0.06 2
Group Mean SD 0.24 0.17 0.08 
 
Table 3.2: Group mean difference in PETCO2 between baseline and oxygen breathing using 3 different techniques  
(SRB – sequential rebreathing; SD – standard deviation). 
 
 breathing only using a non-rebreathing system, group mean PETCOFor O2 2 reduced from 
5.32% (SD 0.18) at baseline to 5.06% (SD 0.18) during hyperoxia (Figure 3.3a). For O2 with 
added CO  using a non-rebreathing system, group mean PETCO2 2 was 5.34% (SD 0.16) at 
baseline and 5.29% (SD 0.17) during hyperoxia (Figure 3.3b). For a sequential rebreathing 
system, group mean PETCO2 was 5.13% (SD 0.15) at baseline and 5.07% (SD 0.13) during 






















































2 for each individual using (A) pure O2 delivered by a non-rebreathing system, (B) O2 




The difference in group mean PETCO2 values between baseline and hyperoxia was 
significantly different for O2 only and a non-rebreathing system (t-test, p=0.0038) but not for 
the other two techniques.  
 
The sequential rebreathing technique resulted in a significantly lower difference (i.e. a smaller 
difference between baseline and during hyperoxia) of individual PETCO2 values (as reflected 
in the SD values, Table 3.2) than either of the other two techniques (t-test, p=0.0008 and 
p=0.0317 for O2 only and O2 with added CO2, respectively). 
 
The group mean difference in blood flow between the elevated (group mean 5.69%, SD 0.44) 
and homeostatic (group mean 5.03%, SD 0.59) PETCO2 conditions was 0.66%, SD 0.21 i.e. a 
5.00mmHg (SD 1.58mmHg) change. This perturbation of PETCO2 resulted in a significant 
reduction (i.e. in response to a lowering of PETCO2) in retinal arteriolar diameter, blood 
velocity and blood flow of 6.18 μm (p<0.0050), 6.68 mm/sec (p=0.0005), and 3.04 uL/min 
(p<0.0005), respectively (Figure 3.4). 
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Figure 3.5   Change in retinal blood flow (as measured by the Canon Laser Blood Flowmeter, CLBF-100) 
induced by O2 delivered using the sequential rebreathing circuit.  
Oxygen was administered at 5 minutes. The data has been fit with a sigmoid type function; equation y=(((v1-
v2)/(1+euler^(x-v3)/(v4)))+v2) where v1 and v2 are the upper and lower asymptotes, v3 and v4 localize the 




2 Air = 5.00%; PetCO2 O2 = 
4.88%. FiO2  Air = 20.31% ; FiO2 O2 = 93.88%. 
 
3.5 Discussion 
Elevating PO  by simply raising the FIO  without taking any measures to control PCO2 2 2 
resulted in a significant reduction from baseline in mean PETCO2. This group mean reduction 
could be ameliorated using the co-administration of O  and CO2 2 or the sequential rebreathing 
technique. Of the latter two methods, the sequential rebreathing technique had a significantly 
smaller variability of individual PETCO  measurements.  2
   
Non-rebreathing techniques involve the administration of gas using a reservoir bag via a one-
way “demand” valve i.e. a valve that opens at the onset of each inspiration. Expired gas leaves 
the system via a second one-way valve. Riva et al.4 were the first to describe retinal vascular 
effects using 100% O2 and laser Doppler velocimetry. In terms of vision science based 
studies, Harris et al.16,20,21 were the first to consider the potential confounding factor of change 
in PETCO  during hyperoxia by co-administering O  and CO2 2 2 using a non-rebreathing system. 
Roff et al.14 and Chung et al.15 also employed this technique in their ocular blood flow studies. 
Interestingly, these studies have not reported the magnitude of individual variability of 
PETCO . This study demonstrates that the maintenance of homeostatic PETCO2 2 levels using 
non-rebreathing techniques apply to groups as a whole, but are less reliable for individual 
subjects.   
 







arteriolar diameter, blood velocity and blood flow) has been demonstrated. The group mean 
change of PETCO2 of 0.66% produced a group mean 27% change in retinal blood flow i.e. a 
2mmHg “drift” of PETCO2, that invariably occurs using non-rebreathing techniques, results in 
a 10 to 12% artifactual change in blood flow. This emphasizes the importance of using 
breathing circuits that facilitate control of PETCO2 measurements during administration of 
elevated O2.  
 
An alternative method of preventing reduction of PETCO2 with increases in ventilation (as 
induced by exposing subjects to O2) is to increase the dead space of the circuit so that 
rebreathing occurs. Adding circuit dead space may not limit the reduction of PETCO2 with 
hyperventilation as spontaneously breathing subjects (as opposed to those being mechanically 
ventilated) will overcome the effects of rebreathing by increasing respiratory volume. The 
sequential rebreathing method developed by Sommer et al.22 and by Banzett et al.23 utilized in 
this study, passively matches the inhaled CO2 to increases in minute ventilation thereby 
preventing the expected reduction in PCO2 (Figure 3.2).  The sequential rebreathing technique 
is effective irrespective of the pattern of breathing. Compared to a non-rebreathing system and 
adding CO2 to inspired gas, this system has the advantage of avoiding the risk of raising 
PETCO2 and consequently eliciting subject discomfort. The flow of fresh gas (air or O2, not 
containing CO2) is set to just match the patient’s minute ventilation during resting conditions 
while breathing air. This flow is identified by observing that the fresh gas reservoir just 




reservoir bag and is available for re-breathing on the next inspiration. As the flow of the fresh 
gas is fixed, any increases in ventilation will proportionally increase the volume of previously 
exhaled gas that is rebreathed. Only the fresh gas (O2 in this case) contributes to the 
elimination of CO2. As the flow of fresh gas is equal between air and O2, the rate of 
elimination of CO2 is constant across the two conditions. The constant PETCO2 also maintains 
the subjects breathing comfort. Figure 3.5 shows a typical example of the change in retinal 
blood flow (i.e. the magnitude of retinal vascular reactivity) as measured by the Canon Laser 
Blood Flowmeter, CLBF-100, induced by O2 delivery via the sequential rebreathing circuit. 
The CLBF-100 has been described in detail elsewhere.24 
 
Impaired vascular reactivity has been implicated in the pathogenesis of diabetic retinopathy 
and glaucoma.6,16,20,21,25-28 Hyperoxia has been frequently used to provoke vascular reactivity. 
A recent study has shown that endothelin-1 plays a major role in hyperoxia-induced 
vasoconstriction in humans.29 Other factors that may be responsible for regulating vascular 
tone in the retina include the endothelins,30-36 nitric oxide,37 prostacyclins38 and angiotensin.39 
Regulation of blood flow is necessary to maintain structure and function of tissue. This is 
achieved using systemic controls (nervous influences) and / or local factors (metabolic or 
myogenic). The vascular response to metabolic factors, sometimes loosely described as 
autoregulation, stabilizes local blood flow by making the necessary adjustments to ensure a 





In this study, the group mean reduction of PETCO2 was ameliorated by the co-administration 
of O2 and a small amount of CO2 using the non-rebreathing system. CO2 is a potent vasoactive 
agent. Retinal blood flow varies directly with the arterial PCO2, as reflected in the PETCO2. 
However, with this method there were significant intra-subject variations of PETCO2. In 
addition, individuals responded in different ways and thus it would be more difficult to 
standardize hyperoxia using the co-administration of O2 and CO2. In contrast, the sequential 
rebreathing technique was shown to allow the administration of elevated O2 levels without a 
reduction in PETCO2 and, importantly, reduced variability of PETCO2 measurements when 
compared to the non-rebreathing techniques. Steady state manipulation of PETCO2 
unequivocally demonstrated that relatively modest change in PETCO2 resulted in significant 
change of retinal hemodynamics.  
 
3.6 Conclusion 
Published retinal vascular reactivity studies have employed a non-standardized hyperoxic 
stimulus without control of PETCO2 making the results difficult to interpret. Compounded 
vasoconstrictive effects occur when no control for the reduction of systemic PCO2 levels are 
made. In addition, blood flow measurements taken under these conditions may exhibit 
exaggerated variability due to continuous alterations in PCO . Rigorous control of PETCO2 2 
using a modified commercially available sequential rebreathing circuit will allow the 
establishment of a standardized, reproducible hyperoxic stimulus for the investigation of 
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4.1 Abstract 
Purpose: To simultaneously quantify the magnitude and response characteristics of retinal 
arteriolar diameter and blood velocity induced by an isocapnic hyperoxic provocation in a 
group of clinically normal subjects.  
Methods: The sample comprised 10 subjects (mean age 25 years; range 21-40 yrs). Subjects 
initially breathed air for 5 to 10 minutes followed by oxygen (O2) for 20 minutes, and then air 
for a final 10 minute period using a sequential re-breathing circuit (Hi-OxSR, Viasys). Retinal 
arteriolar diameter and blood velocity measurements were simultaneously acquired with the 
Canon Laser Blood Flowmeter (CLBF-100). The magnitude of the response, the response 
time and response lag of diameter and velocity were calculated.  
Results: In response to hyperoxic provocation, retinal diameter was reduced from control 
values (mean ± SD) of 111.6 ± 13.1μm to 99.8 ± 10.6μm (p<0.001) and recovered after 
withdrawal of hyperoxia. Retinal blood velocity and flow concomitantly reduced from control 
values of 32.2 ± 6.4mm/sec and 9.4 ± 2.5µL/min to 20.7 ± 3.4mm/sec and 5.1 ± 1.3µL/min, 
respectively (p<0.001 for both velocity and flow), and recovered after withdrawal of 
hyperoxia. The response time and response lag were not significantly different for each 
parameter between effect and recovery. The response time and response lag were not 
significantly different between diameter and velocity. 
Conclusions: Arteriolar retinal vascular reactivity to hyperoxic provocation is rapid with a 







was a trend for diameter to respond before velocity to the isocapnic hyperoxic provocation, 
the response characteristics were not significantly different between diameter and velocity.  
 
Keywords: Vascular reactivity, Laser Doppler velocimetry, retinal blood flow.
 
4.2 Introduction 
The blood supply to the inner retina is derived from the central retinal artery while the 
choriocapillaris supplies the outer retina and photoreceptors. The retinal tissue is one of the 
most metabolically active in the body and, as a result, an uninterrupted nutrient supply is 
essential.1 The inner retinal blood vessels (i.e. past the lamina cribrosa) are thought to be 
unique due to the absence of an autonomic nerve supply to regulate vascular tone.2 Blood 
supply to the inner retina is regulated via local feedback signals that alter retinal perfusion in 
response to changes in systemic blood pressure or the concentration of certain metabolites.3,4 
In particular, retinal blood flow is strongly dependent on the partial pressure of oxygen 
(PO ).5-92
 
The retinal vasculature can be non-invasively visualized and, consequently, its hemodynamic 
parameters quantified. Impairment of vascular reactivity has been demonstrated in the 
pathogenesis of various ocular diseases including diabetic retinopathy.6,10-12 Administration of 
O2 has previously been employed as a stimulus to provoke and assess the magnitude of the 
retinal vascular response. Vasoconstriction of retinal vessels13,14 and the resulting reduction of 
retinal hemodynamic parameters has been demonstrated using a variety of measurement 
techniques.5,6,7,8,9,15-24 However, none of these studies have utilized a technique that is capable 





The aim of this study was to quantify the magnitude and response characteristics of retinal 
arteriolar diameter, blood velocity and blood flow induced by a hyperoxic provocation in a 
group of clinically normal subjects. There are two unique aspects to this study. First, we used 
a technique that allows the simultaneous quantification of vessel diameter and centre-line 
blood velocity to calculate retinal blood flow in μL/min. Second, we used a unique system 
validated in our laboratory25,26 to administer isocapnic hyperoxia. This overcomes the 
drawbacks of previous studies due to inadequate control of PCO2 when implementing 
hyperoxia. The precise sequence of hemodynamic events underlying retinal vascular 
reactivity will be elucidated by simultaneously investigating the change in diameter and 
velocity relative to the onset of the stimulus and to each other. 
 
4.3 Materials and Methods 
4.3.1 Sample 
The sample comprised 10 clinically normal subjects (5 male: 5 female; mean age 25 years, 
SD 6 years). Only subjects who were 40 years or younger with no media opacities were 
included i.e. NO<1, NC<1, P <1, C<1 (Lens Opacity Classification System III).27 All subjects 
had a LogMAR visual acuity of 0.00, or better. Subjects were excluded if they exhibited any 
eye disease, any cardiovascular or respiratory disorders, a refractive error greater than ±6.00 
DS or ±2.00 DC, glaucoma or diabetes in a first degree relative, or medications with known 




medications). None of the subjects were smokers. All participants were asked to refrain from 
caffeine-containing drinks or snacks for at least 12 hours prior to their study visit. The study 
was approved by the University of Waterloo Office of Research Ethics and the University 
Health Network Research Ethics Board, Toronto. Informed consent was obtained from each 
subject after explanation of the nature and possible consequences of the study according to the 
tenets of the Declaration of Helsinki.  
 
4.3.2 Gas Delivery System 
The sequential rebreathing system comprised a fresh gas reservoir and an expiratory gas 
reservoir, each connected to the patient by one-way valves. The inspiratory and expiratory 
limbs were interconnected by a single PEEP valve, allowing exhaled gas to be rebreathed 
when the gas in the inspiratory limb was depleted. This system was assembled by adding a 
gas reservoir to the expiratory port of a commercial 3-valve oxygen delivery system (Hi-
OxSR, ViasysHealthcare, Yorba Linda, CA). Flow from the gas tanks was controlled using 
standard rotometers as flowmeters. This method has been described in detail in previous 
publications.25,26  
 
4.3.3 Canon Laser Blood Flowmeter
The principal underlying the CLBF-100 is based on the Doppler effect. Laser light 







to the velocity of the moving particle. A vessel that exhibits Poiseuille flow will have a range 
of velocities and thus a range of frequency shifts up to a maximum frequency shift (Δfmax) that 
corresponds to the maximum velocity of the blood moving at the centre of the vessel (since 
resistance is developed at the vessel wall). Light scattered from stationary tissue is unshifted 
and acts as the reference frequency from which a relative change in retinal blood velocity is 
measured.28 By utilizing two photomultipliers separated by a known angle, the maximum 
frequency shift is subtracted to allow the absolute quantification of centre-line blood velocity 
irrespective of the angle between the moving particle and reflected beam.29,30 A red diode 
laser (675nm, 80μm x 50μm oval) is used to measure velocity every 0.02 seconds across a 2 
second measurement window resulting in a velocity-time trace. The CLBF-100 also uses a 
green diode vessel tracking laser system (543nm, 1500μm x 150μm rectangle) that is used to 
stabilize, and measure the diameter of the vessel of interest.31,32 The vessel tracking system 
stabilizes measurement site position and allows rejection of velocity measurements involving 
significant saccades. Diameter readings are acquired every 4 milliseconds during the first and 
final 60 milliseconds of the 2 second velocity measurement window. Two sequential 
measurements utilizing different optical paths (path 1 and path 2) are taken to ensure 
consistency and averaged to give one reading. In combination with the average velocity 
(Vmean) over a pulse cycle and diameter (D), flow through the vessel can be calculated from 
1/2.π.D2/4.Vmean.60 (for technical summary see Kida and co-workers33). Magnification effects 
associated with refractive and axial components of ametropia are corrected to provide 
absolute measurements of diameter (μm), velocity (mm/sec) and flow (μL/min). The 
technological principles utilized in this device have been described in detail 
elsewhere.29,30,33,34 In addition this device has been extensively evaluated in clinically normal 
subjects35,36 and those with various types of retinal pathologies.33,37  
 
4.3.4 Procedures 
Each subject was seated for at least 5 minutes prior to commencing measurements to allow 
stabilization of heart rate and blood pressure. An initial air breathing period was employed to 
allow stabilization of baseline parameters e.g. respiration rate, PO2 and PCO2. Retinal 
arteriolar diameter and centreline blood velocity measurements were simultaneously acquired 
from either the supero- or infero-temporal arteriole in one eye of each subject using the 
CLBF-100. A minimum of 5 baseline measurements were acquired while the subject breathed 
air (5 to 10 minutes). The isocapnic hyperoxic stimulus was then initiated and maintained for 
20 minutes. Subsequently, air was re-administered for a further 10 minutes maintaining 
isocapnia to baseline levels. Retinal blood flow measurements were acquired every minute 
over the course of the study (Figure 4.1).  
 
4.3.5 Gas analysis and systemic responses
A rapid response critical care gas analyzer (Cardiocap 5, Datex-Ohmeda, USA) was used to 
quantify the relative concentrations of O and CO2 2 in both the inspired and expired gases on a 
breath-by-breath basis. The relative concentrations O  and CO2 2 are sampled continuously by 




downloaded to a personal computer every 5 seconds (S5 Collect software, Datex-Ohmeda, 
USA). In addition, finger-oxygen saturation, respiration rate and pulse rate were also recorded 
continuously. The fractional concentration of oxygen in the expired breath (FeO2) was chosen 
as the parameter that most closely reflects the change in arterial PO2. Gas data was analyzed 
using box plots that depicted the median, upper 25th and lower 75th percentiles, and outliers of 
end-tidal gas concentrations. Data points lying outside the upper 25th or lower 75th percentiles 
were excluded from the analysis since all of these values were found to be erroneous i.e. these 
points resulted from inappropriate interpretation of tidal waveforms by the gas monitor. Blood 
pressure was measured non-invasively once every 3 minutes over the course of the 
experiment (Cardiocap 5, Datex-Ohmeda, USA).  
 





4.3.6 Function fitting 
Arteriolar diameter and velocity data was fit using a double sigmoidal function of the form: 
y = [(t<20)*(((α-β)/(1+η^(t-γ)))+β)] + [(t>20)*(((β-δ)/(1+θ^(t-ε)))+δ)] (4.1) 
where y is the magnitude of the hemodynamic parameter (i.e. diameter, velocity or flow) at a 
certain time, t, from the initial measurement (t=0). An arbitrary time point (t=20, i.e. 
approximately midway through the procedure) was used to divide the data into 2 sections. The 
exponents η and θ were constrained so that the inflexion points of the function could not 
occur before the O  had been turned on (effect phase) or before the O2 2 had been turned off 
(recovery phase), respectively. For t<20, α and β are the upper and lower asymptotes, 
respectively. γ is the value of t that corresponds to a value halfway between α and β i.e. the 
midpoint of the effect phase of the function. For t>20, β is set as the lower asymptote and δ is 
the upper asymptote (independent of α). ε is the value of t that corresponds to a value halfway 
between β and δ i.e. the midpoint of the recovery phase of the function. α, β, γ, δ and ε were 
varied using the “non-linear regression” module in Statistica (Statsoft, Inc.) to produce a least-
squares fit. As a result, the same mathematical model was utilized for all subjects and all 
hemodynamic parameters but the coefficients of the model varied between subjects and 
hemodynamic parameters of a given subject. An example of the function fitting is shown 
(Figure 4.2).  
 







excluded from the analysis. The velocity data from 2 subjects and diameter data from 1 
subject were not included in the analysis due to either a low r-value (less than 0.60) or 
inappropriate fit of the data. The magnitude of the retinal vascular response of diameter and 
velocity was calculated (i.e. α - β for effect phase and δ - β for recovery phase). The time 
interval between the 5th and 95th percentile of the change in diameter and velocity was 
quantified and referred to as the retinal vascular “response time”. The time interval between 
onset (or cessation) of the hyperoxic stimulus and the midpoint of the effect (i.e. γ), or 




There was an abrupt reduction in vessel diameter, blood velocity and blood flow on initiation 
of hyperoxia. All parameters returned to control values when hyperoxia was discontinued 
(Figures 4.3a and b). Group mean retinal arteriolar diameter was 111.6μm (SD=13.1μm; 
range 85-129μm) prior to isocapnic hyperoxic provocation, decreased to 99.8μm 
(SD=10.6μm) during provocation (two-tailed paired t-test p<0.001) and recovered to 109.9μm 
(SD=11.7μm) on removal of the stimulus. Group mean retinal blood velocity was 32.2mm/sec 
(SD=6.4mm/sec; range 22-42mm/sec) prior to provocation, decreased to 20.7mm/sec 
(SD=3.4mm/sec) during provocation (two-tailed paired t-test p<0.001) and recovered to 
33.3mm/sec (SD=5.0mm/sec). Group mean retinal blood flow was 9.4μL/min 
(SD=2.5μL/min; range 5.4-13.4μL/min) prior to provocation, decreased to 5.1μL/min 

























































































Figure 4.2 Change in retinal arteriolar diameter (upper left), blood velocity (upper right) and blood flow (lower 
left) for a single participant induced by isocapnic hyperoxia using the sequential rebreathing circuit (fit with 




The r-values were 0.77, 0.89 and 0.92 for diameter, velocity and flow respectively. The concentration of expired 


























































O  on 2
O  off 2
Figure 4.3a Upper; Group mean magnitude of retinal arteriolar diameter before, during and 
after the isocapnic hyperoxic provocation. Lower; Group mean magnitude of retinal blood 
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Figure 4.3b Upper; Group mean magnitude of retinal blood flow before, during and after the 
isocapnic hyperoxic provocation. Lower; Group mean magnitude of FeO2 before, during and 
after the isocapnic hyperoxic provocation.  
All participants “oxygen on” and “oxygen off” points are coincident. Diameter, velocity and 
flow data have been fit using a sigmoidal function. The time points detailed include (from left 
to right) group mean baseline magnitude, 5% point, midpoint and 95% point (effect function), 
group mean magnitude during hyperoxia, 5% point, midpoint and 95% point (recovery 







The group mean response time of diameter was 2.37 minutes (SD=0.46 minutes) and 2.22 
minutes (SD=0.60 minutes) for the effect (i.e. after initiation of hyperoxia) and recovery (i.e. 
after cessation of hyperoxia) phases, respectively (Figure 4.3). The group mean response time 
of velocity was 2.68 minutes (SD=0.55 minutes) and 2.55 minutes (SD=0.53 minutes) for the 
effect and recovery phases, respectively (Figure 4.3). The group mean response time of flow 
was 2.54 minutes (SD=0.56 minutes) and 2.28 minutes (SD=0.43 minutes) for the effect and 
recovery phases, respectively (Figure 4.3). The response time during the effect phase was not 
significantly different to the response time during the recovery phase for both diameter and 
velocity (two-tailed paired t-test). Also there was no significant difference between the 
response times of diameter versus velocity.  
 
The group mean response lag of diameter was 2.00 minutes (SD=1.07 minutes) and 1.38 
minutes (SD=0.45 minutes) for the effect (i.e. after initiation of hyperoxia) and recovery (i.e. 
after cessation of hyperoxia) phases, respectively. The group mean response lag of velocity 
was 2.60 minutes (SD=1.19 minutes) and 2.29 minutes (SD=0.87 minutes) for the effect and 
recovery phases, respectively. The group mean response lag of flow was 2.44 minutes 
(SD=1.32 minutes) and 2.03 minutes (SD=1.02 minutes) for the effect and recovery phases, 
respectively. The response lag during the effect phase was not significantly different to the 
response lag during the recovery phase for both diameter and velocity (two-tailed paired t-
test). The diameter response lag was not significantly different than the velocity response lag 





A correction factor was calculated since the change in arterial PO2 was not square wave i.e. 
the time from the onset (or cessation) of oxygen until 50% of the observed change in FeO2 
had taken place. The group mean correction factor was 0.50 minutes for effect and 0.49 
minutes for recovery and was not significantly different between effect and recovery. The 
magnitude of the correction factor relates to a group mean response lag of 1.7 minutes for 
diameter and 2.6 minutes for velocity (mean of effect and recovery phases). 
 
The group mean r-value for diameter and velocity of the fitted functions were 0.843 and 
0.700, respectively.  
 
The inspired and end-tidal gas parameters and relevant systemic measures for air, isocapnic 
hyperoxia and air are detailed in Table 4.1. Only heart rate, FiCO2, FiO2 and FeO2 changed 
significantly as a result of the hyperoxic provocation. The group mean mean arterial blood 
pressure (MAP; [(2/3 * diastolic BP) + (1/3 * systolic BP)] was 81.7 mmHg (SD=10.1mmHg) 
prior to hyperoxic provocation, 80.9 mmHg (SD=6.0mmHg) during provocation and 
81.8mmHg (SD=7.9mmHg) after provocation. There was no significant difference in MAP 






  Inspired O2 End-tidal O2 Inspired CO2 End-tidal CO2 Respiration rate Pulse rate Saturation O2
  (%) (%) (%) (%) (breaths/min) (beats/min) in blood (%) 
Air Mean 19.84 15.10 0.62 5.10 17.22 67.30 97.80 
 SD 0.34 0.58 0.31 0.50 1.59 7.81 1.46 
O2 Mean 91.69 86.23 0.90 4.98 17.61 63.99 98.38 
 SD 7.90 3.29 0.57 0.45 2.45 6.48 1.05 
Air Mean 19.88 16.25 0.67 5.00 17.40 68.89 97.72 
 SD 0.43 0.53 0.38 0.46 2.79 8.16 2.11 
 
Table 4.1: Group mean and SD of inspired and end-tidal O2, inspired and end-tidal CO2, respiration rate, pulse rate and saturation of O2 in blood.  




Retinal blood flow varies inversely with the partial pressure of arterial oxygen (PO2) to 
maintain retinal oxygenation at a relatively constant level6,38 and also varies directly with the 
partial pressure of arterial carbon dioxide (PCO ).192  Numerous studies have investigated 
retinal vascular reactivity using a hyperoxic stimulus. Some have investigated change of 
retinal vessel diameter,13,14,17 whilst others have measured change in aspects of 
hemodynamics using a variety of techniques.5,6,9,15,18,23,24 Alternatively, others have measured 
retinal vessel diameter and separately employed a bi-directional laser Doppler system to 
measure centre-line retinal blood velocity in order to calculate flow.7,8,16,19-22 The technique 
utilized in this study measures centre-line retinal blood velocity using a bi-directional 
photodetector and simultaneously acquires retinal vessel diameter measurements for the 
absolute quantification of retinal blood flow. All of these studies have employed 100% O2 or 
co-administered O  (>90%) and CO2 2 (~5%). None have used a truly isocapnic hyperoxic 
stimulus. Administration of enriched O2 concentrations typically results in the reduction of the 
partial pressure of arterial carbon dioxide (PCO ).39 The change of end-tidal CO2 2 
concentration (PETCO ; the maximum concentration of CO2 2 during each expiration) reflects 
the change in arterial PCO .402  The method of gas delivery used in this study minimizes 
alterations in systemic PCO concentration.262  We have previously shown that this delivery 
system results in stabilization of end-tidal CO2 during hyperoxic provocation, thereby 
isolating the retinal vascular reactivity response to oxygen alone.25 Additionally, a recent 
paper has demonstrated separate vasoconstrictive effects of hyperoxia (i.e. O2 mediated) and 




In general, previous studies utilizing 100% O2 to assess retinal vascular reactivity have tended 
to find a greater magnitude of vasoconstriction, that we attribute to a compounded effect of 
elevated arterial O2 and reduced CO .8,16,20,212  Most of these studies have measured vascular 
reactivity in venules possibly because the derived velocity profile is non-pulsatile. Arterioles 
were used in this study since they are thought to be primarily responsible for the vascular 
reactivity response and obey Poiseuille flow principles to a greater extent (given the more 
circular cross section).  
 
Three previously published studies have investigated the time course of the change in 
diameter or velocity using a hyperoxic stimulus (referred to in this paper as “response time” 
and “response lag”).14,16,19 To the best of our knowledge, this is the first time that the response 
characteristics of arteriolar diameter and blood velocity have been simultaneously quantified 
due to hyperoxic provocation. In addition, the characteristics of the effect and recovery phases 
(i.e after onset and cessation of the hyperoxic stimulus respectively) have not been 
investigated concomitantly. The response characteristics of the retinal arterioles reported in 
this study are comparable to those of previous studies. There was a trend for diameter to 
respond before velocity to the hyperoxic stimulus but neither the response time nor the 
response lag was significantly different between diameter and velocity. Although direct 
comparison is difficult due to difference in study design, Nagaoka et al.42 found that retinal 
arteriolar velocity responded approximately 1.3 minutes prior to diameter in response to cold 
pressor provocation. When considered alongside the results reported in this manuscript, 
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different response characteristics of the retinal vasculature to transmural pressure mediated 
autoregulation as opposed to metabolic mediated vascular reactivity are suggested. Overall, 
there is remarkable similarity in retinal arteriolar response times to two totally different 
perturbations (isocapnic hyperoxia arteriolar constriction occurred at 2.4 minutes while cold 
pressor induced constriction occurred at 2.9 minutes) suggesting a common mechanism of 
hemodynamic alteration.    
 
The change in arterial PO2 was not square wave and as a result a correction factor was 
calculated to compensate for this effect. A finite time is required for O2 to reach the retinal 
vasculature due to physiological delay of gas exchange in the lungs and lung-to-eye 
circulation time. The corrected response lag was therefore the measured response lag of 
diameter and velocity reported above less the influence of the “correction factor”. 
Nevertheless the impact of the correction factor does not influence the differential relationship 
between diameter and velocity. 
 
Homeostatic oxygen supply is primarily maintained during hyperoxia by a reduction of vessel 
diameter,38 although the exact governing mechanism has yet to be fully elucidated. 
Microelectrode animal studies indicate that inner retinal PO2 is well regulated during 
hyperoxia.43 Various biochemical factors that may be responsible for retinal hyperoxia-
induced vasoconstriction include endothelin-144-48 and prostanoids.49 In addition other 
mechanisms have been investigated in the cerebral vasculature involving superoxide 





This study is novel in that it utilized an isocapnic hyperoxic stimulus to provoke retinal 
vascular reactivity. Previous studies have been unable to avoid a concomitant reduction in 
PCO2 during hyperoxia. In addition, the measurement technique utilized to assess retinal 
hemodynamics provided the unique ability to simultaneously quantify retinal blood velocity 
and vessel diameter for the absolute quantification of retinal blood flow. Although there was a 
trend for diameter to respond before velocity to the hyperoxic stimulus neither the response 
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Purpose: The aim was to quantify the magnitude of retinal arteriolar vascular reactivity in 
diabetic patients stratified by severity of retinopathy and age-matched controls.  
Methods: The sample comprised 21 non-diabetic controls (Group 1), 19 patients with no 
clinically visible DR (Group 2), 19 patients with mild-to-moderate non-proliferative DR and 
without clinically evident diabetic macular edema (DME) (Group 3) and 17 patients with 
DME (Group 4). Subjects initially breathed air, followed by O2, whilst maintaining isocapnia. 
Retinal arteriolar diameter and blood velocity measurements were simultaneously acquired.  
Results: Change in blood velocity and wall shear rate (WSR) was significantly less in Groups 
3 and 4 (p<0.0001 and p=0.0002, respectively) than that of Groups 1 and 2. Change in blood 
flow was significantly less in Group 4 (p<0.004) than that of Groups 1 and 2. The change in 
max:min ratio was significantly less in Groups 2 and 4 than Group 1 (p=0.001). There was a 
significant relationship between baseline objective edema index values and vascular 
reactivity. 
Conclusion: The magnitude of vascular reactivity in response to isocapnic hyperoxia was 
reduced in those individuals with clinically evident DR relative to subjects without diabetes. 
The differences in vascular reactivity occurred in the absence of any difference in baseline 
hemodynamic values. Vascular reactivity is impaired in early sight-threatening DR and this 
impairment is related to the objectively defined magnitude of retinal edema. 
Keywords: Retinal blood flow, Laser Doppler velocimetry, hyperoxia, diabetic retinopathy, 





The blood supply to the inner retina is derived from the central retinal artery. The inner retinal 
blood vessels are thought to be unique due to the absence of an autonomic nerve supply to 
initiate changes in vascular tone.1 Blood supply to the inner retina is regulated via local 
feedback signals that alter retinal perfusion.2,3 Vasoconstriction of retinal vessels in response 
to hyperoxia,4-6 and the resulting reduction of parameters that reflect flow, has been 
demonstrated using a variety of measurement techniques.4,6-10  
 
Vascular reactivity represents the response of the vasculature to a given stimulus, such as 
hyperoxia.4 Impairment of retinal vascular reactivity to hyperoxia in diabetic retinopathy, as 
reflected by a reduced hemodynamic response, has been demonstrated previously.7,11-13 
However, previous studies are limited because many have not utilized simultaneous diameter 
and velocity measurements, all did not control for systemic variation in arterial CO2 during 
hyperoxic provocation and none have focused on changes associated with the development of 
early sight-threatening diabetic retinopathy. 
 
The aim of this study was to quantify the magnitude of change of retinal arteriolar diameter, 
blood velocity and blood flow induced by an isocapnic hyperoxic provocation in diabetic 
patients clinically stratified by retinopathy status and in age-matched subjects without 
diabetes. In addition, volunteers underwent non-invasive, objective assessment of diabetic 
macular edema (DME) using the Macular Edema Module (MEM) of the Heidelberg Retina 
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Tomograph II.14 There are four unique aspects to this study. First, we used a technique that 
allowed the simultaneous quantification of vessel diameter and centre-line blood velocity to 
calculate volumetric retinal blood flow in micro-liters per minute. Second, we used a unique 
standardized system15 to administer isocapnic hyperoxia. In addition, a larger and clinically 
defined sample was used in this study. Finally, we correlated the retinal hemodynamic 




5.3 Materials and Methods 
5.3.1 Sample 
Using previously published data from our laboratory,4 the vascular reactivity response of 
healthy young subjects in terms of change of retinal blood flow in response to isocapnic 
hyperoxia was found to be 4.3 μL/min and the SD of the difference between baseline and 
recovery was 0.85 μL/min. Assuming a 50% reduction in vascular reactivity response when 
comparing healthy subjects to our most advanced diabetic retinopathy group,13 the difference 
between groups in order to reach statistical significance would need to be 0.72 μL/min  (i.e. 
[50% of 4.3 μL/min] / 3). Therefore, the standardized effect size (difference between means / 
SD) was calculated to be 0.85 and the resulting sample size using an alpha of 0.05 and power 
of 0.9 was 16 per group. The sample comprised 21 non-diabetic, age-matched controls (Group 
1; mean age 49 yrs, SD 10 yrs), 19 patients with no clinically visible DR (Group 2; mean age 
52 yrs, SD 11 yrs), 17 patients with mild-to-moderate non-proliferative DR as defined by the 
ETDRS16 (Group 3; mean age 51 yrs, SD 12 yrs) and 17 patients with diabetic macular edema 
(DME) (Group 4; mean age 55 yrs, SD 8 yrs)(Table 5.1). The diabetic groups were stratified 
for increasing risk for the development of DME (Groups 2 to 4). The number of patients 































1 49  -- -- 7 M:14 F -- 5.7  
(10) (0.9) 
2 52  10  7 8 M: 11 F 0.072  10.5  
(11) (9) (0.014) (4.7) 
3 51  14  12 9 M: 8 F 0.083  7.8  
(12) (10) (0.019) (3.8) 
4 55  13  7 13 M: 4 F 0.084  10.0  
(8) (8) (0.014) (3.8) 
 
Table 5.1: Group mean age, duration of diabetes, number treated with insulin, male to female ratio, A1c and 




Volunteers were allocated into groups according to their retinal status using dilated stereo 
fundus biomicroscopy (by agreement of 2 clinicians). All volunteers were aged between 30 
and 70 years and had a LogMAR VA of 0.3 or better. Volunteers were excluded if they 
exhibited any eye disease (apart from DR for Groups 2, 3 and 4) or had undergone ocular 
surgery, any cardiovascular (except well controlled systemic hypertension) and respiratory 
(except treated asthma) disorders, a refractive error greater than ±6.00 DS or 2.00 DC and 
glaucoma in a first degree relative. None of the volunteers were regular smokers or had 
undergone retinal laser treatment. All volunteers were asked to refrain from caffeine-
containing drinks or snacks for at least 8 hours prior to their study visit. Lens clarity was 
graded using the Lens Opacity Classification System III (LOCS III).17 The study was 
approved by the University Health Network Research Ethics Board, Toronto and the 
University of Waterloo Office Research Ethics. Informed consent was obtained from each 
volunteer after explanation of the nature and possible consequences of the study according to 
the tenets of the Declaration of Helsinki.  
 
5.3.2 Isocapnic hyperoxia delivery system
The isocapnic hyperoxia delivery system comprised a sequential re-breathing circuit made up 
of a fresh gas reservoir, an expiratory gas reservoir and a face-mask (Hi-OxSR, 
ViasysHealthcare, Yorba Linda, CA). The inspiratory and expiratory limbs were 
interconnected by a single positive end-expiratory pressure (PEEP) valve, allowing exhaled 
gas to be re-breathed when the gas in the inspiratory limb was depleted. Flow from gas tanks 
containing air (baseline) or oxygen (hyperoxia) respectively was controlled using standard 
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rotometers as flowmeters. This method has been described in detail in a previous 
publication.15
 
5.3.3 Quantification of retinal vessel diameter, blood velocity and flow 
The principal underlying the quantification of retinal hemodynamics is based on the Doppler 
effect. Laser light (frequency=f) reflected from a moving particle is shifted in frequency (Δf) 
that is proportional to the velocity of the moving red blood cells. A vessel that exhibits 
Poiseuille flow will have a range of velocities and thus a range of frequency shifts up to a 
maximum frequency shift (Δfmax) that corresponds to the maximum velocity of the blood 
moving at the centre of the vessel. By utilizing two photomultipliers separated by a known 
angle, the maximum frequency shift detected by each photomultiplier is subtracted to allow 
the absolute quantification of centre-line blood velocity irrespective of the angle between the 
moving particle and reflected beam.18,19  
  
The Canon Laser Blood Flowmeter (CLBF; Canon, Tokyo, Japan) utilizes a red diode laser 
(675nm, 80µm x 50µm oval) to measure velocity every 0.02 seconds across a 2 second 
measurement window resulting in a velocity-time trace. The CLBF also uses a green diode 
laser system (543nm, 1500µm x 150µm rectangle) that is used to measure vessel diameter and 
maintain centration of the laser at the measurement site.20,21 The vessel tracking system allows 
post-acquisition rejection of velocity measurements impacted by significant saccades. 
Diameter readings are acquired every 4 milliseconds during the first and final 60 milliseconds 
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of the 2 second velocity measurement window. Two sequential measurements utilizing 
different optical paths (path 1 and path 2) are taken to ensure consistency and averaged to 
give one reading. In combination with the average velocity (Vmean) over a pulse cycle and 
diameter (D), flow through the vessel can be calculated using 1/2.π.D2/4.Vmean.60. 
Magnification effects associated with refractive and axial components of ametropia are 
corrected to provide absolute measurements of diameter (μm), velocity (mm/sec) and flow 
(μL/min). The technological principles utilized in this device have been described in detail 
elsewhere.18,19,22,23 In addition, this device has been extensively evaluated in volunteers 
with,23-25 and without,4,26-28 retinal diseases. 
 
5.3.4 Quantitative assessment of retinal edema 
A confocal scanning laser tomograph that sequentially acquires two-dimensional section 
images along the optical axis was employed. The distribution of reflected light intensity along 
the optical axis for a given pixel is described by the z-profile or confocal intensity profile. 
Studies have demonstrated a broadening of the z-profile signal width and a decrease in peak 
reflectance intensity in areas of retinal edema.29 Normalization of the reflectance values 
reduces the variation in intensity between successive scans. The MEM technique of the 
Heidelberg Retina Tomograph II (HRT; Heidelberg Engineering, Heidelberg, Germany) 
determines the z-profile signal width (at half peak height) and peak reflectance intensity.29 






One eye of each subject was randomly assigned to the study if both eyes met study criteria. 
Volunteers attended for 2 visits. Visit 1 was used to establish eligibility and baseline 
characteristics, determine group assignment, undertake objective assessment of DME and to 
familiarize the volunteer with the technique used to quantify retinal hemodynamics. Three 
sets of MEM images centered on the fovea were acquired at visit 1 for each volunteer. Visit 2 
was used to quantify retinal vascular reactivity to isocapnic hyperoxia (detailed in the next 
paragraph). Refraction, LogMAR visual acuity, resting blood pressure and random blood 
glucose level were assessed prior to dilation of the study eye with 1% Tropicamide (Alcon 
Canada Inc). At least five retinal hemodnamic measurements were attempted using the CLBF 
at baseline and then also during isocapnic hyperoxia. Goldmann intraocular pressure 
assessment was undertaken after retinal blood flow measurements had been acquired. Axial 
length was measured by I3 System ABD A-scan ultrasound (I3 Innovative Imaging Inc, 
Sacramento, CA) to correct blood flow measurements for magnification effects due to 
ametropia. The median time interval from initial visit to hyperoxia visit was 8 days.  
 
Volunteers initially breathed air for 10 minutes followed by oxygen (O2) for 10 minutes, using 
a sequential re-breathing circuit (Hi-OxSR) to maintain isocapnia.  An initial air breathing 
period was employed to allow stabilization of baseline parameters e.g. respiration rate, partial 
pressure of arterial oxygen (PO2) and the partial pressure of arterial carbon dioxide (PCO2), as 
indicated by measurements of end-tidal oxygen (P O ) and carbon dioxide (PET 2 ETCO ). Retinal 2
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hemodynamic measurements were simultaneously acquired from an arteriole within 1 disc 
diameter from the optic nerve head using a straight vessel segment in one eye of each 
volunteer. Measurements were acquired during the second 5 minute period of each paradigm 
(i.e. a 5 minute stabilization period was employed during air and oxygen breathing prior to 
acquisition of retinal hemodynamic measurements).  
 
5.3.6 Gas analysis and systemic vascular responses
A rapid response critical care gas analyzer (Cardiocap 5, Datex-Ohmeda, USA) was used to 
quantify the relative concentrations of O and CO2 2 in both the inspired and expired gases on a 
breath-by-breath basis. The relative concentrations of O  and CO2 2 were sampled continuously 
by the gas analyzer and the inspired O , inspired CO , P2 2 ETO and P2 ETCO2 were downloaded to 
a personal computer every 5 seconds (S5 Collect software, Datex-Ohmeda, USA). In addition, 
finger-oxygen saturation, respiration rate and pulse rate were also recorded continuously. 
P thETCO2 was analyzed by calculating the upper 10  and lower 90th percentiles. Data points 
lying outside the upper 10th or lower 90th percentiles were excluded from the analysis since all 
of these values were found to be erroneous i.e. these points resulted from inappropriate 
interpretation of tidal waveforms by the gas monitor. Blood pressure was also measured non-
invasively once every minute over the course of the hyperoxic paradigm (Cardiocap 5, Datex-





A post acquisition analysis of the CLBF velocity waveforms was performed using a 
standardized protocol to remove aberrant waveforms affected by eye movement, tear film 
breakup, or improper tracking of the measurement laser. The maximum number of acceptable 
pulse cycles was used in the data analysis for each measurement (with a minimum of 1 
complete velocity waveform required). In addition, maximum to minimum (max:min) 
velocity ratio was calculated during air breathing and compared to that during oxygen 
breathing for each individual. This ratio reflects vascular compliance, where an elevation of 
max:min ratio indicates increased vascular rigidity (the site of this change can be up-stream 
of, down-stream of, or at the CLBF measurement site). In the physiological situation, 
compliance is expected to reduce and rigidity increase during hyperoxia due to increased 
tonus of the vessel wall. In addition, wall shear rate (WSR= mean velocity * 8 / diameter)30 
was calculated because change is shear stress is believed to alter blood flow and this 
mechanism is thought to be disturbed in diabetes and atherosclerosis.30,31  
 
The normality of each hemodynamic parameter as a function of group and condition was 
confirmed prior to the use of parametric statistics. A normal distribution was confirmed for all 
parameters apart from max:min velocity ratio which was log transformed for statistical 
analysis. The change in each of the hemodynamic parameters in response to provocation 
within each group was determined using paired two-tailed t-tests. Repeated measures 
ANOVA was used to determine any differences between the baseline hemodynamic 
parameters between groups and any difference in the response of the hemodynamic 
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parameters between the groups. The dependant variables were diameter, velocity, blood flow, 
max:min velocity ratio and WSR. The within subject factor was isocapnic hyperoxia and the 
between subject factor was group. The magnitude of change of each of the homodynamic 
parameters was correlated with systemic mean arterial blood pressure, duration of diabetes, 
A1c values and the edema index values within 500μm and 1500μm radii of the fovea. Two-




There were no significant differences between the groups for all primary outcome measures at 
baseline. 
 
Group mean baseline and effect magnitudes of retinal arteriolar diameter, blood velocity, flow, 
max:min velocity ratio and WSR for each group are shown in Table 5.2. The magnitudes of 
change of each of these parameters in response to isocapnic hyperoxia are shown in Figure 
5.1. Retinal arteriolar diameter significantly decreased in response to isocapnic hyperoxia in 
groups 1, 3 and 4 (p<0.005); group 2 exhibited a non-significant trend towards 
vasoconstriction (p=0.090). Retinal blood velocity, flow, and WSR significantly decreased in 
response to isocapnic hyperoxia in all groups (p≤0.0002, p<0.0001 and p≤0.005, 



























34.8  36.4  31.9  32.4  
(8.2) (7.6) (7.0) (7.8) 
Velocity O2 
(mm/sec) 
21.0  23.9  24.7  26.4  
(5.8) (5.7) (6.3) (5.0) 
Flow air 
(μL/min) 
10.2  11.4  9.9  10.4  
(3.5) (2.8) (3.3) (3.2) 
Flow O2 
(μL/min) 
5.8  7.1  7.3  7.6  
(2.3) (2.0) (3.1) (2.5) 
Max:min air 3.1  3.9  4.1  4.1  
(0.8) (1.9) (2.5) (2.2) 
Max:min O 5.1  4.6 5.3  3.8  2
(2.7) (1.9) (3.7) (1.4) 
WSR air (s-1) 1280  1262  1142  1159  
(350) (286) (247) (331) 
WSR O  (s-1) 807 838 911 970 2
(242) (142) (202) (210) 
 
Table 5.2: Group mean diameter, velocity, flow, max:min velocity ratio and WSR during air and oxygen 
breathing as a function of group  






































































































































Figure 5.1 Change in retinal arteriolar diameter (upper left), blood velocity (middle left), blood flow (lower left), 
max:min velocity ratio (upper right), and wall shear rate (middle right) with isocapnic hyperoxia provocation as 
a function of group. For each graph the centre of the box represents the group mean response, the limits of the 
box represent ±1 SE and the whiskers represent ±1 SD standard deviation. Open circles represent outlier values 
and stars represent extreme values. Extreme values are outside the 3 box length range from the upper and lower 
value of the box. Group 1; non-diabetic, age-matched controls. Group 2; patients with no clinically visible DR. 
Group 3; patients with mild-to-moderate non-proliferative DR in the absence of clinically evident DME. Group 
4; patients with diabetic macular edema. 
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Group mean reduction in diameter, velocity and flow shown as percentage change in response 
to isocapnic hyperoxia as function of group are shown in Table 5.3. The magnitude of the 
reduction of blood velocity in response to isocapnic hyperoxia was significantly reduced with 
increasing severity of retinopathy (p<0.0001). The responses of groups 3 and 4 were 
significantly less than that of groups 1 and 2 and the response of group 3 was significantly 
less than that of group 2. The magnitude of the reduction of blood flow was significantly 
reduced with increasing severity of retinopathy (p<0.004). The responses of groups 3 and 4 
were significantly less than that of group 1 and the response of group 3 was significantly less 




Group 1 Group 2 Group 3 Group 4 
Diameter  3.7% (4.8%) 2.5% (5.4%) 3.7% (4.8%) 5.5% (6.4%) 
Velocity  40% (8%) 33% (15%) 22% (13%) 17% (13%) 
Flow  44% (9%) 36% (15%) 28% (14%) 26% (16%) 
 
Table 5.3: Group mean reduction in diameter, velocity and flow in percentage change due to isocapnic hyperoxia 
as function of group.  
 
Considering the patients with diabetes as a whole, the vascular reactivity response in terms of 
change in retinal blood flow in patients treated with insulin was not different from those 
treated without insulin (one tailed t-test; p>0.05). 
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The magnitude of the increase of max:min velocity ratio in response to isocapnic hyperoxia 
was significantly reduced with increasing severity of retinopathy (p<0.001). The response of 
group 1 was significantly greater than that of groups 2 and 4. The magnitude of the decrease 
of WSR in response to isocapnic hyperoxia was significantly reduced with increasing severity 
of retinopathy (p=0.0002). The response of group 1 was significantly greater than that of 
groups 3 and 4 and the response of group 2 was significantly greater than that of group 4.  
 
There was no correlation between the magnitude of change of each of the homodynamic 
parameters and age, systemic mean arterial blood pressure, duration of diabetes and A1c 
values.   
 
Group mean baseline and effect values for relevant respiratory and systemic parameters as a 
function of group are shown in Table 5.4. Fractional inspired oxygen (FiO2) changed 
significantly in each group with isocapnic hyperoxic provocation (p<0.0001; paired two-tailed 
t-test). Expired carbon dioxide (PETCO2) did not change in any group. The group mean mean 
arterial blood pressure (MAP; [(2/3 * diastolic BP) + (1/3 * systolic BP)] was not 
significantly different between baseline and isocapnic hyperoxia for any of the groups. Pulse 




Group 1 Group 2 Group 3 Group 4  
PETCO  air (%) 4.9 4.9 4.8 4.9 2
(0.4) (0.5) (0.5) (0.4) 
PETCO  O  (%) 4.8 4.8 4.7 4.9 2 2
(0.4) (0.4) (0.5) (0.4) 
FiO  air (%) 20.0 20.1 20.1 20.1 2
(0.5) (0.2) (0.3) (0.4) 
FiO  O2 2 (%) 92.9 92.8 91.4 92.1 
(2.9) (2.8) (5.1) (4.2) 
MAP air (mmHg) 90.7 91.5 92.0 102.9 
(10.3) (6.8) (9.8) (8.2) 
MAP O  (mmHg) 92.3 91.9 92.8 105.2 2
(10.4) (7.2) (9.9) (9.1) 
PR air (bpm) 65.3 73.2 74.3 78.8 
(9.2) (11.4) (12.9) (11.0) 
PR O  (bpm) 60.8 60.0 71.9 75.8 2
(8.4) (11.1) (13.0) (11.8) 
 
Table 5.4: Group mean baseline and effect values for fractional expired carbon dioxide (PETCO2), inspired 
oxygen (FiO2), mean arterial blood pressure (MAP) and mean pulse rate (PR) during air and isocapnic hyperoxia 




Group mean edema index values within 500μm and 1500μm radii of the fovea as a function of 
group are shown in Table 5.5. Edema index values were significantly greater for group 4 than 
group 1 for both the 500μm and 1500μm radii circles (p≤0.0005; paired two-tailed t-test). 
Edema index values were significantly greater for group 3 than group 1 for the 1500μm circle 
only (p=0.0005; two-tailed t-test). Group 4 was significantly greater than group 2 for both the 
500μm and 1500μm radius circles (p≤0.0005; two-tailed t-test). There was a significant 
correlation between baseline edema index values within the 500μm radius circle and the 
magnitude of change in velocity in response to isocapnic hyperoxia (r=0.3; p=0.03). Baseline 
edema index values within the 1500μm radius circle also correlated with the magnitude of 







Group 1 Group 2 Group 3 Group 4 
500 μm radius 1.12  1.18  1.34  1.55*†  
(0.28) (0.38) (0.24) (0.36) 
1500 μm radius 1.19  1.19  1.39*  1.48*†  
(0.21) (0.24) (0.20) (0.23) 
 
Table 5.5: Group mean edema index values within 500μm and 1500μm radius of the fovea as a function of group 
(* indicates significantly different from Group 1; † indicates significantly different from Group 2). 
 
Group mean renal function indicators as a function of group are shown in Table 5.6. Group 























1 -- -- --  -- -- 
2 139  4.1  73  43.1  8885  28.0  
(2.0) (0.3) (23) (2.0) (5008) (32.8) 
3 138  4.3  77  40.8*  9132  99.8  
(2.0) (0.6) (36) (2.8) (5918) (112.8) 
4 138  4.2  86  41.4  8388  89.2  
(2.0) (0.4) (23) (2.7) (6902) (104.9) 
 
Table 5.6: Group mean blood sodium, potassium, creatinine and albumin, urine creatinine and urine albumin as a 
function of group  





The present study investigated change in retinal arteriolar diameter, blood velocity, flow, 
max:min velocity ratio and WSR induced by an isocapnic hyperoxic provocation in groups of 
diabetic patients stratified by severity of retinopathy and compared to age-matched subjects 
without diabetes. At baseline, there were no differences in the hemodynamic values between 
the groups. The vascular reactivity response in terms of the reduction of blood flow relative to 
baseline was significant in all groups but the magnitude of the change in flow was 
significantly reduced with increasing severity of retinopathy. DME patients and patients with 
moderate DR without clinically evident DME demonstrated significantly reduced vascular 
reactivity compared to age-matched subjects without diabetes and patients with no clinically 
visible DR. Max:min velocity ratio increased significantly as a result of isocapnic hyperoxia 
in each group except the DME group. The magnitude of change of max:min and WSR was 
significantly less in the DME group compared to that of age-matched subjects without 
diabetes. The correlation between the objective assessment of retinal edema and retinal 
vascular reactivity has not been reported previously. Taken as a whole, these results indicate a 
loss of retinal vascular reactivity in patients with moderate DR without clinically evident 
DME, and in patients with DME. Furthermore, the results indicate an inability to increase 
vessel tonus and reduce shear stress (as indicated by the absence of change in max:min 
velocity ratio and WSR, respectively), in response to isocapnic hyperoxic provocation in 




Retinal blood flow varies inversely with the partial pressure of arterial oxygen (PO2) to 
maintain retinal oxygenation at a relatively constant level6,32 and also varies directly with the 
partial pressure of arterial carbon dioxide (PCO ).332  Oxygen supply to the retina during 
hyperoxia is controlled by either a direct reduction of vessel diameter,32 or by change in WSR 
via an up-stream flow-induced mechanism that initiates a secondary retinal diameter 
response;30 however, the exact mechanism by which retinal vessels respond to changes in PO2 
have yet to be fully elucidated. Hyperoxia stimulates ET-1 release from retinal vascular 
endothelial cells in vitro and is the primary factor modulating retinal vascular reactivity 
induced by hyperoxia,34 35 36 in animals  and humans.   
 
Previously published studies have investigated retinal vascular reactivity using diabetic 
patients and a non-isocapnic hyperoxic stimulus.7,12,13 A reduced magnitude of vascular 
reactivity to hyperoxia relative to subjects without diabetes has been demonstrated in patients 
with a spectrum of diabetic retinopathy severity up to that of proliferative retinopathy. These 
studies have been limited because many have not utilized simultaneous diameter and velocity 
measurements, all did not control for systemic variation in arterial CO2 during hyperoxia and 
none have focused on changes associated with the development of early sight-threatening 
diabetic retinopathy culminating in DME. Most of these studies have measured vascular 
reactivity in venules. We studied the retinal arteriolar response since the arterioles are known 
to be primarily responsible for the regulation of vascular reactivity and more closely obey 




Work form our laboratory37 has assessed homeostatic arteriolar diameter, velocity and flow in 
groups of patients that were very similar to the present study. There were no significant 
differences found in diameter, velocity or flow across the groups, however, there was a 
significant elevation of max:min velocity ratio with increasing risk of development of DME 
reflecting decreased vascular compliance with increasing severity of DR. Considering the 
results of this study, impairment of vascular reactivity would seem to  occur concomitantly 
with the loss of vessel compliance reported by Guan et al.37 Importantly, this study found that 
the vascular reactivity response between the groups was significantly different but the 
baseline hemodynamic parameters were not different. These findings probably resulted from 
the relative differences in sample size between this study and that of Guan et al.37 and an 
increased sensitivity of the vascular reactivity parameters to detect hemodynamic disturbance. 
The present study investigated change in max:min velocity ratio and WSR across groups 
before and during isocapnic hyperoxia. Functional hemodynamic indices such as max:min 
velocity ratio, resistivity index, pulsatility index and WSR have been investigated previously 
using the retinal vasculature.25,37,38 Increased peripheral arterial stiffness (measured in the arm 
and ankle) has been positively correlated with severity of DR.39 Resistivity and pulsatility 
indices were not used in this study because of the extraneous influence of downstream 
impedance.40,41  
 
WSR is a measure of shear stress i.e. shear stress = WSR * viscosity. To the best of our 
knowledge, this study is the first to detail WSR in groups of diabetic patients and age-
matched subjects without diabetes, and the change of WSR in response to isocapnic 
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hyperoxia. A short-term increase in WSR using a hypoxic stimulus in cats has previously 
been demonstrated.30 Our work agrees with Nagoaka et al.30 by demonstrating a decrease in 
WSR during a hyperoxic stimulus in all groups except those with DME. Our results show that 
patients with DME are unable to regulate WSR in response to isocapnic hyperoxic 
provocation. It has previously been shown that increased shear stress results in increased 
hydraulic conductivity across the vessel wall42 and the propensity for edema formation.   
   
MEM allows the objective assessment of retinal edema and has previously been shown to 
have a high sensitivity and good specificity for detection of DME.14,43 No previous 
publications investigating change in vascular reactivity in DR have used objective techniques 
for the assessment of retinal edema. In addition, the method used to deliver isocapnic 
hyperoxia in this study has previously been shown to reduce variability of end-tidal CO2 
measurements.15 The correlation between the magnitude of the vascular reactivity response 
and the edema index suggests a continuum of edema formation and impairment of vascular 
reactivity with increasing severity of DR. 
  
The reason for impairment of vascular reactivity in patients with diabetes is uncertain but may 
include structural alterations to the smooth muscle cells (SMCs) or pericytes and functional 
alterations of the endothelial cells.44,45 The endothelium determines, in part, the regulation of 
retinal blood flow. This is achieved principally via ET-1 and nitric oxide. ET-1 is upregulated 
in diabetes,46 however the sensitivity and / or response to ET-1 is impaired in diabetes.47,48 
ET-1 upregulation results in increased media-to-lumen ratio, matrix accumulation and 
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vascular remodeling.46 These influences may be important in the altered vascular 
responsiveness to endothelin-1 noted by some authors.49,50 Nitric oxide (NO) also plays an 
important role in regulation of retinal blood flow.51 NO bioactivity is reduced in diabetes due 
to decreased production, or inactivation,52 resulting in increased arterial stiffness due to 
alteration of the collagen / elastin ratio of the vessel wall.53 Taken as a whole, these vascular 
remodeling changes will result in reduced compliance and vascular reactivity. Alternatively, 
the method of control of blood glucose may impact the vascular reactivity response since 
insulin is known to have vasoactive properties.54 However, the vascular reactivity response in 
terms of change in retinal blood flow in patients treated with insulin was not different from 
those treated without insulin. 
 
In diabetes, SMCs undergo abnormal growth, proliferation and migration55 thereby preventing 
normal function. In addition, pericytes are capable of responding to changes in oxygen 
concentration56 and can regulate endothelin-1 and iNOS release from endothelial cells.57 As 
pericytes are progressively reduced in number during DR, impairment of vascular reactivity 
may be due, in part, to loss of pericytes. 
 
We hypothesize that increasing arterial stiffness and a reduced vascular reactivity response 
are important in the development of retinal edema. Retinal arterioles are the resistance vessels 
of the retina and control downstream hydrostatic pressure.58 An absence of an effective 
vascular reactivity control mechanism will result in increased hydrostatic pressure at the level 
of the capillary bed. According to Starling’s law, increased hydrostatic pressure will result in 
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the net movement of fluid out of the vascular compartment into the extra-cellular space and 





This study utilized an isocapnic hyperoxic stimulus to assess retinal vascular reactivity in 
patients stratified by retinopathy status and subjects without diabetes. Isocapnic hyperoxia 
resulted in a significant reduction of retinal arteriolar blood velocity and flow for all 
participants. The magnitude of change in blood velocity and flow in response to isocapnic 
hyperoxia was reduced in those individuals with clinically evident diabetic retinopathy 
relative to subjects without diabetes. A reduced change in max:min velocity ratio and WSR in 
response to isocapnic hyperoxia in patients with DME was also demonstrated. The differences 
in vascular reactivity occurred in the absence of any difference in baseline hemodynamic 
values. Vascular reactivity is impaired in early sight-threatening DR and this impairment is 
related to the magnitude of edema. Altered production or sensitivity to various biochemical 
factors and / or structural / functional changes of the endothelial cells, smooth muscle cells or 
pericytes may be involved in the relatively early development of DR. A prospective study 
investigating change in the retinal vascular reactivity response and functional hemodynamic 
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6 Retinal arteriolar hemodynamic response to an acute 
hyperglycemic provocation in early and sight-threatening diabetic 
retinopathy 
 
Gilmore ED, Hudson C, Nrusimhadevara RK, Ridout R, Harvey PT, Mandelcorn M, Lam 
WC, Devenyi RG. In Submission (Diabetologia)  
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Purpose: To quantify the magnitude of change of retinal arteriolar diameter, blood velocity, 
blood flow, maximum to minimum (max:min) velocity ratio and wall shear rate (WSR) 
induced by a hyperglycemic provocation in a group of diabetic patients stratified by 
retinopathy and compare to age-matched subjects without diabetes.  
Methods: The sample comprised 20 non-diabetic controls (Group 1; mean age 49 yrs, SD 10 
yrs), 19 patients with no clinically visible DR (Group 2; mean age 52 yrs, SD 11 yrs), 18 
patients with mild-to-moderate non-proliferative DR (Group 3; mean age 51 yrs, SD 12 yrs) 
and 18 patients with diabetic macular edema (Group 4; mean age 55 yrs, SD 9 yrs). Retinal 
hemodynamic measurements using the Canon Laser Blood Flowmeter (CLBF-100) were 
acquired before and 1 hour after drinking a standardized oral glucose load drink. The 
magnitude of the retinal vascular response as well as max:min velocity ratio and WSR was 
calculated and compared across groups.  
Results: A significant change in blood glucose level was observed for all groups (p<0.05). 
The change in blood glucose elevation was significantly less in Group 1 compared to the other 
Groups. No significant change in arteriolar diameter, blood velocity, blood flow, max:min 
velocity ratio and WSR was found in patients with diabetes and in age-matched subjects 
without diabetes.  
Conclusion: The results of this study indicate that retinal blood flow is unaffected by acute 
elevation of blood glucose using an oral glucose load drink in patients with diabetes and age-
matched subjects without diabetes. 
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Disturbance of retinal hemodynamics is an accepted surrogate marker of early diabetic 
retinopathy (DR).1-6 In the context of this paper, hemodynamics is a term that covers all 
indices of blood flow assessment. Published studies investigating change in homeostatic 
retinal blood flow in patients with diabetes (relative to that of non-diabetic subjects) show 
conflicting results.2,3,7-16 More recently, our group has reported a loss of retinal arteriolar 
vascular compliance17 and a reduced magnitude of vascular reactivity (Gilmore et al., In 
Submission 2006) as representing some of the earliest and most prominent hemodynamic 
disturbances in early DR.  
 
Published studies investigating the retinal vascular response to hyperglycemia are also 
conflicting. Some authors have reported increased retinal blood flow2,3,18,19  while others 
report no change in retinal blood flow20,21 in response to elevated blood glucose. The apparent 
disparity of these results may be partly attributable to the different techniques used to measure 
retinal hemodynamics, the inclusion of patients with differing morphological and varying 
glycemic control characteristics, the use of different methodologies to provoke hyperglycemia 
and the use of differing sites to measure blood flow.  
 
The aim of this study was to quantify the magnitude of change, if any, of retinal arteriolar 
diameter, blood velocity, blood flow, max:min velocity ratio and wall shear rate (WSR) 
induced by an acute hyperglycemic provocation in groups of diabetic patients with early and 
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sight-threatening DR and in age-matched subjects without diabetes. The diabetic patients 
were clinically stratified by retinopathy status. In addition, volunteers underwent non-
invasive, objective assessment of diabetic macular edema (DME) using the Macular Edema 
Module (MEM) of the Heidelberg Retina Tomograph II.22 There are unique aspects to this 
study. (1) We used a technique that allowed the simultaneous quantification of vessel 
diameter and centre-line blood velocity to calculate volumetric retinal blood flow in 
microlitres per minute and utilized a defined retinal arteriolar measurement site. (2) We used a 
standardized oral glucose load drink to elevate blood glucose. (3) Relative to previously 
published studies, a large sample of clinically defined patients with early and sight-
threatening DR was recruited. (4) We quantified change in functional hemodynamic indices in 
response to hyperglycemia as a function of severity of DR. (5) Change in retinal blood flow 
parameters in response to hyperglycemic provocation were correlated with non-invasive, 




6.3 Materials and Methods 
6.3.1 Sample 
Kida et al.19 demonstrated a 30% elevation of retinal arteriolar blood flow in healthy subjects 
in response to elevated blood glucose and found a 66% reduction in that response when 
comparing healthy subjects to patients with impaired glucose tolerance and branch retinal 
vein occlusion. Using previously published data from our laboratory,23 group mean 
homeostatic blood flow values in healthy young subjects was found to be 9.4 μL/min (SD=2.5 
μL/min) and the SD of the difference between baseline and recovery in response to hyperoxic 
provocation was 0.85 μL/min. Considering the combined results of these studies, healthy 
subjects would be expected to manifest a 30% increase of the homeostatic blood flow value 
i.e. 9.4 μL/min * 30% = 3.13 μL/min. The difference between groups in order to reach 
statistical significance would need to be 0.70 μL/min (i.e. [33% of 9.4 μL/min] / 3). 
Therefore, the standardized effect size (difference between means / SD) was calculated to be 
0.82 and the resulting sample size using an alpha of 0.05 and power of 0.9 was 18 per group. 
The sample comprised 22 non-diabetic controls (Group 1; mean age 49 yrs, SD 10 yrs), 18 
patients with no clinically visible DR (Group 2; mean age 52 yrs, SD 11 yrs), 18 patients with 
mild-to-moderate non-proliferative DR and an absence of clinically evident DME (Group 3; 
mean age 51 yrs, SD 12 yrs) and 17 patients with diabetic macular edema as defined by the 



















1 49  7 M:15 F -- -- -- 
(10) 
2 52  8 M: 10 F 10  0.072  7 
(11) (9) (0.014) 
3 51  9 M: 9 F 14  0.083  12 
(12) (10) (0.019) 
4 55  12 M: 5 F 13  0.084  7 
(9) (8) (0.014) 
 
Table 6.1: Group mean age, duration of diabetes, number treated with insulin, male to female ratio, A1c and 
random glucose as a function of group. 
(A1c: glycosylated hemoglobin. M; male, F; female) 
 
Diabetic patients were stratified into groups according to their retinal status using dilated 
stereo fundus biomicroscopy. Volunteers were aged between 30 and 70 years and had a 
LogMAR VA of 0.3 or better. Volunteers were excluded if they exhibited any eye disease 
(apart from DR for groups 2, 3 and 4) or had undergone ocular surgery, any cardiovascular 
(except well controlled systemic hypertension) and respiratory (except treated asthma) 
disorders, a refractive error greater than ±6.00DS or ±2.00DC and glaucoma in a first degree 
relative. None of the volunteers were regular smokers or had undergone retinal laser 
treatment. All volunteers were asked to refrain from caffeine-containing drinks or snacks for 
at least 8 hours prior to their study visit. Lens clarity was graded using the Lens Opacity 
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Classification System III (LOCS III).25 The study was approved by the University Health 
Network Research Ethics Board, Toronto and the University of Waterloo Office of Research 
Ethics. Informed consent was obtained from each volunteer after explanation of the nature 
and possible consequences of the study according to the tenets of the Declaration of Helsinki.  
 
6.3.2 Oral glucose tolerance test (glucose load drink) 
An oral glucose load drink (75 grams glucose suspended in 300ml water) was given to all 
participants after fasting for a minimum of 8 hours. Diabetic patients were asked to omit their 
usual doses of insulin or oral hypoglycemic agents during this fasting period.  
 
6.3.3 Quantification of retinal vessel diameter, blood velocity and flow 
The principal underlying the quantification of retinal hemodynamics is based on the Doppler 
effect. Laser light (frequency=f) reflected from a moving particle is shifted in frequency (Δf) 
that is proportional to the velocity of the moving red blood cells. A vessel that exhibits 
Poiseuille flow will have a range of velocities and thus a range of frequency shifts up to a 
maximum frequency shift (Δfmax) that corresponds to the maximum velocity of the blood 
moving at the centre of the vessel. By utilizing two photomultipliers separated by a known 
angle, the maximum frequency shift at each photomultiplier is subtracted to allow the 
absolute quantification of centre-line blood velocity irrespective of the angle between the 




The Canon Laser Blood Flowmeter (CLBF; Canon, Tokyo, Japan) utilizes a red diode laser 
(675nm, 80µm x 50µm oval) to measure velocity every 0.02 seconds across a 2 second 
measurement window resulting in a velocity-time trace. The CLBF also uses a green diode 
laser system (543nm, 1500µm x 150µm rectangle) that is used to measure vessel diameter and 
maintain centration of the laser at the measurement site.28,29 The vessel tracking system allows 
post-acquisition rejection of velocity measurements impacted by significant saccades. 
Diameter readings are acquired every 4 milliseconds during the first and final 60 milliseconds 
of the 2 second velocity measurement window. Two sequential measurements utilizing 
different optical paths (path 1 and path 2) are taken to ensure consistency and averaged to 
give one reading. In combination with the average velocity (Vmean) over at least one pulse 
cycle and diameter (D), flow through the vessel can be calculated using 1/2.π.D2/4.Vmean.60. 
Magnification effects associated with refractive and axial components of ametropia are 
corrected to provide absolute measurements of diameter (μm), velocity (mm/sec) and flow 
(μL/min). The technological principles utilized in this device have been described in detail 
elsewhere.19,26,27,30 In addition, this device has been extensively evaluated in volunteers 
with,19,31,32 and without,23,33-35  retinal diseases and following therapeutic intervention.36
 
6.3.4 Quantitative assessment of retinal edema 
A confocal scanning laser tomograph that sequentially acquires two-dimensional section 
images along the optical axis was employed. The distribution of reflected light intensity along 
the optical axis for a given pixel is described by the z-profile or confocal intensity profile. The 
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MEM technique of the Heidelberg Retina Tomograph II (HRT; Heidelberg Engineering, 
Heidelberg, Germany) determines the z-profile signal width (at half peak height) and peak 
reflectance intensity. Studies have demonstrated a broadening of the z-profile signal width and 
a decrease in peak reflectance intensity in areas of retinal edema.37 Normalization of the 
reflectance values reduces the variation in intensity between successive scans. Edema index 
values are generated that represent the z-profile signal width divided by normalized 
reflectance intensity for each pixel within the image. MEM has been demonstrated to have 
high sensitivity and good specificity for the detection of DME.22 The average edema index of 
all pixels within the 500μm and 1500μm radius circles was calculated.  
  
6.3.5 Procedures 
One eye of each subject was randomly assigned to the study if both eyes met the study 
criteria. Volunteers attended for 2 visits (median interval between first and second visit was 
21 days). Visit 1 was used to establish eligibility and baseline characteristics, determine group 
assignment, and undertake objective assessment of DME and to familiarize the volunteer with 
the technique used to quantify retinal hemodynamics. Three sets of MEM images centered on 
the fovea were acquired at visit 1 for each volunteer. Visit 2 was used to quantify retinal 
vascular response to hyperglycemia. Refraction, logMAR visual acuity, resting blood pressure 
and random blood glucose level were assessed prior to dilation of the study eye with 1% 
tropicamide (Alcon Canada). Retinal hemodynamic measurements were acquired from a 
retinal arteriole approximately 1 disc diameter from the optic nerve head at a straight vessel 
segment and distant from bifurcations in one eye of each volunteer. At least five retinal 
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hemodynamic measurements were attempted using the CLBF at baseline and 1 hour after 
consuming the glucose load drink i.e. the expected peak of glucose profile. Random blood 
glucose levels were assessed prior to, and directly following, the second set of CLBF 
measurements. Axial length was measured by I3 System ABD A-scan ultrasound (I3 
Innovative Imaging Inc, Sacramento, CA) to correct blood flow measurements for 
magnification effects due to ametropia.  
 
6.3.6 Analysis 
A post acquisition analysis of the CLBF velocity waveforms was performed using a 
standardized protocol to remove aberrant waveforms affected by eye movement, tear film 
breakup, or improper tracking of the measurement laser. The maximum number of acceptable 
pulse cycles was used in the data analysis for each measurement (with a minimum of 1 
complete velocity waveform required). In addition, maximum to minimum (max:min) 
velocity ratio was calculated before and during hyperglycemia for each individual. This ratio 
reflects vascular compliance, where an elevation of max:min velocity ratio indicates increased 
vascular rigidity (the site of this change can be up-stream of, down-stream of, or at the CLBF 
measurement site). In addition, WSR (mean velocity * 8 / diameter)38 was calculated because 
change is shear stress is believed to alter blood flow and this mechanism is thought to be 
disturbed in diabetes and atherosclerosis.38,39  
 
The normality of each hemodynamic parameter as a function of group and condition was 
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confirmed prior to the use of parametric statistics. A normal distribution was confirmed for all 
parameters apart from max:min velocity ratio and WSR which were log transformed for 
statistical analysis. The change in each of the hemodynamic parameters in response to 
provocation within each group was determined using paired two-tailed t-tests. Repeated 
measures ANOVA was used to determine any differences between the baseline hemodynamic 
parameters between groups and any difference in the response of the hemodynamic 
parameters between the groups. The dependent variables were diameter, velocity, blood flow, 
max:min velocity ratio and WSR. The within subject factor was hyperglycemia and the 
between subject factor was group. The magnitude of change of each of the hemodynamic 
parameters was correlated with systemic mean arterial blood pressure, duration of diabetes, 
A1c values and the edema index values within 500μm and 1500μm radii of the fovea. Two-




There were no significant differences between the groups for all retinal hemodynamic 
outcome measures at baseline.  
 
Table 6.2 details blood glucose before and 1 hour after ingestion of glucose. At baseline, 
group 1 blood glucose was significantly lower than groups 2, 3, and 4 (p≤0.016). Blood 
glucose increased significantly in all groups (p<0.0001) and this increase was significantly 
different between the groups (p<0.0001). The change in blood glucose was significantly less 
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Group 1 Group 2 Group 3 Group 4 

























Table 6.2: Group mean (SD) baseline, effect and change in glucose as function of group.  
 
Group mean baseline and effect magnitudes of retinal arteriolar diameter, blood velocity, 
flow, max:min velocity ratio and WSR for each group are shown in Table 6.3. Retinal 
arteriolar diameter, blood velocity, flow, max:min velocity ratio and WSR did not change 




Group 1 Group 2 Group 3 Group 4  
Diameter pre-glucose 
(μm) 
110.0 114.3 115.0 113.9 
 (12.4)  (7.4)  (9.4)  (13.5) 
Diameter post-glucose 
(μm) 
108.2 113.3  114.6  109.1  
 (12.5) (8.7) (9.1) (10.0) 
Velocity pre-glucose 
(mm/sec) 
34.0  35.9  33.9  33.6  
(6.2) (7.6) (10.1) (7.8) 
Velocity post-glucose 
(mm/sec) 
35.1  35.8  34.9  34.5  
(7.0) (6.4) (9.4) (8.2) 
Flow pre-glucose 
(μL/min) 
9.8  11.2  10.9  10.0  
(2.7) (3.0) (4.6) (3.3) 
Flow post-glucose 
(μL/min) 
9.8  10.9  11.0  10.2  
(2.8) (2.7) (4.1) (3.4) 
Max:min pre-glucose 3.3  3.8  3.8  3.9  
(0.7) (1.9) (1.3) (2.1) 
Max:min post-glucose 3.5  4.1 4.2  4.2  
(0.7) (1.7) (1.7) (2.2) 
WSR pre-glucose  1263  1264  1156  1198  
(s-1) (272) (263) (308) (300) 
WSR post-glucose  1327 1253 1186 1228 
(s-1) (317) (239) (276) (343) 
 
Table 6.3: Group mean mean functional hemodynamic indices before and after ingestion of glucose as a function 
of group  






























Figure 6.1 Change in retinal arteriolar diameter, blood velocity, blood flow, max:min velocity ratio, wall shear 
rate with isocapnic hyperoxia as a function of group. For each group the centre of the box represents the group 
mean response, the limits of the box represent ±1 SE and the whiskers represent ±1 SD. Open circles represent 
outlier values and stars represent extreme values. Extreme values are outside the 3 box length range from the 
upper and lower value of the box. Group 1; non- diabetic, age-matched controls. Group 2; patients with 
Group 1 Group 2 Group 3 Group 4









































































































no clinically visible DR. Group 3; patients with mild-to-moderate non-proliferative DR in the absence of 
clinically evident DME. Group 4; patients with DME.  
 
Considering the patients with diabetes as a whole, the vascular reactivity response in terms of 
Change of flow was significantly correlated with change in blood glucose for the non-diabetic 
 
change in retinal blood flow in patients treated with insulin was not different from those 
treated without insulin (one tailed t-test; p>0.05). 
 
group only (r=0.52; p=0.027). Change in flow was not correlated with change in blood 
glucose for any of the diabetic patient groups.  
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 r = 0.5209, p = 0.0267
 




Group mean edema index values within 500μm and 1500μm radii of the fovea as a function of 
group are shown in Table 6.4. Edema index values were significantly larger for group 4 
compared to groups 1 and 2 for both the 500μm and 1500μm radius circles (p≤0.0005). 
Edema index values of group 3 were also significantly larger than those of group 1 for the 
1500μm circle only (p=0.0005). There was no correlation between baseline edema index 
values within the 500μm or 1500μm radius circle and the magnitude of change in diameter, 




Group 1 Group 2 Group 3 Group 4 
500 μm radius 1.12  1.18  1.34  1.55*†  
(0.28) (0.38) (0.24) (0.36) 
1500 μm radius 1.19  1.19  1.39*  1.48*†  
(0.21) (0.24) (0.20) (0.23) 
Table 6.4: Group mean edema index values within 500μm and 1500μm radius of the fovea as a function of 
group. 





There were no significant differences between the groups for all retinal hemodynamic 
outcome measures at baseline and none of the parameters changed as a result of glucose 
ingestion in any of the groups. Interestingly, change of flow was significantly correlated with 
change in blood glucose for the non-diabetic group only. There was no correlation between 
baseline edema index values and the magnitude of change in diameter, velocity or flow in 
response to the oral glucose load drink. 
 
Chronic hyperglycemia is an established risk factor for the development of DR.40,41 Chronic 
hyperglycemia increases the influx of glucose into the retina42-44 that causes altered retinal 
biochemistry and subsequently precipitates the morphological changes of DR. Both fasting 
blood glucose levels and the response to an oral glucose tolerance test are typically used to 
detect diabetes. At baseline, 3 participants in the clinically normal group had blood glucose 
levels greater than 7.0mmol/L.45 Two of these individuals had an oral glucose tolerance test 
response that was inside normal limits. The third individual showed a marginally elevated oral 
glucose tolerance test response at 1 hour post load (11.9mmol/L, reference value 
11.1mmol/L)45; however, the normal time point for assessment of OGTT is 2 hours post load 
when blood glucose values are expected to be lower for non-diabetic individuals.  
 
Published studies investigating differences in homeostatic retinal blood flow in patients with 
diabetes (relative to that of non-diabetic subjects) show conflicting results. Patients with 
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background diabetic retinopathy have been reported to exhibit either increased,7-10 or 
decreased,2,3,11-14 blood hemodynamics. Others reported no significant change in blood 
hemodynamics.15 Recent work from our own laboratory has shown a significant elevation of 
max:min velocity ratio with increasing risk of development of DME suggesting decreased 
vascular compliance with increasing severity of DR; interestingly, there were no significant 
differences found in diameter, velocity or flow across the groups.17
 
Studies investigating the retinal vascular response to acute hyperglycemia are also 
conflicting.2,18-21 Bursell et al.2  measured blood flow using cine fluorescein angiography and 
a glucose clamp methodology in a group of diabetic subjects without retinopathy. They found 
a significant increase in flow between the various glucose levels employed in their study. 
Kida et al.19 evaluated arteriolar retinal blood flow using the CLBF after ingestion of a 
glucose load drink in clinically normal subjects and those who had been diagnosed with 
branch retinal vein occlusion (BRVO). Patients were separated into either normal or impaired 
glucose tolerance groups based on their 2 hour post-load glucose level.46 At the 1 hour time 
point, retinal blood flow had significantly increased in the clinically normal group relative to 
baseline and the response was significantly greater than that of the patient group. At the 2 and 
3 hour time points, the retinal blood flow had significantly increased from baseline for both 
the clinically normal group and the BRVO patients with normal glucose tolerance but, 
interestingly, not those patients with impaired glucose tolerance. Garhofer et al.18 found 
increased retinal blood flow in a group of non-diabetic subjects in response to an acute 
elevation of blood glucose. Blood flow was calculated using velocimetry measurements 
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(Oculix, Berwyn, PA, USA) and venular diameter determination using the Retinal Vessel 
Analsyer (Imedos, Germany). According to these authors, an increase in velocity (rather than 
diameter) precipitated the observed change in blood flow.  
 
Grunwald et al.47 measured changes in retinal blood velocity and combined venular diameter 
measurements to calculate flow in a group of diabetic patients with no or mild DR. These 
poorly controlled patients were initially hyperglycemic (mean glucose measurement 
21.7mmol/L). The patients’ blood glucose levels were returned to ‘normal’ values (mean 
5.8mmol/L) following exogenous insulin injection and blood flow values were seen to 
decrease by approximately 15%. However, the authors point out that the administration of 
glucose (to elevate blood glucose) may not be directly comparable to that of administration of 
insulin (to reduce blood glucose) which is known to have vasoactive effects.48
 
Sullivan et al.21 found no change in blood flow in response to acute hyperglycemia. However, 
the diabetic subjects in their study had a relatively long duration of type 1 diabetes and 
therefore were unable to react to the glucose stimulus (due to a loss of vascular compliance). 
This is in keeping with other studies that have found a significant change of flow in patients 
without diabetes18 and in patients with normal glucose tolerance.19 Recent work for our 
laboratory has shown a increase of max:min velocity ratio (suggesting a loss of retinal 
vascular compliance) and a loss of vascular reactivity with increasing severity of non-
proliferative diabetic retinopathy (Gilmore et al., In Submission 2006). In this study, we found 
a significant correlation between change in blood glucose and change in blood flow for the 
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non-diabetic subject group only. 
 
The results of the present study show that retinal arteriolar blood flow is unaltered during 
acute increase of blood glucose in patients with diabetes and in age-matched subjects without 
diabetes. To the best of our knowledge, this is the first published study to employ a bi-
directional laser Doppler technique to quantify blood velocity and simultaneously quantify 
arteriolar diameter in a group of patients with diabetes stratified by retinopathy status and a 
group of age-matched subjects without diabetes. The results of this study are in agreement 
with Fallon et al20 and Sullivan et al.21 The present study also investigated change in max:min 
velocity ratio and WSR in response to the hyperglycemic provocation. These indices have 
been shown to be sensitive to alterations in retinal hemodynamics in patients with diabetes17,49 
(Gilmore et al., In Submission 2006), and other patient populations.32 Neither the max:min 
velocity ratio nor WSR changed as a result of the hyperglycemic provocation in any of the 
groups. In addition, the method of control of blood glucose may impact the vascular reactivity 
response since insulin is known to have vasoactive properties.50 However, the vascular 
reactivity response in terms of change in retinal blood flow in patients treated with insulin was 
not different from those treated without insulin. 
 
In support of our results, is the fact that glucose has a low basal retinal influx51 and glucose 
transport operates near saturation level at normal physiological glucose concentrations.52 
Glut-1 is one of the most important glucose transporters and is responsible for the movement 
of glucose across the inner and outer blood retinal barriers.53 Glut-1 expression is unchanged 
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during acute increase of blood glucose preventing increased glucose uptake across bovine 
retinal endothelial cells.51  
 
Conversely, other published studies have documented increased retinal blood hemodynamics 
during short-term hyperglycemic episodes in cats and mini-pigs.54,55 By contrast, Ben-Nun et 
al.56 and Puchowitz et al.57 reported no change in retinal blood flow during hyperglycemia in 
cats and rats, respectively. Although these studies have employed different species and 
methodologies to quantify retinal blood flow, there is clearly no consensus as to whether 
blood flow changes during an acute increase of blood glucose. 
 
The limitations of this study are that a single set of retinal blood flow measurements were 
acquired 1 hour after ingestion of a glucose-load drink. There may be retinal hemodynamic 
changes induced by hyperglycemia at shorter,18 or longer,19 time periods than that measured 
in this study. We chose the 1 hour post-ingestion time point to acquire blood flow 
measurements at peak blood glucose values.58 The response to elevated glucose levels was 
only measured in major arterioles of the retina; however, this site represents the resistance 
vessels of the retinal vasculature. In addition, the insulin status of the diabetic patients was 
unknown. The power of the study, calculated using the largest difference between the groups 
was 13%. Although we cannot say for certain that we have not committed a type II error, the 
lack of response in any of the groups leads us to believe that acute changes in blood glucose 






The main finding of our study is unaltered retinal arteriolar blood flow 1 hour post acute 
blood glucose increase in patients with diabetes and in age-matched subjects without diabetes. 
In addition, retinal arteriolar diameter, blood velocity, max:min velocity ratio and WSR were 
unchanged as a result of the acute hyperglycemic provocation. The results of this study do not 
support the view that retinal blood flow is affected by an acute increase of blood glucose in 
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Purpose: To quantify the magnitude of change of retinal hemodynamics induced by a 
combined isocapnic hyperoxic / hyperglycemic provocation in groups of diabetic patients and 
in age-matched volunteers without diabetes and to compare the response to that of an 
isocapnic hyperoxic provocation alone. 
Methods: The sample comprised 17 non-diabetic controls (Group 1), 15 patients with no 
clinically visible diabetic retinopathy (DR) (Group 2), 16 patients with mild-to-moderate non-
proliferative DR (Group 3) and 15 patients with diabetic macular edema (Group 4). Retinal 
hemodynamic measurements were acquired at baseline (homeostatic blood glucose levels and 
breathing air) and 1 hour after drinking a standardized oral glucose load drink using isocapnic 
hyperoxia. The magnitude of change of retinal arteriolar diameter, velocity, blood flow, 
max:min velocity ratio and WSR was calculated and compared across groups.  
Results: Retinal blood velocity and flow significantly decreased in all groups (p≤0.001 and 
p≤0.0002, respectively). Max:min velocity ratio significantly increased (p≤0.005), and WSR 
significantly decreased (p≤0.0002), in groups 1, 2 and 3 but not group 4. The vascular 
reactivity response was not significantly different across the groups. The age-matched non-
diabetic group demonstrated a reduced response of change in flow (p=0.009) and WSR 
(p=0.010) to the combined hyperoxic / hyperglycemic provocation compared to that of 
hyperoxia alone.  
Conclusions: The vascular reactivity response to a combined hyperoxic / hyperglycemic 
provocation produced a pronounced reduction in blood flow. Unlike the response to hyperoxia 
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alone, the vascular reactivity response was not significantly different across the groups. This 
suggests that hyperglycemia may influence the retinal vascular reactivity response to 
hyperoxia. 
 
Keywords: Retinal blood flow, Laser Doppler velocimetry, hyperglycemia, diabetic 






Vascular reactivity represents the hemodynamic response of the vasculature to a given 
stimulus, such as hyperoxia1 (Gilmore et al., In Submission 2006) or hypercapnia.2 Vascular 
reactivity in response to hyperoxia with simultaneous hyperglycemia has previously been 
reported to be impaired in humans.3,4 By contrast, other authors have reported no effect of 
hyperglycemia on hyperoxia induced retinal vascular reactivity in humans.5 However, 
previous studies are limited because many have not utilized simultaneous diameter and 
velocity measurements to calculate retinal blood flow in absolute units and all did not control 
for systemic variation in arterial CO2 during hyperoxic provocation. In addition, a unique 
aspect of this study is the focus on changes associated with the development of early sight-
threatening diabetic retinopathy (DR) culminating in diabetic macular edema (DME). 
Impairment of vascular reactivity during acute hyperglycemia may yield important 
information about the pathophysiology associated with the development of early DR.  
 
Previous work from our laboratory has shown that hyperoxia induced change of blood flow in 
early DR is impaired and this impairment precedes change in homeostatic blood flow 
parameters; vascular reactivity is a more sensitive marker of vascular dysfunction in early DR 
than homeostatic blood flow assessment (Gilmore et al., In Submission 2006). Following on 
from this work, we used the same techniques to investigate the impact of acute hyperglycemia 
on vascular reactivity in early DR; we were unable to reveal any impact of hyperglycemia on 
vascular reactivity. This study advances the work by investigating the effect of a combined 
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hyperoxic / hyperglycemic stimulus on vascular reactivity. We hypothesize that 
hyperglycemia reduces the retinal vascular reactivity response to a hyperoxic stimulus.  
 
The aim of this study was to quantify the magnitude of change of retinal hemodynamics 
induced by a combined isocapnic hyperoxia / hyperglycemic provocation in groups of 
diabetic patients clinically stratified by retinopathy status and in age-matched subjects without 
diabetes. The response to the combined hyperoxia / hyperglycemia provocation will be 
compared to that of an isocapnic hyperoxic provocation alone using volunteers common to 
both paradigms (Gilmore et al., In Submission 2006). Volunteers also underwent non-
invasive, objective assessment of diabetic macular edema (DME) using the Macular Edema 
Module (MEM) of the Heidelberg Retina Tomograph II.6 We correlated the retinal vascular 
reactivity response to a combined hyperoxic / hyperglycemic provocation with the objective 




7.3 Materials and Methods 
7.3.1 Sample 
Using previously published data from our group,1 the vascular reactivity response of healthy 
young subjects in terms of change of retinal blood flow in response to isocapnic hyperoxia 
was found to be 4.3 μL/min and the SD of the difference between baseline and recovery was 
0.85 μL/min. Assuming an approximate 50% reduction in vascular reactivity response when 
comparing healthy subjects to our most advanced diabetic retinopathy group7 (Gilmore et al., 
In Submission 2006), the difference between groups in order to reach statistical significance 
would need to be 0.72 μL/min  (i.e. [50% of 4.3 μL/min] / 3). Therefore, the standardized 
effect size (difference between means / SD) was calculated to be 0.85 and the resulting 
sample size using an alpha of 0.05 and power of 0.9 was 16 per group. The sample comprised 
17 non-diabetic controls (Group 1; mean age 49 yrs, SD 10 yrs), 15 patients with no clinically 
visible DR (Group 2; mean age 54 yrs, SD 11 yrs), 16 patients with mild-to-moderate non-
proliferative DR 8 (Group 3; mean age 51 yrs, SD 12 yrs) and 15 patients with DME (Group 






















1 49  -- -- 6 M:11 F -- 
(10) 
2 54  6  5 5 M: 10 F 0.070 
(0.010) (9) (5) 
3 51  15  12 8 M: 7 F 0.084 
(0.019) (12) (10) 
4 55  13  6 11 M: 4 F 0.087 
(0.014) (8) (9) 
 
Table 7.1: Group mean age, duration of diabetes, number treated with insulin, male to female ratio, and A1c 
value.   
(A1c: glycosylated hemoglobin. M; male, F; female) 
 
Volunteers were stratified into groups according to their retinal status using dilated stereo 
fundus biomicroscopy. All volunteers were aged between 30 and 70 years and had a logMAR 
VA of 0.3 or better. Volunteers were excluded if they exhibited any eye disease (apart from 
DR for groups 2, 3 and 4) or had undergone ocular surgery, any cardiovascular (except well 
controlled systemic hypertension) and respiratory (except treated asthma) disorders, a 
refractive error greater than ±6.00 Dioptres sphere or ±2.00 Dioptres cylinder and glaucoma 
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in a first degree relative. None of the volunteers were regular smokers or had undergone 
retinal laser treatment. All volunteers were asked to refrain from caffeine-containing drinks or 
snacks for at least 8 hours prior to their study visit. Lens clarity was graded using the Lens 
Opacity Classification System III9 (LOCS III). The study was approved by the University of 
Waterloo Office of Research Ethics and the University Health Network Research Ethics 
Board, Toronto. Informed consent was obtained from each volunteer after explanation of the 
nature and possible consequences of the study according to the tenets of the Declaration of 
Helsinki.  
 
7.3.2 Oral glucose tolerance test (glucose load drink) 
An oral glucose load drink (75 grams glucose suspended in 300ml water) was given to all 
participants. Diabetic patients were asked to fast for a minimum of 8 hours and to omit their 
usual doses of insulin or oral hypoglycemic agents during this fasting period.  
 
7.3.3 Isocapnic hyperoxia delivery system
The isocapnic hyperoxia delivery system comprised a sequential re-breathing circuit made up 
of a fresh gas reservoir, an expiratory gas reservoir and a face-mask (Hi-OxSR, 
ViasysHealthcare, Yorba Linda, CA). The inspiratory and expiratory limbs were 
interconnected by a single positive end-expiratory pressure (PEEP) valve, allowing exhaled 
gas to be re-breathed when the gas in the inspiratory limb was depleted. Flow from gas tanks 
containing oxygen and air respectively was controlled using standard rotometers as 
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flowmeters. This method has been described in detail in a previous publication.10
 
7.3.4 Quantification of retinal vessel diameter, blood velocity and flow 
The principal underlying the quantification of retinal hemodynamics is based on the Doppler 
effect. Laser light (frequency=f) reflected from a moving particle is shifted in frequency (Δf) 
that is proportional to the velocity of the moving red blood cells. A vessel that exhibits 
Poiseuille flow will have a range of velocities and thus a range of frequency shifts up to a 
maximum frequency shift (Δfmax) that corresponds to the maximum velocity of the blood 
moving at the centre of the vessel. By utilizing two photomultipliers separated by a known 
angle, the maximum frequency shift at each photomultiplier is subtracted to allow the 
absolute quantification of centre-line blood velocity, irrespective of the angle between the 
moving particle and reflected beam.11,12  
 
The Canon Laser Blood Flowmeter (CLBF; Canon, Tokyo, Japan) utilizes a red diode laser 
(675nm, 80µm x 50µm oval) to measure velocity every 0.02 seconds across a 2 second 
measurement window resulting in a velocity-time trace. The CLBF also uses a green diode 
laser system (543nm, 1500µm x 150µm rectangle) that is used to measure vessel diameter and 
maintain centration of the laser at the measurement site 13,14. The vessel tracking system 
allows post-acquisition rejection of velocity measurements impacted by significant saccades. 
Diameter readings are acquired every 4 milliseconds during the first and final 60 milliseconds 
of the 2 second velocity measurement window. Two sequential measurements utilizing 
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different optical paths (path 1 and path 2) are taken to ensure consistency and averaged to 
give one reading. In combination with the average velocity (Vmean) over a pulse cycle and 
diameter (D), flow through the vessel can be calculated using 1/2.π.D2/4.Vmean.60. 
Magnification effects associated with refractive and axial components of ametropia are 
corrected to provide absolute measurements of diameter (μm), velocity (mm/sec) and flow 
(μL/min). The technological principles utilized in this device have been described in detail 
elsewhere.11,12,15,16 In addition, this device has been extensively evaluated in volunteers 
with,16-18 and without,1,19-21 retinal diseases and following therapeutic intervention.22
 
7.3.5 Quantitative assessment of retinal edema 
A confocal scanning laser tomograph that sequentially acquires two-dimensional section 
images along the optical axis was employed. The distribution of reflected light intensity along 
the optical axis for a given pixel is described by the z-profile or confocal intensity profile. The 
MEM technique of the Heidelberg Retina Tomograph II (HRT; Heidelberg Engineering, 
Heidelberg, Germany) determines the z-profile signal width (at half peak height) and peak 
reflectance intensity. Studies have demonstrated a broadening of the z-profile signal width and 
a decrease in peak reflectance intensity in areas of retinal edema.23 Normalization of the 
reflectance values reduces the variation in intensity between successive scans. MEM has been 





One eye of each subject was randomly assigned to the study if both eyes met study criteria. 
Volunteers attended for 2 visits. Visit 1 was used to establish eligibility and baseline 
characteristics, determine group assignment, and undertake objective assessment of DME and 
to familiarize the volunteer with the technique used to quantify retinal hemodynamics. Three 
sets of MEM images centered on the fovea were acquired at visit 1 for each volunteer. Visit 2 
was used to quantify the retinal vascular response to a combined hyperoxic / hyperglycemic 
provocation. Refraction, logMAR visual acuity, resting blood pressure and random blood 
glucose level were assessed prior to dilation of the study eye with 1% tropicamide (Alcon 
Canada). Retinal hemodynamic measurements were simultaneously acquired from an arteriole 
approximately 1-2 disc diameters from the optic nerve head using a straight vessel segment in 
one eye of each volunteer. At least five retinal hemodynamic measurements were acquired 
using the CLBF at baseline and 1 hour after glucose ingestion (while breathing oxygen under 
isocapnic conditions). Intraocular pressure was measured by Goldmann applanation 
tonometry after retinal blood flow measurements had been acquired. Axial length was 
measured by I3 System ABD A-scan ultrasound (I3 Innovative Imaging Inc, Sacramento, CA) 
to correct blood flow measurements for magnification effects due to ametropia.  
 
The response to the combined hyperoxia / hyperglycemia provocation was compared to the 
response of an isocapnic hyperoxic provocation alone determined at a separate visit (Gilmore 




7.3.7 Gas analysis and systemic vascular responses
A rapid response critical care gas analyzer (Cardiocap 5, Datex-Ohmeda, USA) was used to 
quantify the relative concentrations of O and CO2 2 in both the inspired and expired gases on a 
breath-by-breath basis. The relative concentrations of O  and CO2 2 were sampled continuously 
by the gas analyzer and the inspired O , inspired CO , P2 2 ETO and P2 ETCO2 were downloaded to 
a personal computer every 5 seconds (S5 Collect software, Datex-Ohmeda, USA). In addition, 
finger-oxygen saturation, respiration rate and pulse rate were also recorded continuously. 
P thETCO2 was analyzed by calculating the upper 10  and lower 90th percentiles. Data points 
lying outside the upper 10th or lower 90th percentiles were excluded from the analysis since all 
of these values were found to be erroneous i.e. these points resulted from inappropriate 
interpretation of tidal waveforms by the gas monitor. Blood pressure was also measured non-
invasively once every minute over the course of the hyperoxic paradigm (Cardiocap 5, Datex-
Ohmeda, USA).  
 
7.3.8 Analysis 
A post acquisition analysis of the CLBF velocity waveforms was performed using a 
standardized protocol to remove aberrant waveforms affected by eye movement, tear film 
breakup, or improper tracking of the measurement laser. The maximum number of acceptable 
pulse cycles was used in the data analysis for each measurement (with a minimum of 1 
complete velocity waveform required). In addition, maximum to minimum (max:min) 
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velocity ratio was calculated during air breathing and compared to that during oxygen 
breathing for each individual. This ratio reflects vascular compliance, where an elevation of 
max:min ratio indicates increased vascular rigidity (the site of this change can be up-stream 
of, down-stream of, or at the CLBF measurement site). In the physiological situation, 
compliance is expected to reduce and rigidity increase during hyperoxia due to increased 
tonus of the vessel wall. In addition, wall shear rate (WSR= mean velocity * 8 / diameter)24 
was calculated because change is shear stress is believed to alter blood flow and this 
mechanism is thought to be disturbed in diabetes and atherosclerosis.24,25  
 
The normality of each hemodynamic parameter as a function of group and condition was 
confirmed prior to the use of parametric statistics. A normal distribution was confirmed for all 
parameters apart from max:min velocity ratio which was log transformed for statistical 
analysis. The change in each of the hemodynamic parameters in response to provocation 
within each group was determined using paired two-tailed t-tests. Repeated measures 
ANOVA was used to determine any differences between the baseline hemodynamic 
parameters between groups, any difference in the response of the hemodynamic parameters 
between the groups and any difference in the response between combined hyperoxia / 
hyperglycemia and hyperoxia alone within each group. The dependant variables were 
diameter, velocity, blood flow, max:min velocity ratio and WSR. The within subject factor 
was glucose and isocapnic hyperoxia and the between subject factor was group. The 
magnitude of change of each of the homodynamic parameters was correlated with systemic 
mean arterial blood pressure, duration of diabetes, A1c values and the edema index values 
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within 500μm and 1500μm radii of the fovea. Two-tailed t-tests were utilized to determine 
differences between testing conditions, where appropriate. 
 
7.4 Results 
There were no significant differences between the groups for all the retinal hemodynamic 
outcome measures at baseline. 
 
Group mean baseline and effect magnitudes of retinal arteriolar diameter, blood velocity, 
flow, max:min velocity ratio and WSR for each group are shown in Table 7.2. The 
magnitudes of change of each of these parameters in response to combined hyperoxic / 

































































































































Figure 7.1Change in retinal arteriolar diameter (upper left), blood velocity (middle left), blood flow (lower left), 
max:min velocity ratio (upper right), and wall shear rate (middle right) following combined hyperglycemic / 
hyperoxic provocation as a function of group.  
For each graph the centre of the box represents the group mean response, the limits of the box represent ±1 SE 
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and the whiskers represent ±1 SD standard deviation. Open circles represent outlier values and stars represent 
extreme values. Extreme values are outside the 3 box length range from the upper and lower value of the box. 
Group 1; non-diabetic, age-matched controls. Group 2; patients with no clinically visible DR. Group 3; patients 
with mild-to-moderate non-proliferative DR in the absence of clinically evident DME. Group 4; patients with 
DME. 
 
Retinal arteriolar diameter did not change significantly in any group (Bonferroni corrected 
p<0.01) in response to a combined hyperoxic / hyperglycemic provocation. Retinal blood 
velocity and flow significantly decreased in all groups (p≤0.001 and p≤0.0002, respectively). 
Max:min velocity ratio significantly increased (p≤0.005), and WSR significantly decreased 
(p≤0.0002), in groups 1,2 and 3 but not group 4.  
 
The magnitude of change of the retinal hemodynamic outcome measures in response to 





Group 1 Group 2 Group 3 Group 4  
Diameter air /  108.4 115.7 113.2 113.9 
pre-glucose (μm)  (10.0)  (8.3)  (9.8)  (13.5) 
Diameter O  /  104.0 111.5 109.6 109.1 2
post-glucose (μm)  (11.3)  (8.4)  (12.4)  (14.2) 
Velocity air /   33.4  37.0  34.5  35.0  
pre-glucose (mm/sec) (7.0) (8.1) (7.3) (11.0) 
23.0*  25.5*  26.3*  25.5*  Velocity O  /  2
post-glucose (mm/sec) (5.7) (6.1) (6.2) (7.1) 
Flow air /        9.3  11.8  10.7  11.0  
pre-glucose (μL/min) (2.4) (3.1) (3.8) (4.4) 
6.0*  7.6*  7.7*  7.1*  Flow O  /     2
post-glucose (μL/min) (2.3) (2.3) (3.2) (2.1) 
Max:min air /  3.5  4.1  3.6  3.5  
pre-glucose (1.6) (2.2) (1.3) (0.9) 
Max:min O  /  4.5*  5.3* 4.7*  4.5  2
post-glucose (1.8) (3.1) (2.0) (1.8) 
WSR air /     1242  1285  1216  1221  
pre-glucose (s-1) (290) (275) (206) (362) 
WSR O  /     886* 918* 966* 1010 2
post-glucose (s-1) (220) (202) (204) (298) 
 
Table 7.2: Group mean diameter, velocity, flow, max:min ratio and WSR during air / pre-glucose and during 
oxygen / post-glucose as a function of group.  
(max:min; maximum to minimum ratio of velocity, WSR; wall shear rate). *; indicates significantly different 
from baseline (air). 
 
Using data from volunteers common to both paradigms, the magnitude of change of flow 
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(p=0.009) and WSR (p=0.010) was significantly less for the age-matched non-diabetic group 
to the combined hyperoxic / hyperglycemic provocation than that of hyperoxia alone 
(Bonferroni corrected p=0.01). For the non-diabetic group, flow reduced by 43.8% in 
response to isocapnic hyperoxia but only reduced by 36.0% in response to the combined 
hyperoxic / hyperglycemic provocation, while WSR reduced by 36.8% in response to 
hyperoxia and by 27.3% in response to the combined hyperoxic / hyperglycemic provocation. 
There were no significant differences in any of the outcome parameters between the combined 
hyperoxic / hyperglycemic provocation and hyperoxia alone for any of the diabetic groups.  
 
Group mean reduction in diameter, velocity and flow shown as percentage change in response 
to the combined hyperoxic / hyperglycemic provocation as function of group are shown in 
Table 7.3.  
Group mean change 
(%)  
Group 1 Group 2 Group 3 Group 4 
Diameter  -4.0%  -3.6%  -3.2%  -4.1%  
(6.0%) (4.4%) (6.7%) (4.7%) 
Velocity  -30.5%  -30.6% -23.1%  -24.2%  
(12.0%)  (11.4%) (13.8%) (10.6%) 
Flow  -36.0%  -35.5% -27.8%  -31.5%  
(11.8%)  (11.1%) (14.6%) (12.6%) 
 
Table 7.3: Group mean change in diameter, velocity and flow in percentage change due to combined hyperoxic / 
hyperglycemic provocation as function of group.  




Considering the patients with diabetes as a whole, the vascular reactivity response in terms of 
change in retinal blood flow in patients treated with insulin was not different from those 
treated without insulin (one tailed t-test; p>0.05). 
 
There was a significant correlation between the magnitude of change in blood glucose and age 
(r=0.339; p=0.007). There were no other correlations evident between change in the 
hemodynamic parameters and age, systemic mean arterial blood pressure, duration of diabetes 
and A1c values. 
 
Group mean baseline and effect values for relevant respiratory and systemic parameters as a 
function of group are shown in Table 7.4. Fractional inspired oxygen (FiO2) changed 
significantly in each group with combined hyperoxic / hyperglycemic provocation (p<0.0001; 
paired two-tailed t-test). Expired carbon dioxide (PETCO2) did not change in any group. The 
group mean mean arterial blood pressure (MAP; [(2/3 * diastolic BP) + (1/3 * systolic BP)] 
was not significantly different between baseline and combined hyperoxic / hyperglycemic 
provocation for any of the groups. Pulse rate did not change significantly in any group with 




Group 1 Group 2 Group 3 Group 4  
PETCO  air /  4.8 5.0 5.1 5.1 2
pre-glucose (%) (0.4) (0.4) (0.3) (0.4) 
PETCO  O  /   4.8 5.0 5.1 5.0 2 2
post-glucose (%) (0.4) (0.5) (0.4) (0.4) 
FiO  air /          20.5 20.1 20.0 20.2 2
pre-glucose (%) (1.7) (0.2) (0.5) (0.6) 
FiO  O2 2 /         92.5* 92.8* 92.8* 93.1* 
post-glucose (%) (4.5) (2.5) (2.8) (2.5) 
MAP air /        89.4 94.9 93.1 99.2 
pre-glucose (mmHg) (7.5) (8.3) (8.8) (9.8) 
MAP O  /        90.7 94.4 94.7 102.7 2
post-glucose (mmHg) (7.2) (8.1) (8.4) (8.8) 
PR air /            66.3 72.9 74.3 78.8 
pre-glucose  (bpm) (7.0) (8.3) (12.9) (11.0) 
PR O  /           63.0 70.1 71.9 75.8 2
post-glucose (bpm) (6.7) (9.2) (13.0) (11.8) 
 
Table 7.4: Group mean fractional expired carbon dioxide (PETCO2) and inspired oxygen (FiO2) mean arterial 
blood pressure (MAP) and mean pulse rate during air / pre-glucose and during oxygen / post-glucose as a 
function of group.  
*; indicates significantly different from baseline. 
 
Table 7.5 details blood glucose before and 1 hour after ingestion of glucose. At baseline, 
group 1 blood glucose was significantly lower than groups 3 and 4 (p=0.001). Blood glucose 
increased significantly in all groups (p≤0.0005). The increase in blood glucose was 






Group 1 Group 2 Group 3 Group 4 
Baseline  5.5  7.7  8.1  9.4  
(mmol/L) (0.7)  (2.3)  (3.7)  (2.6)  
Effect  8.9*  14.8*  16.0*  18.2*  
(mmol/L) (3.0)  (4.7)  (4.1)  (3.8)  
Change  3.4  7.1  7.9  8.7  
(mmol/L) (3.0)  (4.5)  (2.4)  (2.6)  
 
Table 7.5: Group mean (SD) baseline, effect and change in glucose as function of group.  
*; indicates significantly different from baseline. 
 
Group mean edema index values within 500μm and 1500μm radii of the fovea as a function of 
group are shown in Table 7.6. Edema index values were significantly greater for group 4 than 
group 1 and 2 for both the 500μm and 1500μm radii circles (p≤0.0005; paired two-tailed t-
test). Edema index values were significantly greater for group 3 than group 1 for the 1500μm 






Group 1 Group 2 Group 3 Group 4 
500 μm radius 1.09 1.14  1.32  1.56*†  
(arbitrary units) (0.29) (0.40) (0.24) (0.39) 
1500 μm radius 1.17  1.16  1.39*  1.48*†  
(arbitrary units) (0.21) (0.23) (0.20) (0.24) 
 
Table 7.6: Group mean edema index values within 500μm and 1500μm radius of the fovea as a function of 
group.  
(* indicates significantly different from Group 1; † indicates significantly different from Group 2) 
 
There was no correlation between baseline edema index values within the 500μm or 1500μm 
radius circle and the magnitude of change in diameter, velocity or flow in response to 
combined hyperoxic / hyperglycemic provocation.  
 
Group mean renal function indicators as a function of group are shown in Table 7.7. Group 
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2 139   4.1      72   43.1   8245 26.1 
(2.0) (0.3) (23) (2.1) (4286) (36.1) 
3 138  4.3    77     40.8* 9132 49.6 
(2.4) (0.6) (36) (2.8)  (5918) (43.2) 
4 138   4.3  90   41.0   6708 70.1 
(2.6) (0.4) (24) (2.6) (4408) (66.2) 
 
Table 7.7: Group mean blood sodium, potassium, creatinine and albumin, urine creatinine, and urine albumin as 
a function of group.  





The present study investigated change in retinal arteriolar diameter, blood velocity, flow, 
max:min velocity ratio and WSR induced by a combined isocapnic hyperoxic / hyperglycemic 
provocation in a group of diabetic patients stratified by severity of retinopathy and compared 
to age-matched subjects without diabetes. The vascular reactivity response in terms of the 
reduction of blood flow relative to baseline was significant in all groups but the magnitude of 
the change in flow was not significantly different across the groups. The magnitude of change 
of flow and WSR was significantly less for the age-matched non-diabetic group to the 
combined hyperoxic / hyperglycemic provocation than that of hyperoxia alone i.e. within 
group comparison. There were no significant differences in any of the hemodynamic outcome 
parameters between the combined hyperoxic / hyperglycemic provocation and hyperoxia 
alone within any of the diabetic groups.  
 
An intriguing finding of this study was that the age-matched non-diabetic group demonstrated 
a reduced response of change in flow and WSR to the combined hyperoxic / hyperglycemic 
provocation compared to that of hyperoxia alone. Careful examination of the characteristics of 
the age-matched non-diabetic group showed that 3 of them had possible impaired glucose 
tolerance (IGT). When these subjects were excluded from the analysis, the difference in flow 
and WSR response between the combined hyperoxic / hyperglycemic provocation and that of 
hyperoxia alone was not significant (note this finding was based on a sample size of 14). This 
suggests that hyperglycemia may influence the retinal vascular reactivity response to 
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hyperoxia in patients with IGT.  
 
Unlike the response to hyperoxia alone (Gilmore et al., In Submission 2006) which showed a 
step profile of reduced reactivity with increasing severity of retinopathy, the vascular 
reactivity response to a combined hyperoxic / hyperglycemic provocation was not 
significantly different across the groups. This suggests that hyperglycemia may influence the 
retinal vascular reactivity response to hyperoxia. 
 
Previous work from our laboratory has demonstrated that blood flow significantly decreases 
in patients with diabetes and subjects without diabetes in response to isocapnic hyperoxia 
alone; however, the magnitude of the change in flow is significantly less in response to 
hyperoxia in patients with more severe mild-to-moderate non-proliferative DR (Gilmore et al., 
In Submission 2006), indicating a loss of vascular reactivity with increasing severity of 
retinopathy. Also, we have shown that retinal blood flow is not affected by short-term 
increases of blood glucose in patients with diabetes and subjects without diabetes (Gilmore et 
al, In Submission 2006). In agreement with our previous work, we showed that WSR 
decreased significantly in response to hyperoxic / hyperglycemic provocation in each group 
except the DME group. WSR is a measure of shear stress i.e. shear stress = WSR * viscosity. 
To our knowledge, this study details for the first time WSR in groups of diabetic patients and 
age-matched non-diabetic subjects, and the change of WSR in response to a combined 
hyperoxic / hyperglycemic provocation. This finding suggests that patients with DME have 
impaired ability to regulate shear stress in response to provocation. Max:min velocity ratio 
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significantly increased in all group of the present study except that of the DME group. This 
finding is the same as that of the response to isocapnic hyperoxia alone (Gilmore et al., In 
Submission 2006) and indicates increased pulsatility characteristics of retinal arteriolar blood 
flow in patients with DME. 
 
Previously published studies have investigated retinal vascular reactivity using a non-
isocapnic oxygen stimulus in patients with diabetes during homeostatic conditions and 
hyperglycemia.3-5 These studies have reported either no difference of the magnitude of 
vascular reactivity response to hyperoxia during normoglycemic and hyperglycemic 
conditions,5 or an impaired vascular reactivity response during hyperglycemia.3,4 However, 
these studies are limited because of small sample sizes, many have not utilized simultaneous 
diameter and velocity measurements and all did not control for systemic variation in arterial 
CO2 during hyperoxic provocation. In contrast to our study, none have focused on changes 
associated with the development of early sight-threatening DR, culminating in DME. Most of 
the previous studies have measured vascular reactivity in venules; however, we studied the 
retinal arteriolar response since the arterioles are primarily responsible for the regulation of 
vascular reactivity. The method of control of blood glucose may impact the vascular reactivity 
response since insulin is known to have vasoactive properties.26 However, the vascular 
reactivity response in terms of change in retinal blood flow in patients treated with insulin was 
not different from those treated without insulin. 
 
Patel et al.3 assessed the vascular reactivity response to a non-isocapnic hyperoxic stimulus in 
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patients with diabetes under conditions of normoglycemia and hyperglycemia. They 
concluded that patients with diabetes have impaired vascular reactivity that is exacerbated by 
hyperglycemia (>15mmol/L). A possible explanation for the differences in results between 
that of Patel et al.3 and our study is that a 60% FiO  stimulus (as opposed to >90% FiO2 2) may 
reveal smaller alterations in retinal vascular reactivity between groups. Grunwald et al.4 
induced a reduction in blood glucose level in poorly controlled patients using exogenous 
insulin. Due to the vasoactive properties of insulin,27 the study of Grunwald et al.4 is not 
directly comparable to our study. In agreement with our results, Davies et al.5 reported that 
vascular reactivity was not affected by acute changes of blood glucose. In support of our 
observation is the fact that glucose has a low basal retinal influx28 and glucose transport 
operates near saturation level at normal physiological glucose concentrations.29 Glut-1 is one 
of the most important glucose transporters and is responsible for movement of glucose across 
the inner and outer blood retinal barriers.30 Glut-1 expression is unchanged during short-term 
elevations of glucose preventing increased glucose uptake across bovine retinal endothelial 
cells.28  
 
Vascular reactivity has also been assessed in other vascular beds in animals31 32,33 and humans . 
Hamaty et al.31 reported that short-term hyperglycemia per se did not result in abnormal 
vascular responses in rat tail artery. Houben et al.32 reported that endothelium-dependent or 
independent vasoreactivity was not affected by moderate-to-severe hyperglycemia in humans 
assessed by measuring skin and forearm blood flow. In addition, Capaldo et al.33 were unable 
to detect a difference in change of velocity to a vasodilatory agent in the coronary circulation 
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in normal subjects under baseline and hyperglycemic conditions. Previously published studies 
in animals have investigated preretinal oxygen tension using hyperoxia during hyperglycemia. 
Ernest et al.34 reported increased oxygen tension, whilst others have reported no change in 
pre-retinal tension.35,36 In addition, retinal oxygen consumption has been reported in 





In summary, the results of this study indicate that the vascular reactivity response to a 
combined hyperoxic / hyperglycemic provocation produces a pronounced reduction in blood 
flow. Unlike the response to hyperoxia alone (Gilmore et al., In Submission 2006), the 
vascular reactivity response to a combined hyperoxic / hyperglycemic provocation was not 
significantly different across the groups. The age-matched non-diabetic group that included 3 
suspect IGT individuals, however, demonstrated a reduced response of change in flow and 
WSR to the combined hyperoxic / hyperglycemic provocation compared to that of hyperoxia 
alone (Gilmore et al., In Submission 2006); these effects were not present when the 3 suspect 
IGT individuals were excluded from the analysis. Comparing the vascular reactivity response 
between the combined hyperoxic / hyperglycemic provocation to that of hyperoxia alone, no 
significant differences were found for any of the outcome parameters within any of the 
diabetic groups. The results suggest that individuals with IGT may exhibit reduced vascular 
reactivity to hyperoxia during acute hyperglycemia. Future work will investigate the vascular 
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8 General Discussion 
Disturbance of retinal hemodynamics is a surrogate marker of early diabetic retinopathy (DR). 
Impairment of vascular reactivity to various stimuli has been established. However, studies 
investigating retinal vascular reactivity have been limited by various factors including non-
standardized methods to induce vascular reactivity, different techniques to measure retinal 
hemodynamics, the inclusion of patients with differing morphological and varying glycemic 
control characteristics and the use of differing sites to measure retinal blood flow. Many have 
investigated change in vessel diameter or blood velocity but have not used techniques that 
simultaneously measure diameter and velocity to quantify blood flow in absolute units. 
 
The comparison of 3 different techniques to administer hyperoxia to human subjects 
demonstrated that the sequential rebreathing system stabilized PCO2 and, importantly, 
reduced the variability of an individual’s PCO2 measurement during hyperoxia. Also, we 
demonstrated that modest changes of PCO2 resulted in change of retinal blood flow. Overall, 
we conclude that the sequential rebreathing system is superior to other techniques for the 
provocation, and thereby the assessment, of retinal vascular reactivity (Chapter 3).    
 
Chapter 4 details the vascular reactivity response to hyperoxia using the sequential 
rebreathing system in young, healthy subjects. The Canon Laser Blood Flowmeter (CLBF-
100) was employed to assess retinal arteriolar hemodynamics. The study used an isocapnic 
hyperoxic stimulus to determine retinal vascular reactivity. There was a pronounced reduction 
in diameter, velocity and flow with a maximal effect evident within 4 minutes from stimulus 
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onset. All parameters returned to baseline values when the stimulus was removed. The change 
in retinal blood flow was slightly less than previously published studies using 100% O2, a 
response we attribute to elevated O  levels and compounded reduction of CO2 2. The response 
characteristic of the change in diameter was not significantly different from that of velocity. 
Comparing to cold pressor provocation, the results of this study suggest that different 
response characteristics of the retinal vasculature occur to transmural pressure mediated 
autoregulation as opposed to metabolic mediated vascular reactivity.  
 
Chapter 5 details the change in retinal hemodynamics to isocapnic hyperoxia in a group of 
diabetic patients with mild-to-moderate non-proliferative retinopathy DR and age matched 
subjects without diabetes. DME patients and patients with moderate DR without clinically 
evident DME demonstrated significantly reduced vascular reactivity compared to age-
matched subjects without diabetes and patients with no clinically visible DR. These results 
indicate a loss of retinal vascular reactivity in patients with moderate DR without clinically 
evident DME, and in patients with DME. Furthermore, the results indicate an inability to 
increase vessel tonus and reduce shear stress in response to isocapnic hyperoxic provocation 
in patients with DME. The reasons for this impairment may be structural alterations of the 
smooth muscle cells in the vessel wall, the supporting pericytes, functional alterations of the 
endothelial cells or increased vascular stiffness.   
 
Chapter 6 details the change in retinal hemodynamics to a standardized oral glucose load 
drink in a group of diabetic patients with mild-to-moderate non-proliferative retinopathy DR 
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and age matched subjects without diabetes. None of the hemodynamic parameters changed as 
a result of glucose ingestion in any of the groups. There was no correlation between baseline 
edema index values and the magnitude of change in diameter, velocity or flow in response to 
the oral glucose load drink. Interestingly, change of blood flow was significantly correlated 
with change in blood glucose for the non-diabetic group only. Careful examination of the 
control group revealed that 3 participants had suspect impaired glucose tolerance (IGT). 
When these three participants were excluded from the analysis, there was no significant 
correlation between change in blood glucose and change in flow. This finding suggests that 
patients with IGT may respond differently to acute hyperglycemia than either age-matched 
controls or patients with diabetes.  
 
Chapter 7 details the change in retinal hemodynamics to a combined hyperglycemic / 
hyperoxic provocation in a group of diabetic patients with mild-to-moderate non-proliferative 
retinopathy DR and age matched subjects without diabetes. The vascular reactivity response 
in terms of the reduction of blood flow relative to baseline was significant in all groups but, 
unlike the response to hyperoxia alone, the magnitude of the change in flow was not 
significantly different across the groups. The magnitude of change of flow and WSR was 
significantly less for the age-matched non-diabetic group to the combined hyperoxic / 
hyperglycemic provocation than that of hyperoxia alone i.e. within group comparison. Careful 
examination of the characteristics of the age-matched non-diabetic group showed that 3 
participants had suspected IGT. When these subjects were excluded from the analysis, the 
difference in flow and WSR response between the combined hyperoxic / hyperglycemic 
  243
 
provocation and that of hyperoxia alone was not significant. This suggests that hyperglycemia 
may influence the retinal vascular reactivity response to hyperoxia, especially in patients with 
IGT.  
 
8.1 Future work 
Future work should investigate the vascular reactivity response of patients with IGT. These 
patients may exhibit responses that are different from patients with established diabetes or 
subjects without diabetes. We hypothesize that individuals with IGT manifest distinct changes 
of retinal hemodynamics in response to change of blood glycemic levels since, unlike patients 
with established diabetes, they retain vascular reactivity function. In addition, a graded 
stimulus (i.e. incremental increases in PO ) and / square wave change in PO2 2 may be better 
able to determine subtle changes in vascular reactivity and the timeline of the vascular 
reactivity response between groups of patients, respectively. In addition, the vascular 
reactivity response could be used in conjunction with retinal oximetry measurements to assess 
the degree of physiological impairment in groups of patients with diabetes and in response to 
new therapies. A fuller understanding of biochemical influences to the vascular reactivity 
response can be obtained by measuring certain blood markers in patients with e.g. 
intracellular adhesion molecule. Investigation of vascular reactivity in patients with diabetes 
using stimuli other than hyperoxia e.g. carbon dioxide may also provide more useful 




9 Appendix A: Frequency-of-seeing characteristics of the short-
wavelength sensitive visual pathway in clinically normal subjects 
and diabetic patients with focal sensitivity loss. 
 
Gilmore ED, Hudson C, Nrusimhadevara RK, et al. Frequency of seeing characteristics of the 
short wavelength sensitive visual pathway in clinically normal subjects and diabetic patients 
with focal sensitivity loss. Brit J Ophthalmol 2005;89(11):1462-1467. 
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Aims: To define the frequency-of-seeing (FOS) characteristics of the short-wavelength (SW) 
sensitive visual pathway in normal subjects and in diabetic patients with focal SW sensitivity 
loss. 
Methods: For clinically normal subjects, FOS was assessed at two retinal locations (4.24° 
and 9.90° eccentricity) for both white-on-white (WW) and SW stimulus parameters. Inter-
examination variability was quantified for the clinically normal subjects only. For patients 
with diabetes, FOS was assessed inside an area of focal SW sensitivity loss, and at the same 
eccentricity in the quadrant diametrically opposite, using SW stimulus parameters only.  
Results: For clinically normal subjects, the group mean SW FOS slope was significantly 
flatter (p<0.0001) than that of WW at both locations. The co-efficient of repeatability for SW 
FOS slope was ±41.55dB-1 (relative to a group mean sensitivity of 23.98dB-1) and ±19.98dB-1 
(group mean sensitivity 16.15dB-1) for 4.24° and 9.90°, respectively. For the patients with 
diabetes, the group mean SW FOS slope was significantly flatter (p=0.02), and group mean 
SW threshold significantly higher (p=0.007) in the area of focal SW sensitivity loss than that 
of the non-focal sensitivity loss location. 
Conclusions: The results of this study suggest that the clinical utility of SW automated 
perimetry will be limited by a greater magnitude of measurement variability, as indicated by a 
flatter FOS slope compared to conventional perimetry.   
Keywords: Short-wavelength perimetry (SW), frequency-of-seeing (FOS), short-term 




Short-wavelength automated perimetry (SWAP) detects glaucomatous visual field damage 
earlier than white-on-white (WW).1-4 Other studies have investigated progression of visual 
field defects using SWAP5-8  and also demonstrated SW field loss in diabetic retinopathy and 
maculopathy9-14 prior to the occurrence of WW loss. SWAP may represent a useful clinical 
tool to aid the management of various ocular diseases.  
 
SWAP exhibits a greater between-subject variability and a greater short-term fluctuation (SF; 
i.e. variation of sensitivity within an examination), than WW perimetry.15-19 These two factors 
will reduce the potential of SWAP to detect abnormality and progression i.e. visual field loss 
will have to be greater to reach significance in areas of high variability.17  For WW perimetry, 
the lower the sensitivity at a given stimulus location the higher the SF.20  SF only provides an 
estimate of within-examination variability. The magnitude of within-examination variability 
is determined by the frequency-of-seeing (FOS) function21 that describes the probability of 
detecting a stimulus as a function of intensity. The flatter the slope of the FOS function, the 
greater the within-examination variability. Previous studies have shown shallower slopes in 
areas of visual field loss in glaucoma patients for WW and motion stimuli.22-25   
 
The influence of sensitivity level and stimulus location on SWAP SF has to be established. 
This factor limits the accuracy of threshold determination and also governs the optimum 
bracketing procedure employed to estimate threshold. The aims of the study were to define 
the influence of; 1) Stimulus location on the FOS characteristics of the WW and SW sensitive 
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visual pathways in clinically normal subjects; and 2) Localized sensitivity loss on the FOS 
characteristics of the SW sensitive visual pathway in a diabetic patient group with focal DME.  
 
9.3 Materials and Methods 
9.3.1 Sample 
Sixteen clinically normal subjects (10 males) and 10 patients with diabetes (6 males) 
participated in the study. The study was approved by the Research Ethics Board of the 
University Health Network, Toronto. Written informed consent was obtained from all 
volunteers.  
 
9.3.2 Clinically normal group
The average age of the sample was 26 years (SD 8 years, 20-47 years). Ten right eyes and 6 
left eyes were chosen at random. Inclusion criteria consisted of a logMAR visual acuity of 
0.00, or better, a normal fundus appearance (stereo-biomicroscopy using dilated pupils) and 
normal visual fields (assessed by a minimum of one perimetry examination using Humphrey 
Field Analyzer (HFA) II program 24-2). Exclusion criteria comprised (i) a distance refractive 
error of > ±6.00DS or ±1.50DC, (ii) family history of glaucoma, (iii) a Goldmann IOP greater 
than or equal to 22mmHg (iv) CNS disorders or psychiatric illness, (v) systemic medication 
with known CNS effects and (vi) significant lenticular opacities (graded by the Lens Opacity 
Classification System III i.e. NO>1, NC>1, P>1, C>1).26  
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9.3.3 Patients with diabetes 
The average age of the sample was 55 years (SD 9 years, 38-66 years). Five right eyes and 5 
left eyes were used. Inclusion criteria consisted of a logMAR visual acuity of 0.50, or better, 
clinically evident focal diabetic macular edema and repeatable sensitivity loss (i.e. ≥5 
contiguous stimulus locations of significantly reduced sensitivity as assessed by SWAP and 
horizontal hemifield asymmetry analysis9) on each of 2 separate occasions. Exclusion criteria 
were the same as those imposed for the clinically normal group, apart from LOCS III criteria. 
 
9.3.4 Visits 
All volunteers attended for two visits. Only the results from the second visit were analysed, 
thereby minimizing learning effects for both perimetric paradigms.27 Visit 1 was used to 
undertake refraction, VA and fundus examination and to perimetrically train volunteers (using 
WW and SW program 10-2). For the clinically normal group, visit 2 comprised two sessions 
comprising 4 FOS runs each (one before and one after lunch). The order of stimulus condition 
was randomised between subjects and retained for the post-lunch session. At visit 2, nine 
clinically normal subjects underwent WW stimulus parameters first. For the patients with 
diabetes, visit 2 comprised program 10-2 SWAP followed by 2 FOS test runs using SW 
stimulus parameters only. Volunteers were given rests every 5 minutes to minimize fatigue.28 
The same FOS program was used for both clinically normal subjects and patients with 
diabetes. 




A HFA II model 740 (Carl Zeiss Meditec, Dublin, U.S.A.) and custom FOS software was 
utilized. The patient’s correction was adjusted for a viewing distance of 30cm. For the WW 
stimulus parameters, a 10cd/m2 background luminance and a Goldmann III (0.431° subtense) 
white stimulus were utilized. For the SW stimulus parameters, a high intensity yellow 
background (100cd/m2) in conjunction with a Goldmann V (1.724° subtense) blue stimulus 
were utilized.29 Maximum stimulus intensity (i.e. 0dB) was 10,000 apostilbs and 65 apostilbs 
for WW and SW stimulus parameters, respectively. Stimulus duration was 200ms. Fixation 
was assessed using the corneal reflex monitor and the Heijl-Krakau technique. 
 
9.4 Frequency-of-seeing (FOS)
When performance is expressed as probability, psychometric functions are ogival, or S-
shaped, in form. Volunteers were given five minutes to adapt to the background luminance 
prior to starting each FOS determination. For the clinically normal group, sensitivity was 
assessed at the fovea and five other retinal locations (at 5.66° eccentricity along the 135°, 
225° and 315° meridians, and at 4.24° and 9.90° along the 45° meridian) using an initial 4dB 
crossing of threshold and then a 2dB reversal. FOS functions were assessed at the 4.24° and 
9.90° locations (one per location) along the 45° meridian at each session (Figure 10.1). For 
the patients with diabetes sensitivity was assessed for a location inside an area of focal SW 
sensitivity loss and at the same eccentricity in the quadrant diametrically opposite and at 2 
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other locations (one in each of the 2 remaining quadrants). A hemifield asymmetry analysis 
using SWAP program 10-2 identified localized areas of focal SW sensitivity loss.9 The 
hemifield asymmetry analysis compared individual asymmetry across the midline to 


















2250 3150 4°, 4° location      
FOS point  
Figure 9.1 Schematic diagram showing position of FOS stimulus locations for clinically normal subjects (right 
eye).  
Frequency-of-seeing stimulus locations were fixed for all subjects at 4.24º (i.e. polar co-ordinates 3º, 3º) and 
9.90º (i.e. polar co-ordinates 7º, 7º) along the 45º meridian. Supra-threshold stimuli were presented at 5.66º (i.e. 
polar co-ordinates 4º, 4º) along the 135º, 225º and 315º meridians.   
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For FOS testing, stimuli were presented randomly at pre-set sensitivity levels (selected by the 
operator) above and below the estimated threshold. The FOS functions were determined using 
8 sensitivity levels (two separate FOS test runs comprising 4 sensitivity levels each). Ten 
presentations were made at each sensitivity level. Sensitivity levels were selected for the first 
FOS run at ±1dB & ±3dB relative to the estimated threshold. The sensitivity levels for the 
second FOS run were then empirically chosen based upon the results of the first run. 
Volunteers who exhibited more than 25% false positive / negative responses or fixation losses 
were excluded from the analysis. Supra-threshold stimuli were randomly presented in order to 
introduce spatial uncertainty with the aim of maintaining global attention of the subject. No 
subjects were excluded due to excessive false positive / negative or fixation losses. 
 
9.4.1 FOS function fitting
The FOS data was fit using the following function: 
P(I)= 1- [0.5^(- (S / α)^β)] 
where, P(I) is the probability of stimulus detection, S is sensitivity (dB), α is a point on the x-
axis (i.e. sensitivity) that corresponds to a certain performance level.30 For this study, α was 
taken at 0.5 or 50% FOS. β is the slope of the central portion of the function. Statistica 
(Statsoft, Inc.) was used to produce a least-squares fit of the function. Sensitivity was 
compared within a given stimulus parameter (since comparison of sensitivity between WW 
and SW parameters is invalid due to differing dynamic ranges). Sensitivity was taken at 50% 
FOS. 
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9.5 Statistical analysis 
For the clinically normal group, slope and r-value (i.e. goodness of fit) of the FOS functions 
were compared between the different stimulus parameters (WW / SW). Sensitivity (i.e. 50% 
FOS) was also included in the analysis to determine significant interactions with FOS slope 
and to monitor systematic change in sensitivity across the two sessions (i.e. fatigue). A 
repeated measures Analysis of Variance (ANOVA) was undertaken on the data with slope and 
sensitivity as dependent variables and stimulus condition, eccentricity and session as the 
within-subject factors (SPSS Inc, Chicago, IL). For the diabetic patient group, slope and 
sensitivity were compared between locations for SW stimulus parameters using Student’s t-
test (two-tailed).  
 
Inter-session variability was quantified using the co-efficient of repeatability (COR)31 for the 
clinically normal group using visit 2 session 1 and session 2 data i.e. 1.96*SD of the 
differences across sessions.  
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9.6 Results 
9.6.1 Clinically normal group 
FOS functions of each clinically normal individual are shown for WW and SW stimulus 
parameters in Figures 9.2 and 9.3, respectively. Test times to complete each session were not 

























































































Figure 9.2 Individual FOS functions using WW stimulus parameters for clinically normal subjects  
(Upper; Visit 1. Lower; Visit 2. Left; 4.24° eccentricity. Right; 9.90° eccentricity). 




























































































Figure 9.3 Individual FOS functions using SW stimulus parameters for clinically normal subjects  
(Upper; Visit 1. Lower; Visit 2. Left; 4.24° eccentricity. Right; 9.90° eccentricity). 
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9.6.2 Group mean slope 
Group mean FOS slope data is shown in Table 9.1. The SW slopes were found to be 
significantly flatter than those attained using WW parameters (p<0.0001) and the slopes for 
both stimulus conditions were significantly flatter at 9.90° than at 4.24° (p=0.0198) (Figures 
9.2 and 9.3). The interaction of slope, stimulus parameter and eccentricity was not significant. 
 
 WW 4.24º WW 9.90º SW 4.24º SW 9.90º 
 Session1 Session2 Session1 Session2 Session1 Session2 Session1 Session2
Sensitivity (dB)         
Mean 34.78 34.59 32.17 31.93 32.83 31.78 29.65 28.54 
         
SD 1.76 1.28 1.88 1.50 2.63 2.40 3.41 2.89 
Slope (dB-1)         
Mean 39.15 34.19 31.68 29.74 26.40 21.56 14.94 17.35 
         
SD 14.20 10.52 12.70 13.85 17.80 11.36 8.78 9.00 
 
Table 9.1 Mean sensitivity and FOS slope for WW and SW stimulus parameters at 4.24º and 9.90º eccentricity 
for clinically normal subjects.    
 
9.6.3 Group mean sensitivity
Group mean FOS sensitivity data is shown in Table 9.1. Sensitivity was significantly higher at 
4.24° than at 9.90° (p<0.0001). Sensitivity was not significantly different across sessions. 
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9.6.4 Group mean r-values 
Group mean FOS r-value data is shown in Table 9.2. r-values were consistently lower using 
SW stimulus parameters and at the more eccentric stimulus location. 
 
 WW 4.24º WW 9.90º SW 4.24º SW 9.90º 
 Session 1 Session 2 Session 1 Session 2 Session 1 Session 2 Session 1 Session 2
r-value         
Mean 0.99 0.98 0.99 0.97 0.96 0.97 0.94 0.94 
         
SD 0.02 0.02 0.03 0.03 0.05 0.04 0.06 0.04 
Table 9.2 Mean r-value for WW and SW stimulus parameters at 4.24º and 9.90º eccentricity for clinically normal 
subjects.    
 
9.6.5 Repeatability of FOS determination
Inter-session variability was quantified using the co-efficient of repeatability (COR) (Table 
9.3) The COR was calculated for the clinically normal group using the session 1 and session 2 
data gathered at visit 2.  
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 W W S W 
 4.24º 9.90º 4.24º 9.90º 
Sensitivity (dB)     
COR +/-2.85 +/-3.38 +/-3.86 +/-4.19
     
Mean 34.68 32.05 32.31 29.09 
Slope (dB-1)     
COR +/-30.76 +/-29.91+/-41.55+/-19.98
     
Mean 36.67 30.71 23.98 16.15 
Table 9.3 COR of sensitivity and FOS slope for WW and SW stimulus parameters at 4.24º and 9.90º eccentricity 
for clinically normal subjects.    
 
9.6.6 Patients with diabetes 
Figure 9.4 shows typical FOS functions for a location within, and distant from, an area of 
focal sensitivity loss for a patient with diabetes. 
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Figure 9.4 Individual horizontal hemifield analysis (right eye) and FOS functions using SW stimulus parameters 
for a patient with diabetes  
(Upper; location distant from area of focal SW sensitivity loss. Lower; location within area of focal SW 
sensitivity loss. SWAP; Short-wavelength automated perimetry). 
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9.6.7 Group mean slope 
The group mean SW slope values for the diabetic patients are shown in Table 9.4. The SW 
slopes derived from the focal sensitivity loss location were found to be significantly flatter 
than those from the non-focal sensitivity loss location (p=0.007).  
 





Sensitivity (dB)   
Mean 23.29 18.07 
   
SD 4.80 5.05 
Slope (dB-1)   
Mean 16.59 7.87 
   
SD 8.61 4.12 
Table 9.4 Mean sensitivity and FOS slope for SW stimulus parameters at the DME and non-DME location for 
patients with diabetes.    
 
9.6.8 Group mean sensitivity
The group mean SW sensitivity values for the diabetic patients are shown in Table 9.4. SW 
sensitivity attained at the focal sensitivity loss location were significantly lower than those 
attained at the non-focal sensitivity loss location (p=0.02).  
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9.6.9 Group mean r-values 
Using SW stimulus parameters, the group mean r-value at the non-focal sensitivity loss 
location was 0.964 (SD 0.04). At the focal sensitivity loss location, the group mean r-value 
was 0.925 (SD 0.06). r-values were consistently lower at the focal sensitivity loss location.  
 
Figure 9.5 illustrates the relationship between SW sensitivity (@ 50% FOS) and SW FOS 
slope for the clinically normal subjects and patients with diabetes. It clearly shows a 
curvilinear relationship between sensitivity and slope, with FOS slope becoming flatter in 
locations of lower sensitivity. 
 



















 4.24 location (control)
 9.90 location (control)
 non-sens loss (diabetic)
 sens loss (diabetic)
Figure 9.5 Relationship between SW sensitivity (@ 50% FOS) and SW FOS slope for all volunteers. 
 Clinically normal group: 4.24° location (filled circles); 9.90° location (filled squares). Patients with 
diabetes: location distant from area of focal sensitivity loss (open diamonds); location within area of focal 
sensitivity loss (open triangles). A logarithmic best fit line has been fit to all the data (r=0.6). 




For the clinically normal group, the group mean slope of the FOS function using SW stimulus 
parameters was significantly flatter than that of WW (p<0.0001). For the patients with 
diabetes, SW FOS slope was flatter in locations of focal sensitivity loss compared to the non-
focal sensitivity loss locations (p=0.007) (Figure 9.5). 
 
It has been established that SWAP exhibits greater SF than that of WW perimetry15,18,32; 
however, these studies have been based upon double determinations of staircase estimations 
of threshold. This study found FOS slope in clinically normal subjects to be approximately 
38% and 53% flatter for SW than WW perimetry at 4.24° and 9.90°, respectively. Previous 
studies have tended to underestimate the magnitude of threshold variability for SWAP.15,18,32 
This underestimation may be attributed to the staircase estimation of threshold that in turn is 
used to estimate SF.  
 
For the clinically normal group, the group mean COR for sensitivity was found to be greater 
for the more eccentric locations and for SW perimetry, indicating greater variability. The 
magnitude of COR for slope was found to be higher than group mean slope for SW perimetry 
i.e. the magnitude of variation of the measurement was found to be higher than magnitude of 
the measurement per se. The absolute sensitivity value was lower for SW automated 
perimetry parameters.  For WW, the magnitude of the COR for slope was found to be lower 
than the group mean slope.  
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For WW perimetry, decrease in sensitivity is accompanied by a flattening of the slope of the 
FOS function20 and glaucomatous patients show enhanced variability when compared to 
clinically normal subjects.33 For the clinically normal group, the FOS slopes for both stimulus 
conditions were significantly flatter at 9.90°, while sensitivity was significantly higher at 
4.24°. For the patients with diabetes, the results demonstrated that the slope of the SW FOS 
function was significantly flatter in locations within focal sensitivity loss. Consideration of all 
the SW data in terms of a plot of sensitivity versus FOS slope clearly showed a curvilinear 
relationship, with slope becoming flatter in locations of lower sensitivity. 
 
In summary, the results of this study confirm that the clinical utility of SWAP will be limited 
by an increased magnitude of threshold variability compared to that of WW automated 
perimetry. Despite evidence that SWAP improves the detection of early visual field loss, its 
utility as a routine clinical tool needs to be treated with caution as a result of exaggerated 
threshold variability.  
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Aims: To define the variability and repeatability of retinal thickness measurements using the 
Retinal Thickness Analyzer (RTA) and to elucidate any interaction between eccentricity (i.e. 
position relative to the fovea) and variability and repeatability.   
Methods: The sample comprised 20 normal subjects of mean age 33 years. Each subject 
attended for 2 visits. Repeated RTA scans were acquired centred on the fovea and for any one 
of the four possible non-foveal scan areas. The mean retinal thickness (SD) was calculated for 
a series of concentric circular bands centred on fixation. A repeated measures analysis of 
variance (ANOVA) was used to determine any significant interaction between the variability 
of RTA thickness values and eccentricity.  
Results: The group mean co-efficient of variation and co-efficient of repeatability were 
highest at the fovea. The repeated measures ANOVA revealed that the within-test variability 
of RTA measurements varied significantly with eccentricity (p<0.0001). Similarly, the 
between-test repeatability varied significantly with eccentricity (p=0.045). 
Conclusion: The significantly elevated within-test variability, and between-test repeatability, 
in the foveal area needs to be considered when using the RTA to evaluate patients with 
macular disease.  
 
Keywords: Eccentricity, variability, repeatability, RTA, retinal thickness, retinal topography.  




Ocular diseases that result in alterations of retinal thickness include diabetic macular edema 
(DME), glaucoma, age-related maculopathy, vascular occlusion and macular hole. Established 
clinical techniques are non-quantitative and relatively insensitive to small changes in retinal 
thickness because they rely on the subjective assessment of the clinician1. Reliable, 
quantitative and sensitive methods to determine retinal thickness will lead to more accurate 
diagnosis and effective management. For example, the Retinal Thickness Analyzer (RTA; 
Talia Technology Ltd, Neve-IIan, Israel) has been extensively evaluated in clinically normal 
subjects2-8 9-27, patients with various retinal diseases  and following various interventions28-31. 
Retinal thickness measurements using the RTA have been shown to correlate with other 
techniques7, 27, 32 4,7 and histological assessment . Importantly, the within-session global (as 
opposed to local) variability of the RTA has been estimated to be approximately 11-23μm, 
while the between-session repeatability was approximately 11-31μm2-5,8,10,16. Despite 
previous anecdotal comments about a possible effect2, no studies have systematically 
examined the relationship between RTA measurement variability and repeatability and 
eccentricity. To the best of our knowledge, this study is the first study to elucidate an 
interaction between eccentricity and RTA measurement variability and repeatability. For the 
purposes of this study, eccentricity was defined as the distance of the retinal thickness 
measurement (co-ordinates x, y) relative to the position of the fovea (co-ordinates 0, 0). 
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10.3 Materials and Methods 
10.3.1 Sample 
The sample comprised 20 normal subjects of mean age 33 years (SD 8 years, range 22-51 
years). Informed consent was obtained from each subject. The study followed the tenets of the 
Declaration of Helsinki and was approved by the University of Waterloo Office of Research 
Ethics and the Toronto University Health Network Research Ethics Board. One eye of each 
subject was assigned to the study: ten right, and ten left, eyes were selected. Inclusion criteria 
comprised a logMAR visual acuity of 0.0, or better, and a normal fundus appearance. Visual 
acuity was assessed using a 96% contrast Regan logMAR chart. Stereo fundus 
biomicroscopy, through a dilated pupil, was carried out to ensure the exclusion of significant 
ocular pathology. Exclusion criteria included a distance refractive error of greater than ±6.00 
dioptres sphere and / or ±1.50 dioptres cylinder, a history of ocular disease, or surgery, and a 
family history of glaucoma, or diabetes, in a first degree relative. Subjects with significant 
lenticular opacities, as assessed by the Lens Opacity Classification System III33 were 
excluded: significant lenticular opacity was defined as nuclear colour >2; nuclear opalescence 
>2; cortical cataract >1; and posterior sub-capsular cataract >1. Recent publications have 
demonstrated that RTA measurement can be adversely affected by lenticular opacity8, 27. 
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10.3.2 Retinal Thickness Analyzer
The RTA comprises a laser slit biomicroscope and digital camera attached to an ophthalmic 
table, a patient headrest and a personal computer (software version 4.075). In brief, a green 
helium-neon laser light of 543nm wavelength is scanned across the retina to produce sixteen 
discrete slit images within a 3mm x 3mm area of retina. The reflected slit images are recorded 
digitally. Retinal thickness is derived from the separation between the anterior (i.e. at, or close 
to, the internal limiting membrane, ILM) and posterior (i.e. at, or close to, the retinal pigment 
epithelium, RPE) reflectance interfaces34 for 16 points along each slit using densitometry. 
Consequently, the derivation of retinal thickness is dependent upon the clarity of RTA slit 
image. Patient fixation is aided by means of an internal fixation target that can be moved. 
Depth resolution and depth precision are reported to be 5-10μm and 50μm, respectively3. A 
more detailed explanation of the RTA optical principles have been described elsewhere3-5,23. 
 
10.3.3 Procedures 
Each subject attended for 2 visits within a maximum 4 week period (mean interval 7 days, 
range 1-30 days). At both visits, the study eye of each subject was dilated using 1% 
Mydriacyl. Retinal thickness was initially assessed using the 5 default fixation locations of the 
RTA (i.e. centred on the fovea, supero-temporal, supero-nasal, infero-temporal and infero-
nasal). Subsequently, the fovea-centred scan area, and any one of the four possible non-foveal 
scan areas (since RTA thickness values are not significantly different between the 4 
meridians5) were each repeated 6 times using an alternating paradigm. The position of the 
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non-foveal scan was constant for a given subject but was systematically varied between 
subjects. Only the fovea-centred and the selected non-foveal scans, from the initial 5 default 
scans, were included in the analysis. A single, experienced RTA operator was used 
throughout (EG).  
 
10.3.4 Analysis 
Circular band analysis. This method of analysis was chosen since it was relatively robust to 
misalignment of successive RTA images. The scanned area of each image was divided into 
concentric circular bands using the radial analysis feature. Radii ranged from 200 to 3000μm 
and successive circles, centred on the fixation target, were separated by 200μm (Figure 10.1). 
The mean retinal thickness value within each concentric circular band was calculated for each 
individual. The variability of the mean thickness values was compared during, and between 
visits, for each concentric circular band, using the co-efficient of variation (COV = SD / 
mean) and co-efficient of repeatability (COR = 1.96 x SD of the differences between visits 1 
and 2), respectively. The number of retinal thickness values used to calculate the mean varied 
between 4 (0 to 200μm band) and 61 (1400 to 1600μm band) according to the position and 
area of the circular band relative to the fovea. 
    










 600μm circle 
Figure 10.1 Schematic diagram showing the default RTA scan locations.  
(f = fovea, SN = superonasal, ST = superotemporal, IN = inferonasal, IT = inferotemporal) and the radii used for 
the circular band analysis (ranging from 200–3000 µm radii, centred on the fixation target, in 200 µm steps). 
 
Spoke analysis. A spoke analysis was also undertaken to negate the influence, if any, of the 
number of retinal thickness values used to calculate the mean in each circular band. This 
approach addressed the unequal number of data points used to generate the means for the 
circular band analysis. Using the spoke analysis, the mean of three retinal thickness values in 
each band was calculated extending from the fovea along one of the principal meridians (i.e. 
45°, 135°, 225°, or 315°). The COV was then calculated for each band of the spoke as a 
function of visit. 
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Point-wise analysis. A point-wise analysis was undertaken to determine if the magnitude of 
retinal thickness per se was related to the variability of thickness measurements. Images were 
registered across visits (i.e. aligned) and the mean and SD of thickness values of all points 
was calculated. The mean and SD of the point-wise thickness data in the seven scans within 
each session were plotted to elucidate any relationship between measurement variability and 
retinal thickness.  
 
10.3.5 Statistics 
A repeated measures analysis of variance (ANOVA) was used to determine any significant 
interaction between the variability of RTA thickness values and eccentricity. Variability of 
retinal thickness was the dependent variable; visit (i.e. 1 or 2) and eccentricity were the 
within-subject factors. Intra-class correlation coefficients were also calculated to determine 
the reliability of the RTA thickness measurements across visits.  




The group mean profile of retinal thickness is shown in Figure 10.2, upper. The group mean 
retinal thickness was thinnest at the fovea (136.2μm, SE 6.9), thickest at 1000-1800μm from 
the fovea (186.7μm, SE 4.8) and then declined with further increase in eccentricity (163.6μm, 
SE 4.7). Individual retinal thickness values ranged from 86.7μm to 219.8μm (median value 
133.5μm) for the central radius (0-200μm from the fovea). 




















































































































































































































































































Figure 10.2 Upper; Group mean profile of retinal thickness (0-3000μm) derived using the circular band analysis 
for visits 1 (filled circle) and 2 (open square). Middle; Group Mean profile of COV derived using the circular 
band analysis for visits 1 (filled circle) and 2 (open square). Lower; Bar chart showing group mean COR derived 
from the circular band analysis.  
Error bars represent ± 1 standard error of the mean (COV ; co-efficient of variation. COR ; co-efficient of 
repeatability).  
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The group mean COR of retinal thickness is shown in Figure 10.2, lower. It was highest at the 
fovea (40.3μm compared to a mean effect of 136.2μm), lowest at 600-1000μm (16.6μm 
compared to a mean effect of 172.7μm) eccentricity, then increased up to 2000-2200μm 
(25.5μm compared to a mean effect of 175.6μm) eccentricity and subsequently decreased 
with further increase in eccentricity (21.5μm @ 2600-3000μm compared to a mean effect of 
164.3μm).  
 
The repeated measures ANOVA revealed that the variability in retinal thickness 
measurements across visits was not significant (p=0.455). The variability in retinal thickness 
measurements (i.e. within-visit) as a function of eccentricity was significant (p<0.0001). 
Similarly, the variability in retinal thickness measurements across visits (i.e. repeatability) as 
a function of eccentricity was significant (p=0.045). Intra-class correlation coefficients 
calculated for each eccentricity ranged between 0.79 (1800-2000 μm) and 0.91 (2600-2800 
and 2800-3000μm) and were significantly correlated across visits (p<0.0001). 
 
The spoke analysis demonstrated a similar relationship between COV and eccentricity, and 
similar magnitudes of COV, to that of the circular band analysis. The point-wise analysis 
showed that there was no relationship between retinal thickness and the variability of the 
retinal thickness measurements. 




This study describes the local variability and repeatability of retinal thickness measurements 
using the RTA in a group of normal subjects with minimal, if any, media opacities. It is the 
first study to elucidate the interaction between eccentricity and RTA measurement variability 
and repeatability. Within-test variability was found to vary significantly with change in 
eccentricity from the fovea (p<0.0001). Similarly, the between-test repeatability was found to 
vary significantly with eccentricity (p=0.045). The within-test variability, and between-test 
repeatability, were both most pronounced at the fovea.  
 
The retinal thickness values obtained from our sample are generally in good agreement with 
previous histological studies35,36. Hogan and co-workers35 reported mean foveal thickness 
values of 130μm and while Straatsma and co-workers36 reported values for foveal thickness of 
100μm. Conversely, Fine and Yanoff37 reported mean foveal thickness values of 200μm based 
upon histological techniques. Generally, with the exception of Konno and co-workers7, 
published RTA studies have tended to find higher retinal thickness values when compared to 
our retinal thickness values. The difference in the magnitude of retinal thickness between the 
results reported in this, and previous RTA studies, may be attributed to the strict exclusion 
criteria employed in this study in relation to lens opacity. The light scattering effect induced 
by media opacities will result in blurred retinal slit images and an artifactual increase of 
retinal thickness values. Interestingly, a more recent study has found values of mean retinal 
thickness that are in very close agreement with our findings8. 
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The variability and repeatability of RTA measurements have been reported in various 
published studies2-5,8,10,16. These authors found global mean COV values ranging from 10.6μm 
to 23μm. The retinal thickness values of any individual need to exceed the normal range of 
values to an extent greater than the magnitude of the COV before a significant difference in 
retinal thickness can be claimed. However, these studies have assessed variability over 
relatively large scan areas and did not address the issue of the interaction of RTA 
measurement variability with eccentricity. The magnitudes of COV found in this study are 
similar to those previously reported when relatively large scan areas are compared (by 
interpolation of areas under the COV profiles in Figure 10.2, middle).  
 
Change in retinal thickness over time of any individual needs to exceed the magnitude of the 
COR before significance can be claimed. Previous studies2-4,10, 16 evaluated repeatability by 
calculating the standard deviation of RTA measurements divided by the mean (across two 
visits). These studies found repeatability values ranging from 10.8μm to 19μm but did not 
consider any possible interaction of RTA repeatability and eccentricity and therefore 
calculated average indices that reflected repeatability for relatively large scan areas. The 
magnitudes of COR found in this study are high compared to those previously reported. This 
can be explained in part by the use of the COR index (which represents 1.96 x SD of the 
differences in RTA measurements across visits) and, more importantly, by the local variation 
in COR revealed in this study. In addition, the intra-class correlation coefficients 
demonstrated that the data was highly correlated within- and between-visits. 
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The circular band analysis resulted in a different number of data points within each circular 
band area i.e. 28 (i.e. 4 points x 7 scans) to 427 (i.e. 61 points x 7 scans). The spoke analysis 
(which resulted in 3 data points within each circular band) demonstrated a similar relationship 
between COV and eccentricity, and similar magnitudes of COV, with that of the circular band 
analysis. We conclude that the variation in COV as a function of eccentricity is not 
attributable to the differences in sampling rate across the circular bands. 
 
The point-wise analysis demonstrated no relationship between retinal thickness and the 
variability of the retinal thickness measurements (as assessed by the SD of the 7 scans). The 
COV and COR are most prominent in areas of greatest change in retinal topography, 
particularly in the region of the foveal pit. This may in part be explained by the possible 
impact of involuntary physiological eye movements, and reduced nerve fibre layer (NFL) 
thickness at the fovea resulting in a localized reduction of reflectance intensity. Also, the 
ability of the RTA software algorithm to identify the anterior and posterior reflecting slit 
interfaces may be limited in areas of minimal retinal thickness. The possible impact of 
involuntary physiological eye movements as a further contributor to this local variation in 
RTA measurement variability and repeatability cannot be excluded. Interestingly, the test-
retest measurement variability of confocal scanning laser tomography has also been 
demonstrated to be significantly greater in areas of greatest change of retinal topography38,39. 
Such an effect can be anticipated to impact upon other reflectance based scanning laser 
imaging systems. 
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We report a significant interaction between eccentricity and RTA measurement variability and 
repeatability. The group mean COV (11% at fovea and 3.5 to 5.0% elsewhere) and COR 
(40.3μm at the fovea and 16.6 to 25.5μm elsewhere) were highest at the fovea. Measurement 
variability and repeatability was not attributable to the magnitude of retinal thickness per se 
but instead, was most evident in areas of greatest change of retinal topography. The 
exaggerated within-test variability and between-test repeatability in the foveal area needs to 
be considered when using the RTA to evaluate patients with macular pathology. Confidence 
limits to determine abnormality relative to a normal database, and change in retinal thickness 
relative to baseline for a given individual, need to take into account the increased variability 
and repeatability in areas of greatest rate of change in retinal topography in order to maximize 
the sensitivity of the RTA. 
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